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ABSTRACT OF THE DISSERTATION 
 
Post-Translational Regulation of FAS-Mediated PPAR? Activation 
by 
Anne P L Jensen-Urstad 
Doctor of Philosophy in Molecular Cell Biology 
Washington University in St. Louis, 2013 
Professor Clay F Semenkovich, Chairperson 
The liver is a central organ to whole-body metabolism and mediates many of the 
adaptive responses to changes in nutrient availability, such that the appropriate energy 
sources are used and blood glucose levels maintained, whether directly after a meal or after a 
twelve-hour fast. The adaptive responses to fasting in liver are largely mediated by the 
nuclear receptor peroxisome proliferator-activated receptor ?, or PPAR?.  
PPAR? can be activated by a de novo synthesized lipid ligand—16:0/18:1-
glycerophosphocholine (16:0/18:1-GPC)—the synthesis of which is dependent on fatty acid 
synthase (FAS), but little is known about the regulation of this pathway. My thesis focused 
on post-translational mechanisms controlling endogenous activation of PPAR? in the liver 
and used mouse liver and a hepatocyte cell line as model systems.  
 In addition to its role in PPAR? activation during fasting, FAS helps store excess 
calories as fat during feeding. We demonstrated that this paradoxical relationship involves the 
differential regulation of FAS in at least two distinct subcellular pools: cytoplasmic and 
membrane-associated FAS, the latter being attached to membranes by a strong peripheral 
membrane association. To find candidate proteins mediating FAS membrane localization we 
used a proteomics approach to identify compartment-specific FAS-associated proteins. We 
identified three proteins—Septin-2, Septin-7, and 40S ribosomal protein S18—that in two 
different liver model systems associate with FAS exclusively in the membrane fraction. 
xii 
 
Because the septins are involved in membrane structuring and scaffolding, these proteins may 
be involved in FAS membrane localization.  
The ratio of cytoplasmic to membrane FAS specific activity was increased with 
fasting or in the absence of insulin, indicating higher cytoplasmic FAS activity under 
conditions associated with PPAR? activation. This effect was due to a nutrient-dependent and 
compartment-selective covalent modification of FAS: cytoplasmic FAS was preferentially 
phosphorylated during feeding or insulin treatment at Thr-1029 and Thr-1033, which flank a 
dehydratase domain catalytic residue. Mutating these sites to alanines promoted PPAR? 
target gene expression. mTORC1, a mediator of the feeding/insulin signal to induce 
lipogenesis, emerged as a mediator of FAS phosphorylation, inhibiting cytoplasmic FAS 
activity and reducing PPAR? target gene expression in a FAS-dependent manner. 
Next, we investigated the role of ligand transport in FAS-mediated PPAR? activation. 
16:0/18:1-GPC is synthesized in the cytoplasm and it is not known how it reaches the nuclear 
PPAR?. We identified phosphatidylcholine transfer protein (PCTP) as a possible transport 
protein for this ligand. PCTP knockdown in Hepa1-6 hepatocytes caused dramatic reductions 
in expression of PPAR? target genes, and PCTP co-immunoprecipitated with PPAR?. 
Immunofluorescent imaging showed that starvation of cells caused an accumulation of PCTP 
in the nucleus, consistent with a shuttling function controlled by nutrition. Using mass 
spectrometry, we demonstrated that PCTP binds 16:0/18:1-GPC. We further showed that the 
binding of this ligand to PCTP is FAS-dependent: in mice with liver-specific knockout of 
FAS, the amount of 16:0/18:1-GPC bound to PCTP in the nucleus was significantly reduced.  
Together, these findings suggest that multiple modes of post-translational regulation 
of FAS combined with regulation of lipid delivery by PCTP control fasting-induced PPAR? 
activation in liver.   
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Introduction and Significance 
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Portions of this chapter are adapted from: Jensen-Urstad APL, Semenkovich CF. “Fatty acid 
synthase and liver triglyceride metabolism: housekeeper or messenger?” Biochim Biophys 
Acta 2012. 1821(5):747-53.  
 
HEPATIC LIVER METABOLISM IN HEALTH AND DISEASE 
 The liver plays a central role in both glucose and lipid metabolism. Through a finely 
tuned regulation of hepatic glycolysis, gluconeogenesis, glycogen synthesis and 
glycogenolysis, the liver enables the control of blood glucose levels within certain narrow 
physiological limits both in the fed and fasted state. This process becomes disturbed in type II 
diabetes, in which dysregulation of hepatic glucose metabolism combined with reduced 
glucose uptake by peripheral tissues lead to hyperglycemia. The liver is the hub for lipid and 
lipoprotein production, secretion, uptake, and breakdown, as well as the primary regulator of 
plasma cholesterol levels. In healthy individuals, the regulation of lipid metabolism and 
glucose metabolism in the liver are tightly interlinked, allowing for appropriate substrate 
utilization both after meals and during periods of fasting (reviewed in [1]). In diabetes, both 
glucose and lipid metabolism become disturbed, as does this nutrient-responsive adaptation. 
 
Hepatic lipid metabolism: lipoprotein synthesis, secretion, and uptake 
 Systemic transport of lipids is primarily carried out by lipoproteins, complexes of 
lipid and protein (apolipoproteins) with a core of neutral lipids (triglycerides, diglycerides, 
cholesterol esters) and a surface monolayer of amphipathic phospholipids and proteins that 
promotes interaction of the lipoprotein with the aqueous environment of the blood. As the 
liver is the key organ for synthesis, secretion, and uptake of lipoproteins, the basics of 
lipoprotein metabolism will be reviewed below.  
 Lipoproteins are synthesized and secreted by the liver and, to a smaller extent, by the 
small intestine. They transport lipid to peripheral tissues (primarily adipose tissue and 
muscle) and return to the liver for uptake and breakdown or  recycling. During their time in 
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the circulation, lipoproteins are modified by losing lipid to peripheral tissues; by lipid 
exchange with other lipoproteins, remodeling their relative lipid compositions (such as 
through the action of cholesterol ester transfer protein (CETP) that exchanges cholesterol 
esters for triglycerides); and by loss or gain of apolipoproteins. Some lipoproteins are 
involved in reverse lipid transport, i.e. the transport of lipids from peripheral tissues to the 
liver (an important example being reverse cholesterol transport by HDL from macrophages to 
the liver, from which the cholesterol is then excreted as bile).   
 Lipoproteins can be roughly divided into five classes: chylomicrons and their 
remnants, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL), 
intermediate-density lipoproteins (IDL), and high-density lipoprotein (HDL). Generally, the 
density of a lipoprotein increases as the ratio of protein to lipid increases, hence VLDL is 
lipid-rich and protein-poor while HDL is protein-rich and lipid-poor. These classes of lipids 
differ in their lipid composition and their associated apolipoproteins. The apolipoproteins can 
function as ligands for lipoprotein receptors stimulating their uptake (such as the LDLR 
binding domain on apoB100) or as activators or inhibitors of various lipid metabolic enzymes.   
 Important apolipoproteins include apoB100, which is present in VLDL, IDL, and 
LDL; apoB48 (a truncated version 48% the size of apoB100), which is present in 
chylomicrons and chylomicron remnants; and apoA1, which is present in HDL. Most 
apolipoproteins can be synthesized in the liver with the important exception of apoB48, 
which in humans is only synthesized in the small intestine. ApoB48 lacks the LDL receptor 
binding capacity and so has a different plasma clearance profile from apoB100. In mice, 
apoB48-containing lipoproteins are synthesized in the liver as well, an important distinction 
between mouse and human lipoprotein metabolism (along with the absence of CETP, in 
mice; hamsters are actually more similar to humans in that they have CETP and cannot 
synthesize hepatic apoB48, and are so sometimes used as an alternative rodent model for 
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lipoprotein metabolism [2, 3]). 
 The liver synthesizes and secretes VLDL (which is hydrolyzed in the circulation to 
IDL and then LDL) and a precursor form of HDL. VLDL is synthesized in the Golgi and ER 
of hepatocytes through stepwise lipidation of an apolipoprotein. After entering the circulation, 
lipoproteins deliver lipids to peripheral tissues by lipolysis and may be remodeled by the gain 
or loss of apolipoproteins or by lipid exchange via CETP. Finally, LDL and IDL bind to 
receptors on the surface of hepatocytes (primarily the LDL receptor (LDLR) and LDL-related 
protein (LRP)). Largely due to the regulation of LDL uptake from circulation via LDLR, the 
liver is the primary regulator of plasma cholesterol. The receptor-bound lipoproteins are 
endocytosed into hepatocytes and their lipids are stored or re-packaged into VLDL for 
secretion. HDL made by liver or intestine takes up cholesterol from peripheral tissues, may 
be remodeled by lipid exchange by CETP, and is taken up by the liver in part by scavenger 
receptor-BI (SR-BI), after which its cholesterol is converted to bile acids and excreted. 
 Chylomicrons are synthesized in the small intestine from dietary fat following a meal 
and are transported to the vena cava, bypassing the liver to directly deliver lipids (primarily 
triglycerides) to peripheral tissues. They eventually reach the liver in the form of chylomicron 
remnants and the cholesterol and remaining triglycerides they carry are taken up by the liver 
for storage or (re-)secretion.  
  
Hepatic lipid metabolism: extra- and intrahepatic lipid sources 
 The liver takes up fat from circulation: free fatty acids (FFAs), dietary fats 
(cholesterol and to a smaller degree triglycerides) from intestinally derived chylomicron 
remnants, lipids from LDL and IDL, and lipids from HDL (primarily cholesterol). The FFAs 
are mostly derived from adipose tissue lipolysis that, in a healthy insulin sensitive individual, 
occurs mainly during fasting. Uptake of FFAs is not regulated, so FFA uptake by the liver is 
5 
 
directly proportional to the FFA concentration in plasma, and should increase during fasting 
in order to be used for fuel via fatty acid oxidation.  
 In addition to exogenous lipid uptake, lipids can be synthesized completely de novo in 
the liver by fatty acid synthase (FAS). These lipids can be further incorporated into 
phospholipids, diglycerides or triglycerides; however, in most cases FAS-derived lipids are a 
quantitatively minor contributor to stored and secreted lipid, as will be reviewed in detail 
below. De novo synthesis of cholesterol is more quantitatively important, and the bulk of 
cholesterol synthesis takes place in the liver.  
 Lipids can be stored in the liver as intrahepatic lipid droplets and released as needed: 
excessive lipid stored in this manner is referred to as fatty liver. Lipid droplets have a 
structure resembling lipoproteins: they contain a core of neutral/esterified lipids (such as 
triglycerides and cholesterol esters) surrounded by an amphipathic phospholipid monolayer 
and various structural proteins (reviewed in [4] and [5]). A large proportion of the lipid 
incorporated into VLDL for secretion seems to be derived from intrahepatic lipid droplets [6-
8]. The mechanism by which lipids are transferred from lipid droplets to lipoproteins is 
debated, with evidence both for a hydrolysis-reesterification cycle whereby droplet lipids are 
hydrolyzed to FFAs that enter the ER and are re-esterified in the ER lumen prior to 
incorporation into lipoproteins [7, 9], and for direct fusion of lipid droplets (presumably pre-
existing in the ER lumen) with pre-VLDL [10]. 
 
The fasting response 
Under nutrient-replete conditions, the primary fuel of the liver is glucose rather than 
fat. Dietary fat in the form of chylomicron remnants is taken up by the liver, but fatty acids 
are not subjected to β-oxidation and instead are incorporated into triglycerides for storage in 
lipid droplets or secretion in VLDL. De novo synthesis of fatty acids by FAS may make a 
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modest contribution to storing energy as fat when nutrients are present in excess.  
“The fasting response” refers to the adaptive changes in metabolism that occur during 
fasting or starvation in order to maintain blood glucose levels and provide alternative energy 
in the form of ketones. During fasting, the primary fuel of the liver switches to fat. Plasma 
insulin levels fall, relieving inhibition of lipases and stimulating lipolysis in peripheral tissues 
(primarily adipose tissue). This increases the levels of plasma free fatty acids (FFAs), which 
are taken up by the liver. 
In the liver, fatty acids from peripheral tissues and from intrahepatic lipid droplets are 
catabolized through ?-oxidation to form acetyl-CoA, which is either channeled into the TCA 
cycle or used as substrate to produce ketones that provide energy to other tissues when 
glucose is scarce. ?-oxidation also produces reducing equivalents in the form of FADH2 and 
NADH. Energy in the form of ATP from the TCA cycle and electron transport chain (via 
acetyl-CoA from ?-oxidation) and reducing equivalents directly derived from ?-oxidation are 
used to fuel gluconeogenesis. The process of fatty acid catabolism and glucose anabolism 
during fasting is thus interrelated through the dependency of gluconeogenesis on ?-oxidation 
for energy. 
An important protein for the fasting response in the liver is peroxisome proliferator-
activated receptor ? (PPAR?), which promotes the transcription of genes necessary for the 
fasting response (such as those encoding enzymes involved in ?-oxidation and ketogenesis). 
PPAR? will be discussed in more detail below. 
 
Hepatic lipid metabolism in the metabolic syndrome and diabetes  
The prevalence of type II diabetes is estimated to be 13% among adult Americans 
[11] and 6% (6.4%) among adults worldwide [12]. The metabolic syndrome is estimated to 
affect 24% of adult Americans [13] (criteria as defined by the National Cholesterol Education 
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Program (NCEP)).  Both diabetes and the metabolic syndrome are risk factors for 
cardiovascular disease [14, 15], which is the leading cause of death worldwide [16]. Because 
the liver is central to controlling systemic glucose and lipid metabolism, it is also central to 
understanding the pathogenesis of diabetes and for designing treatments. Many of the most 
important hyperlipidemia and diabetes drugs currently available, including metformin, statins, 
and fibrates, have the liver as their site of action. 
The diagnostic criteria for type II diabetes includes a fasting plasma glucose level 
over 126 mg/dl or 7.0 mmol/l (according to WHO and ADA recommendations [17, 18]). The 
hallmark of type II diabetes is insulin resistance, which refers to a state in which the tissues of 
the body have a decreased sensitivity and responsiveness to insulin. Because of this decreased 
responsiveness, higher levels of insulin must be produced by the pancreas in order to elicit 
desired responses, which include stimulating peripheral tissues to take up glucose and 
suppressing glucose synthesis by the liver. Type II diabetes refers to what happens when, 
because of resistance to the actions of insulin, the insulin present is no longer enough to 
maintain appropriate blood glucose levels, leading to hyperglycemia. 
The metabolic syndrome refers to risk factors that together increase the risk of 
diabetes and cardiovascular disease. The criteria for metabolic syndrome differ between 
institutions (IDF, WHO, NCEP, and AHA), but all include some combination and definition 
of central obesity, high plasma triglycerides, low HDL cholesterol, high blood pressure, and 
high fasting blood glucose or insulin resistance. These risk factors are interrelated and tend to 
cluster together. 
In insulin resistance, insulin fails to suppress lipolysis in peripheral tissues even when 
nutrients are abundant, resulting in high circulating levels of FFAs that are taken up by the 
liver. Increased FFA uptake and perhaps increased de novo synthesis of fat in the liver 
overwhelms the capacity for fatty acid oxidation, leading to fat accumulation and eventually 
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the development of hepatosteatosis or fatty liver (non-alcoholic fatty liver disease, NAFLD). 
Fatty liver has been estimated to affect a fifth to a third of adult Americans (21.4% in a 
nationally representative cohort from 1988 to 1994 [19] and 31% in a cohort from Dallas 
county from 2000 to 2002 [20]) and is associated with insulin resistance [21] and a high BMI 
[20, 21]. NAFLD thus constitutes one of the major metabolic disorders along with diabetes 
and heart disease accompanying the obesity epidemic.  
Hepatosteatosis can progress to nonalcoholic steatohepatitis (NASH), which in 
addition to fat accumulation is marked by inflammation, hepatocyte injury and/or fibrosis. A 
significant proportion of patients with NASH develop cirrhosis (10-29% within 10 years 
[22]), which in turn may progress into hepatocellular carcinoma, a type of cancer with very 
poor prognosis: the 5-year survival rate is less than 10% [23].  
Fatty liver can be diagnosed noninvasively (as was done in the studies estimating 
NAFLD mentioned above, where ultrasound [19] and proton magnetic resonance 
spectroscopy were used [20]). Diagnosing the presence of hepatic inflammation or fibrosis, 
however, requires a liver biopsy. Therapeutic options for NAFLD are very limited; there is 
currently no medical or surgical treatment for NAFLD approved by the FDA or the EMA. 
Weight loss or treatment with  the insulin-sensitizing thiazolidinedione drugs improve 
steatosis and inflammation [24, 25]; the latter, however, cause significant weight gain. There 
is thus a need for novel non-invasive diagnostic methods and for novel therapies for NAFLD 
and NASH. 
The strong association between insulin resistance and fatty liver has led to speculation 
of a bidirectional cause-and-effect relationship between the two, in essence a vicious cycle 
wherein the fatty liver caused by insulin resistance further exacerbates the insulin resistance. 
However, there are many examples of mouse models that exhibit fatty liver but have normal 
or improved insulin sensitivity [26, 27], and examples of genetic defects in humans that cause 
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fatty liver but do not affect insulin sensitivity [26]. These data suggest that fatty liver does not 
necessarily cause insulin resistance in itself [27].  
In addition to fatty liver, changes in hepatic lipoprotein metabolism lead to the 
dyslipidemia that accompanies the metabolic syndrome and insulin resistance, characterized 
by the so-called lipid triad: high levels of plasma triglycerides, low levels of HDL cholesterol, 
and the presence of small, dense LDL (sdLDL) (reviewed in [28]). Additionally, increased 
postprandial triglyceride and apoB48 levels are a hallmark of diabetic dyslipidemia [29, 30] 
and is in part due to increased intestinal chylomicron production [31, 32] and decreased 
clearance of chylomicron remnants by the liver [32, 33]. These lipid abnormalities are 
atherogenic and promote cardiovascular disease, the leading cause of death among diabetics 
(52% of type II diabetics in a multinational study by the WHO) [34] and overall (30% 
worldwide)  [16].  
The high level of plasma triglycerides is primarily due to an overproduction of 
triglyceride-rich VLDL by the liver (reviewed in [35]). This, in turn, at least partially 
originates in the increased amount of triglycerides stored in cytosolic lipid droplets resulting 
from fatty liver: stored hepatic triglycerides are quantitatively important components of 
VLDL [6, 7]. In obese patients, the degree of hepatic steatosis correlates positively with 
VLDL secretion rates [36].  
The decrease in HDL cholesterol (both in particle number as reflected by decreased 
apoA1 levels and in cholesterol content of each particle) is due to increased catabolism of 
apoA1 by the liver [37, 38] and increased activity of CETP in the plasma in transferring 
triglycerides from triglyceride-rich lipoproteins such as VLDL to HDL in exchange for 
cholesterol esters, resulting in a net depletion of HDL-associated cholesterol [39]. The 
increase in CETP-mediated lipid exchange is, to some degree, stimulated by the high levels 
of triglyceride-rich VLDL [40]. However, liver insulin receptor knockout (LIRKO) mice, a 
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model for purely hepatic insulin resistance, do not have fatty liver or hypertriglyceridemia, 
yet these mice have the low HDL cholesterol (and conversely, cholesterol-enriched VLDL) 
characteristic of the metabolic syndrome [41]. The studies on LIRKO mice suggest that the 
features of insulin resistance-associated dyslipidemia can be separated into those due to the 
hepatic fat accumulation resulting from peripheral insulin resistance (increased plasma 
triglycerides) and those due to central (hepatic) insulin resistance (decreased HDL 
cholesterol). 
The third component of the lipid triad, the presence of sdLDL, is less directly related 
to intrahepatic lipid metabolism. CETP in the plasma promotes the transfer of triglycerides 
from VLDL to LDL, and the resulting triglyceride-rich LDL is a preferred substrate for 
hepatic lipase on the surface of the liver, which hydrolyses it into sdLDL.  
  
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ?  
The peroxisome proliferator-activated receptors (PPARs) consist of three known 
nuclear receptors that have emerged as clinically significant targets for treatment of metabolic 
syndrome. Each of the three family members, PPAR?, PPAR?, and PPAR?, are key 
metabolic regulators: PPAR? controls fatty acid oxidation and is necessary for the adaptive 
responses to fasting in the liver, PPAR? is necessary for adipogenesis and promotes lipid 
storage in adipose tissue, and PPAR? is important for muscle and liver lipid metabolism.  
Drugs that target PPAR? and PPAR? are currently on the market for treatment of 
metabolic diseases: fibrate drugs target PPAR? and are used to treat dyslipidemia (reviewed 
in [42]) while thiazolidinediones target PPAR? and are used to treat type II diabetes. Fibrates 
are carboxylic acids that bind to PPAR?, thereby functioning as agonistic ligands; fenofibrate 
and gemfibrozil of this drug class are FDA-approved for treatment of hyperlipidemia.  
PPAR? activation by fibrates lowers plasma triglycerides and raises HDL cholesterol. 
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The former is due to increased clearance of plasma triglycerides by the liver [43] and, 
probably, to the decreased availability of fatty acids for triglyceride synthesis due to 
increased ß-oxidation (in mouse [44] and rat [45] liver following fenofibrate treatment). The 
increase in HDL cholesterol is dependent on increased production of the HDL 
apolipoproteins apoAI and apoAII [46, 47]. 
While PPAR? agonists have fallen out of favor due to side effects, PPAR? and 
PPAR? agonists continue to be of therapeutic interest for treating the metabolic syndrome. At 
the time of writing, a dual PPAR?/PPAR? agonist, GFT505, is in phase IIB clinical trials in 
the US and several EU countries for treatment of non-alcoholic hepatosteatosis, and in 
numerous pilot studies for treatment of dyslipidemia, obesity, and type II diabetes.  
 
Function of PPAR? in the fasting response 
PPAR? is expressed in several metabolically active tissues, including liver, muscle, 
and heart. In the liver, PPAR? is a key regulator of fatty acid metabolism and necessary for 
fasting response: PPAR?-null mice are deficient in both ketogenesis and gluconeogenesis and 
are unable to adapt when challenged with fasting, developing hypoglycemia and 
hypoketonemia [48]. PPAR? promotes the cellular uptake and catabolism of fatty acids by 
upregulating genes involved in fatty acid transport, peroxisomal and mitochondrial fatty acid 
?-oxidation, and ketogenesis, leading to an increased uptake and break-down of fatty acids to 
generate ketones, reducing equivalents and ATP when PPAR? is activated during fasting [48, 
49].  
Some important PPAR? target genes/proteins in both mice and humans (reviewed in 
[50]) that are involved in lipid metabolism include: ACO1 (encoded by Acox1), which 
catalyzes the first step in peroxisomal ?-oxidation; carnitine palmitoyl transferase 1 and 2 
(CPT1 and CPT2, encoded by Cpt1a and Cpt2, respectively), which mediate the transport of 
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long-chain fatty acids across the mitochondrial membrane such that they can be oxidized; 
FGF21 (encoded by Fgf21), a hormone important for ketogenesis; apoAI (encoded by Apoa1), 
the key apolipoprotein in HDL; and ATP-binding cassette transporter 1 (ABCA1, encoded by 
ABCA1), a cholesterol transporter. 
PPAR? is also crucial to fasting-induced gluconeogenesis. In the absence of PPAR?, 
mice become hypoglycemic within just hours of fasting onset (probably reflecting the 
reduced liver glycogen in these mice, as glucose levels are primarily maintained by 
glycogenolysis during the first hours of fasting), and the blood glucose continues to drop 
steeply as fasting progresses, reaching a low of less than half of that of the wild type controls 
after 24 hours of fasting (45 mg/dl vs. to 100 mg/dl) [48]. “Fasting” in this study and studies 
on mice and humans cited below refers to complete withdrawal of food but ad lib access to 
water. Fasting data are relative to ad lib feeding (mice) unless otherwise specified or the latest 
meal (humans). “Fasting” will be used interchangeably with “starvation.”  
The importance of PPAR? for fasting-induced gluconeogenesis may largely be due to 
the dependency of gluconeogenesis on fatty acid ?-oxidation for reducing equivalents in the 
form of NADH. ?-oxidation is a quantitatively important source of NADH: in rat liver, 
inhibition of ?-oxidation with bromooctanoate causes an over 60% reduction in NADH levels 
[51]. The decreased hepatic glucose production in PPAR?-null mice stems from a 
dramatically decreased use of lactate as a substrate for gluconeogenesis, despite normal 
lactate levels [52]. Gluconeogenesis from glycerol, on the other hand, is in fact increased 2.5-
fold in PPAR?-null mice [52]. Conversion of one molecule of lactate to pyruvate to 
eventually glyceraldehyde-3-phosphate (G3P) requires the use of two molecules of NADH 
whereas conversion of glycerol to G3P requires none, explaining how this compensatory 
increase in the glycerol-G3P arm of gluconeogenesis in PPAR?-null mice is possible. 
To some degree, PPAR? also affects glucose metabolism via expression of 
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gluconeogenic genes: the expression of pyruvate kinase is decreased 16-fold in fasted 
PPAR?-null mice [52]. However, the gene encoding phosphoenolpyruvate carboxykinase 
(PEPCK), the rate-limiting enzyme in gluconeogenesis, is expressed normally in PPAR?-null 
mice [48, 52]. 
 
Hormonal and nutritional regulation of fasting and PPAR? 
 PPAR? is activated during periods of fasting or starvation. The main physiological 
effects of PPAR? activation are increased plasma ketone levels and maintenance of 
euglycemia. Because regulation of glucose levels is complex, ketone levels are a better 
surrogate for inferring PPAR? activity and will be used as such below. Another surrogate is 
protein or mRNA expression levels of classical PPAR? target genes in the liver such as those 
mentioned above. Expression levels of the mRNA for PPAR? itself increases as well during 
fasting, but follows the same time course as induction of other PPAR? target genes [53], 
suggesting a positive feedback loop. Ligand activation occurs much sooner and is the primary 
method of regulation of PPAR?. 
 Hepatic mRNA levels of the PPAR? target genes ACO1 and CPT1 are unchanged at 
4 hours of fasting and increased 2-fold and over 4-fold, respectively, after 8 hours of fasting 
in mice [53]. Plasma levels of ?-hydroxybutyrate, a ketone body formed from fatty acid 
oxidation/ketogenesis, start increasing after 12 hours of fasting in humans [54] and sometime 
between 6 and 12 hours of fasting in mice (?-hydroxybutyrate levels are unchanged at 6 
hours of fasting [55] but 10-fold increased at 12 hours of fasting [56]), consistent with the 
time needed for the mRNA to be translated into active proteins promoting ketogenesis. We 
can conclude that in mice, PPAR? is activated sometime within the first 8 hours of fasting, 
and its physiological effects become evident within 12 hours of fasting. 
 The many changes in nutrient and hormone levels that accompany fasting make it 
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difficult to pinpoint which specific stimulus that causes this activation of PPAR?. During 
fasting, plasma insulin and leptin levels as well as plasma glucose progressively drop, while 
the levels of plasma free fatty acids and glucagon rise. In mice, insulin levels are down 70% 
by six hours of fasting [55]. In humans, insulin levels decrease at a steady rate immediately 
from the onset of fasting, decreasing by 30% after 6 hours of fasting and 50% after 12 hours 
of fasting [57]. Leptin levels decrease by 50% after 12 hours of fasting in humans [58]; in 
mice, leptin levels are start decreasing after 4 hours of fasting and are down by 75% after 12 
hours of fasting [59]. Plasma free fatty acids increase progressively from the onset of fasting, 
mirroring the decrease in insulin levels, and have increased by 60-70% at 12 hours of fasting 
in humans [57] and mice [60]. Glucagon levels are rapidly and dramatically regulated in mice, 
being increased 5-fold by 6 hours of fasting [55], but much more slowly in humans, where 
glucagon levels are unchanged after 6 hours of fasting and increased 25% by 12 hours of 
fasting [57].  
 In addition, there is species-specific regulation of hormones by fasting. In humans, 
growth hormone also starts rising after 12 hours of fasting and stimulates lipolysis [57]; in 
mice, however, growth hormone secretion is actually suppressed by fasting and does not 
affect lipolysis [59]. Levels of ghrelin, an appetite-stimulating hormone, increase two-fold by 
12 hours of fasting in mice [59], but in humans, ghrelin levels actually decrease with fasting 
(20% by 12 hours and 30% by 24 hours of fasting) [61]. Catecholamines (i.e. epinephrine and 
norepinephrine) and cortisol levels rise and fall cyclically throughout prolonged fasting in 
humans with a drop to below fed levels between 15 and 24 hours after fasting onset [57], and 
are hence probably not involved in the adaptive responses to typical fasting periods. 
 Among these stimuli, plasma glucose, insulin, glucagon, leptin, and FFA levels are 
the most likely candidates for physiological regulators of the fasting response via PPAR?, as 
they are regulated in the same direction in both mice and humans and because of the time 
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course of their increase or decrease in plasma.  
 The role of plasma glucose is difficult to study as an independent variable, and little 
information is available on the effects of glucose deprivation/overload on PPAR? targets in 
liver cell lines. In cultured primary hepatocytes, mRNA expression of Acox1, Cpt1, and Cpt2 
were unchanged by incubation with 20 mM glucose for 5 hours compared to 6 ?mM, but this 
may have been too short of an incubation time to see gene expression effects [62].  
 In mice lacking the liver insulin receptor, plasma ketone levels and expression of the 
PPAR? target gene Cpt1 are twice as high as in wild type mice during ad lib feeding (during 
fasting, plasma ketone levels are the same, Cpt1 expression ~75% higher than in controls) 
[63], suggesting that hepatic insulin signaling is important for suppression of the fasting 
response/PPAR? activity during feeding.  
 Fasting induction of some, but not all, PPAR? target genes is abolished in mice 
lacking glucagon receptor, and treatment of hepatocytes with glucagon induces expression of 
PPAR? target genes and fatty acid oxidation, the latter demonstrated to be in a PPAR?-
dependent manner [64].  
 Mice lacking leptin (ob/ob) have increased expression of Cpt1 in the ad lib fed state 
compared to wild type mice (information is lacking about its fasting induction, however), 
[65], but interpretation with regards to any direct role of leptin in promoting the fasting 
response is complicated by the obesity and insulin resistance of the ob/ob mice; insulin 
resistance would blunt insulin suppression of the fasting response in the fed state, and the 
mice have elevated circulating FFAs. Any role of FFAs in activating the fasting response is 
difficult to study in vivo due to the lack of any single FFA receptor or transporter that can be 
genetically modified, but in vitro, various long-chain fatty acids activate PPAR? 
(demonstrated using a PPRE-containing reporter gene); these experiments were among the 
first studies on PPAR? [66]. 
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 In summary, the interrelationship between circulating nutrients and hormones makes 
it difficult to study the effects of a single nutrient or hormone on PPAR?. However, thanks to 
studies on mice lacking liver insulin receptor and on mice lacking (whole-body) glucagon 
receptor, we can conclude that hepatic insulin signaling is important for suppressing PPAR? 
activity during feeding, while glucagon signaling is important for induction of PPAR? 
activity during fasting. 
 
Ligand activation of PPAR? 
PPAR? is primarily ligand-activated. Ligand binding causes it to adopt an active 
conformation and heterodimerize with the nuclear receptor retinoid X receptor-alpha (RXR?), 
allowing the PPAR?-RXR? complex to bind to peroxisome proliferator response elements 
(PPREs) on target genes and activate gene transcription [67, 68].  
While the fibrate drugs previously described are synthetic agonistic ligands for 
PPAR?, a physiological ligand for PPAR? was only identified recently [69]: in mouse liver, 
the phosphatidylcholine (PC) species 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine 
(16:0/18:1-GPC) acts as an endogenously synthesized PPAR? ligand [69]. The interaction 
between this particular ligand and PPAR? requires the activity of fatty acid synthase (FAS; 
described in more detail below) as well as choline-ethanolamine phosphotransferase-1 
(CEPT1), the enzyme catalyzing the final step in PC synthesis [69, 70].  
It is not known how the 16:0/18:1-GPC ligand reaches PPAR? from CEPT1. CEPT1 
is localized to the ER and nuclear membranes (the active site facing the cytoplasm) [71], 
while PPAR? is localized to the nucleus [72], precluding a direct interaction between CEPT1 
and PPAR?. Simple diffusion of the ligand is unlikely to be a physiologically relevant 
mechanism of transport, as the cytoplasmic movement of amphipathic molecules such as PC 
is extremely inefficient [73]. A more likely possibility is that the PC ligand is transported to 
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PPAR? in association with a soluble lipid-binding protein.  
 
FATTY ACID SYNTHASE 
 Fatty acid synthase (FAS, encoded by Fasn) catalyzes the biosynthesis of saturated 
fatty acids from simple precursors (de novo lipogenesis). The primary product of the FAS 
reaction is palmitate (C16:0), but stearate (C18:0) and shorter fatty acids may also be 
produced. FAS substrates are acetyl-CoA, malonyl-CoA, and NADPH. Acetyl-CoA functions 
as a primer for the reaction, while NADPH provides reducing equivalents. The fatty acid is 
elongated from the initial acetyl-CoA by repeated condensations with malonyl-CoA, which 
donates two carbons in each cycle of condensation. Palmitate synthesis thus requires seven 
cycles of malonyl-CoA addition to an acetyl-CoA primer to yield a saturated, 16-carbon fatty 
acid. 
 The FAS protein exists as a homodimer of 273 kDa subunits. Each monomer contains 
seven protein domains required for fatty acid synthesis: acyl carrier, acyl transferase, ?-
ketoacyl synthase, ?-ketoacyl reductase, ?-hydroxylacyl dehydratase, enoyl reductase, and 
thioesterase (reviewed in [74-76]). However, FAS is only enzymatically active in the dimeric 
form [77]. The monomers were initially thought to be oriented head-to-tail to form the dimer 
[78, 79], but recent structural data demonstrate a head-to-head orientation of the monomers 
that are intertwined at their middle to form an X-shape [80-83]. Mammalian FAS is a type I 
FAS complex with the domains consolidated in a single peptide; prokaryotes and yeast have a 
type II FAS with separate proteins catalyzing the individual reactions. Type II FAS 
complexes capable of synthesizing short-chain (up to 14 carbons) fatty acids are also found in 
mammalian mitochondria [84]. 
 FAS is a soluble protein and thought to be localized in the cytoplasm, although the 
specifics of its subcellular localization are largely unexplored. Its tissue distribution is broad 
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with highest levels in the liver, adipose tissue, and lungs [85, 86]. Whole-body knockout of 
FAS causes embryonic lethality in mice, suggesting that de novo lipogenesis is necessary 
early during development [87]. A likely possibility is that FAS is required to provide lipids 
for cell membranes of the growing embryo. Viable tissue-specific FAS knockout mice have 
been generated, including a liver-specific knockout (discussed below). 
 
Functions of hepatic FAS: Contribution to stored and secreted lipids 
Hepatic FAS synthesizes lipids that are stored as lipid droplets or secreted in VLDL in 
the fed state. In mice, the contribution of liver FAS to secreted VLDL is minor. Ob/ob mice 
have 10-fold increased hepatic de novo lipogenesis compared to lean mice, but no significant 
differences in serum triglycerides [88]. In mice with liver-specific knockout of FAS 
(FASKOL mice), serum triglycerides are normal on a chow diet [69].  
The contribution of de novo lipogenesis to secreted triglycerides has been studied in 
humans in the setting of various diets. On diets low in fat and high in carbohydrate (10% of 
calories as fat and 75% as carbohydrate), de novo lipogenesis makes a significant 
contribution to circulating lipids as almost half of VLDL triglyceride is derived from de novo 
lipogenesis under these conditions [89]. However, a typical Western diet is high in fat as well 
as carbohydrates. In similar studies using diets higher in fat (30% fat and 55% carbohydrate 
or 40% fat and 45% carbohydrate), the contribution of de novo lipogenesis to VLDL 
triglycerides is undetectable or minor, at 0-10% [89, 90]. These diets are more representative 
of the high fat, high carbohydrate content of a typical Western diet, indicating that under 
common dietary conditions, de novo lipogenesis is not a significant contributor to VLDL 
triglycerides. Substituting starch for sugar in a high-carbohydrate diet also decreases the 
contribution of de novo lipogenesis to 0-1% or 5% [91, 92]. Obese individuals do not appear 
to have increased FAS-derived VLDL triglycerides compared to lean individuals [90]. Under 
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the high-fat, high-carbohydrate dietary conditions common in the Western world today, 
hepatic FAS thus appears to be a minor contributor to VLDL triglycerides. 
FAS may contribute to triglycerides stored in hepatic lipid droplets. In rats fed a chow 
diet, 11 ± 1% of hepatic triglycerides are derived from de novo lipogenesis [93]. On a high-
fat diet, de novo lipogenesis is suppressed and only 1.0 ± 0.2% of hepatic triglycerides are 
derived from FAS [93]. FASKOL mice (animals with inactivation of FAS in the liver) on a 
chow diet have normal, rather than decreased, liver triglyceride content [69]. It thus appears 
that the contribution of de novo lipogenesis to stored triglycerides is small in healthy liver.  
In fatty liver, the contribution of FAS to intrahepatic triglycerides may be greater. 
Ob/ob mice have increased hepatic FAS activity and fatty liver [94], but a mechanistic link 
between the two has not been established. In humans with non-alcoholic fatty liver disease, 
one group has reported that 26 ± 7% of hepatic triglycerides are derived from de novo 
lipogenesis [95]. It is unknown how this compares to the triglyceride content of healthy 
human liver. However, even in the setting of hepatic over-accumulation of fat, the 
contribution of FAS appears to be less than that of fats derived from peripheral tissues or 
dietary fat. 
 
Functions of hepatic FAS: FAS-dependent ligand activation of PPAR? 
When liver-specific fatty acid synthase knockout (FASKOL) mice were generated, 
they were surprisingly not protected against hepatic lipid accumulation, but instead developed 
severe hepatic steatosis when on a zero-fat diet or with prolonged fasting [70]. The phenotype 
of fasted or zero-fat diet-fed FASKOL mice is similar to that of PPAR?-null mice: 
hypoglycemia, low serum ketone levels, marked hepatic steatosis, and deficient hepatic fatty 
acid oxidation [49, 70]. Much of this phenotype was corrected by administration of a known 
PPAR? agonist.  
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The deficient PPAR? activation in the absence of both FAS and dietary fat led to the 
hypothesis that “new” fat, derived from de novo lipogenesis or dietary fat, can activate 
PPAR?, whereas “old” fat, derived from peripheral tissues or stored in the liver, cannot. 
Hydrolysis of hepatic triglycerides has also been shown to mediate PPAR? activation [96], 
suggesting that triglycerides of different origins (de novo synthesis vs. free fatty acids 
entering the liver following lipolysis in peripheral tissues) may occupy separate 
compartments in the hepatocyte.  
In addition to activating PPAR? in liver, FAS has been shown to regulate PPAR? in 
macrophages [97] and hypothalamus [98] as well; knock-out of FAS in these tissues leads to 
decreased expression of PPAR? target genes which can be rescued by administration of a 
PPAR? agonist. 
Further study of the FASKOL mouse led to the identification of an endogenous ligand 
for hepatic PPAR?: the phosphatidylcholine species 16:0/18:1-glycerophosphocholine [69], 
also described above. The interaction of this species with PPAR? is dependent on the activity 
of FAS, and inactivation of choline/ethanolamine phosphotransferase 1 (CEPT1), the enzyme 
catalyzing the final step in the Kennedy pathway for phosphatidylcholine biosynthesis, 
mimics the FASKOL phenotype [69]. The dependency of PPAR? activity on FAS is likely 
mediated by its provision of substrate for CEPT1, ultimately producing ligand for PPAR?: 
long-chain fatty acids generated by FAS may be converted to acyl-CoA and then 
diacylglycerol, which can combine with phosphocholine to form phosphatidylcholine in the 
reaction catalyzed by CEPT1. 
A summary of the impact of FAS on hepatic triglyceride metabolism is presented in 
Figure 1. 
 
Modulating hepatic FAS to treat disease  
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  Ob/ob mice have increased hepatic FAS gene expression as well as increased hepatic 
FAS activity compared to lean mice [94]. Knockdown of the transcription factor 
carbohydrate response element binding protein (ChREBP), which promotes the expression of 
FAS as well as other genes, in ob/ob liver decreases hepatic lipid accumulation and decreases 
hepatic lipogenesis, suggesting a link between de novo lipogenesis by FAS and fatty liver 
[99]. However, in a gene expression profiling study of ob/ob animals separated into high 
glucose and lower glucose groups, mice with lower sugars (and thus likely to be more insulin 
sensitive) had higher hepatic expression levels of genes encoding lipogenic enzymes, 
including FAS, as compared to mice with higher sugars [100]. This finding suggests that 
while activation of lipogenic enzymes in the liver is associated with obesity, this effect is 
unlikely to be mechanistically linked to insulin resistance. 
FAS inhibitors have been tested in mouse models of obesity and diabetes. Treatment 
of lean or obese mice with the FAS inhibitor C75 causes dramatic weight loss and 
improvement of hepatic steatosis in obese mice. However, the effect is primarily mediated by 
reduced food intake through inhibition of hypothalamic FAS (in addition to possible effects 
of this particular agent that are independent of FAS), obscuring the potential effects of 
modulating hepatic FAS [101].  
The FAS inhibitor platensimycin is concentrated in the liver when administered orally 
and does not affect food intake [102]. Treatment of high-fructose diet-fed db/db mice with 
platensimycin reduces hepatic FAS activity, hepatic lipid accumulation, and hepatic fatty acid 
oxidation [102]. These data are consistent with roles for hepatic FAS both as a producer of fat 
that may accumulate in liver, and as a generator of lipid signals to nuclear receptors such as 
PPAR?.  
These data also highlight a caveat when considering FAS inhibitors as therapy for 
hepatic steatosis: inhibition of FAS can affect both lipid storage and lipid catabolism, and 
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under conditions where baseline FAS activity is not particularly high, loss of FAS activity 
might aggravate rather than ameliorate hepatic steatosis, as seen in the liver-specific FAS 
knockout mice [70].  
 
Regulation of FAS: Hormonal and nutritional regulation 
Hepatic FAS is known to be regulated by insulin, glucagon, cyclic AMP, fructose, 
glucose, and dietary fat. The long-term effects of hormones and nutrients on FAS expression 
are clear, but their immediate effects are poorly understood.  
  Re-feeding mice or rats a high-carbohydrate diet following a prolonged fast causes a 
robust induction of FAS expression as compared to the fasted or the ad lib-fed state [103-
106]. The effect of carbohydrate re-feeding is mediated by both insulin and glucose. Insulin 
regulates FAS through transcriptional and non-transcriptional mechanisms. Under nutrient-
replete conditions, de novo lipogenesis may promote storage of excess energy in the form of 
hepatic triglycerides. Insulin promotes FAS expression through activation of the transcription 
factors sterol regulatory element binding protein 1c (SREBP-1c) [107] and upstream 
stimulatory factors 1 and 2 (USF1 and USF2) [108, 109]. Conversely, glucagon and cyclic 
AMP inhibit the increase in FAS activity induced by carbohydrate re-feeding in rats [103, 
110, 111].  
  The effect of fasting compared to ad lib feeding on the activity of hepatic FAS is less 
clear. In mice, a 6 hour fast reduces FAS expression levels by 60% compared to ad lib 
feeding [105], and in rats, a 24 hour fast reduces FAS expression by over 90% compared to 
ad lib feeding [106]. However, a 14-hour fast in mice produces no change in FAS activity 
compared to ad lib-fed mice [112]. One potential explanation for the lack of change in FAS 
activity in some circumstance could be a relatively long half-life for the FAS protein. It is 
possible that changes in FAS gene expression might have little effect on FAS enzyme activity 
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in response to certain physiologically relevant periods of fasting as compared to the ad lib fed 
condition. 
  While insulin promotes the expression of FAS, insulin also acutely inhibits the 
enzymatic activity of hepatic FAS, causing a decrease in FAS activity within minutes [112]. 
This inhibition is dependent on the presence of the carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1), which is phosphorylated in response to insulin and 
subsequently associates with FAS [112]. The acute inhibition of FAS by insulin is blunted in 
hyperinsulinemic ob/ob mice [112]. While a clear physiological role for this acute inhibition 
of FAS activity has not been determined, it is possible that the acute effect on FAS by insulin 
primarily affects FAS lipid signals that impact PPAR?. Acute inhibition of FAS in response 
to insulin could then serve to halt the fasting response by PPAR?  and decrease fatty acid 
oxidation when nutrients are abundant. Because the specific activity of FAS is affected, the 
effect is likely post-translationally mediated. In contrast, the long-term effect of insulin on 
FAS is transcriptionally mediated and promotes FAS expression, enabling increased storage 
of energy as fat.  
  Carbohydrates directly promote the expression of hepatic FAS in the liver in addition 
to having an indirect effect by stimulating insulin secretion. Feeding mice a high-glucose or 
high-fructose diet for one week leads to 3-fold and 8-fold, respectively, increases in FAS 
protein [113]. The effect of glucose on FAS expression is mediated by ChREBP [114-117]. 
Hepatic metabolism of glucose by glucokinase (GK) is necessary for the glucose-mediated 
induction of FAS by ChREBP [118]. The insulin-induced activation of SREBP-1c and the 
glucose-induced activation of ChREBP act synergistically to promote FAS expression [118]. 
A connection between lipid/carbohydrate sensing and metabolism is suggested by the finding 
that stearoyl-CoA desaturase (Scd1), an enzyme catalyzing the synthesis of oleate, is 
involved in the carbohydrate-induced induction of FAS and other lipogenic enzymes [113]. 
24 
 
  Dietary fats inhibit FAS expression to decrease de novo lipogenesis when fats are 
already abundant. Polyunsaturated fatty acids (PUFAs) may decrease FAS expression 
through inhibition of SREBP-1c [119] and ChREBP [120] activity. Diets consisting of 10% 
oil inhibit hepatic FAS activity when fed to rats of over the course of 4 weeks, with the 
greatest reduction in rats fed fish oil [121]. Re-feeding rats a carbohydrate-free, high-fat diet 
following fasting suppresses FAS gene expression to levels as low as those seen in rats fasted 
for 24 hours [106].  
 
Regulation of FAS: Transcription and the FAS promoter 
  Transcriptional regulation of FAS has been well characterized. Much of the work on 
transcriptional regulation of FAS has been done in rats, but the FAS promoter is highly 
conserved between species suggesting that studies of the rat FAS promoter are likely to be 
relevant to mice and humans. Regulatory elements and transcription factor binding sites in 
the proximal mouse FAS promoter are shown in Figure 2. 
  As noted above, SREBP-1c is activated by insulin and under appropriate conditions 
promotes expression of lipogenic genes, including FAS. The FAS promoter contains a sterol 
regulatory element (SRE) at -150 as well as tandem SREs at positions -72 and -62 that are 
required for optimal SREBP-1c-mediated activation of FAS expression in rats [122-124]. 
  An inverted CCAAT box at -94 is a binding site for nuclear factor Y (NF-Y) and is 
necessary for inhibition of FAS expression by cyclic AMP [125, 126]. A binding site for the 
transcription factor specificity factor 1 (Sp1) is located nearby at -91 [124]. NF-Y and Sp1 
proteins interact [127] and mediate sterol-induced FAS expression synergistically with 
SREBP-1c [124, 128]. Another transcription factor, X-box binding protein 1 (XBP1), 
increases FAS promoter activity indirectly via SREBP-1c [129]. 
  Also as noted above, ChREBP plays a central role in the glucose-induced 
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transcriptional regulation of FAS as well as other lipogenic and glycolytic genes in the liver 
[114-117]. Glucose promotes the nuclear translocation and activation of ChREBP, while 
polyunsaturated fatty acids and cyclic AMP inhibit ChREBP activity [120, 130]. ChREBP 
binds to a carbohydrate response element (ChRE) located at -7214 in the distal FAS promoter 
in rats to activate FAS transcription [131]. ChREBP appears to be the main regulator of 
glucose-induced FAS expression, as glucose fails to induce an increase in FAS expression in 
ChREBP-null hepatocytes [114]. Mice fed a high-fructose diet have similar amounts of 
nuclear ChREBP protein and ChRE-bound ChREBP protein compared to mice fed a high-
glucose diet, suggesting that dietary fructose and glucose have comparable effects on 
ChREBP [132].  
  In addition to the ChRE, a direct repeat-1 (DR-1) element located between -7110 and 
-7090 in the distal promoter of rat FAS is necessary for full glucose activation of FAS 
expression [133]. Hepatic nuclear factor-4? (HNF-4?) binds to the DR-1 element and 
interacts with ChREBP. Ablation of HNF-4? produces a corresponding decrease in glucose-
induced FAS expression [133]. 
  Liver X receptor (LXR), a transcription factor activated by oxysterols, upregulates 
FAS expression through direct and indirect mechanisms. Indirectly, LXR can promote FAS 
expression by binding to liver X receptor elements (LXREs) in the promoters of the SREBP 
[134] and ChREBP [135] genes to promote their transcription. SREBP and ChREBP in turn 
activate FAS transcription. The LXR-mediated activation of SREBP-1c is the primary 
mechanism of insulin-induced SREBP activation [134]. The physiological relevance of LXR-
mediated transcriptional regulation of ChREBP is debated, as LXR is not necessary for the 
glucose-induced activation of ChREBP [117]. LXR can also bind directly to LXREs located 
at positions -686 to -672 of the mouse FAS promoter to activate FAS transcription [136]. 
  An insulin response element (IRE) containing an E-box DNA binding motif is located 
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at positions -71 to -50 of the FAS promoter, overlapping two tandem SREs. The IRE is 
necessary for insulin-induced FAS expression [137]. USF1 and USF2 bind to the IRE [109]. 
Mutation of the E-box prevents USF binding and abolishes insulin-induced FAS expression. 
However, the importance of USFs in insulin-stimulated FAS expression remains unclear, 
because mutation of the E-box also prevented SREBP-1c binding [108]. 
 
Regulation of FAS: Post-translational regulation   
  While its transcriptional regulation has been well characterized, little has been known 
about post-translational regulation of FAS activity.  
  Transcriptional regulation of FAS may require hours to affect protein levels since 
both FAS mRNA and protein are fairly stable, buffering sudden changes due to increased 
transcription and subsequent translation. There are several reports of FAS protein being 
activated or inhibited in far shorter time frames, as well as reports of changes in FAS activity 
that do not correlate with changes in FAS protein levels.  
  Insulin acutely decreases FAS enzyme activity. In hepatoma cells, FAS activity 
decreases linearly from 2 to 15 minutes after insulin treatment, followed by an increase in 
FAS activity for 75 minutes [112].  Peroxynitrate inhibits FAS activity in adipocytes within 
10 minutes, without any effect on FAS protein levels [138]. Activation and inhibition of FAS 
without corresponding changes in FAS protein levels have been reported in a variety of 
cancer cell lines [139-141]. These data suggest the presence of post-translational regulation 
of FAS.  
  Phosphorylation has been proposed as a mechanism of FAS regulation in cancer cells, 
adipocytes, and liver. In livers from pigeons that were fasted and then re-fed, radiolabeled 
phosphate was incorporated into FAS only in the cytosolic fraction of the liver (the 
membrane fraction was not studied). The phosphorylation event was associated with low 
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FAS activity, and dephosphorylation of FAS by incubation with phosphatases caused a 20-
fold increase in FAS activity [142]. Another inhibitory phosphorylation was demonstrated in 
3T3L1 adipocytes, where FAS threonine phosphorylation was associated with inhibition of 
FAS activity [138]. This phosphorylation event was shown to require AMP-activated kinase 
(AMPK), likely through indirect effects since in vitro kinase assays failed to demonstrate any 
incorporation of labeled phosphate into FAS in the presence of AMPK [138]. These findings 
suggest the presence of an unidentified intermediate kinase step. 
  In human and mouse breast cancer cell lines, the finding that large differences in FAS 
activity between cell lines did not correlate with FAS protein levels prompted an exploration 
of FAS phosphorylation as an alternative mechanism of FAS regulation [140]. Phosphoserine 
and phosphothreonine residues were detected in FAS in cell lines from both species, while 
FAS phosphotyrosine residues were detected in human cells only. Phosphorylation of FAS in 
these cell lines was associated with greater FAS activity [140]. Recently, tyrosine 
phosphorylation of FAS was noted in two different human breast cancer cell lines. Both FAS 
tyrosine phosphorylation and FAS activity were induced by overexpression of human 
epidermal growth factor receptor 2 (HER2) and decreased by HER2 inhibition, and FAS was 
phosphorylated when complexed with HER2 [141]. 
  In addition to phosphorylation, FAS was one of a large number of hepatic metabolic 
enzymes recently found to be lysine acetylated [143]. Acetylation was linked with diverse 
effects on metabolic enzymes, including protein destabilization, activation, and inhibition, 
suggesting that acetylation may play a major role in metabolic regulation. Acetylation of FAS 
could represent a novel mechanism for controlling its activity. 
   Known examples of post-translational regulation of FAS are summarized in Table 1.  
 
CONCLUSIONS AND DISSERTATION OBJECTIVES 
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 A physiological ligand for hepatic PPAR? was identified in 16:0/18:1-
glycerophosphocholine, but is not known how activation of  PPAR? by this ligand is 
regulated—by synthesis, delivery, or breakdown—such that PPAR? is activated within the 
first few hours of food withdrawal and inactivated as soon as nutrients and insulin become 
abundant again. The role of FAS in synthesizing this ligand does little to aid our 
understanding. FAS is thought to be primarily regulated transcriptionally and to be activated 
after feeding. With the long half-life of the FAS protein, transcriptional regulation of FAS 
would be irrelevant for the time frame of fasting-induced changes. The postprandial 
activation of FAS is paradoxical—how can FAS be necessary for endogenous activation of 
the fasting response, when lipogenesis by FAS supposedly occurs after re-feeding? 
 Regulation of ligand synthesis aside, how the poorly soluble 16:0/18:1-
glycerophosphocholine ligand would reach PPAR? in the nucleus from its site of synthesis on 
the cytoplasmic side of the ER and nuclear membranes is also unknown. The regulation of 
ligand transport could be another node of regulation of PPAR? in response to nutrient 
availability or insulin/glucagon action. 
 The objective of the research presented in this dissertation is to define the regulation 
of ligand-based PPAR? activation in the liver. I have focused on two nodes of regulation: that 
of ligand synthesis by FAS, and that of ligand delivery by a lipid-binding protein. Here, I 
present research demonstrating subcellular compartmentalization of FAS protein for different 
physiological functions; post-translational regulation of FAS in the form of compartment-
specific inhibitory phosphorylations of a FAS active site in response to insulin or feeding; 
and nucleo-cytoplasmic transport of endogenously synthesized PPAR? ligand by 
phosphatidylcholine transfer protein (PCTP).  
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FIGURES 
 
 
 
Figure 1. The role of FAS in hepatic lipid metabolism. Fatty acid synthase controls fatty 
acid catabolism through the synthesis of a ligand for PPAR?, which activates fatty acid 
oxidation genes. FAS makes a minor contribution of lipids to stored and secreted 
triglycerides, with the major contributions coming from plasma free fatty acids and dietary 
fats from chylomicron remnants. Abbreviations: 16:0/18:1 GPC, 16:0/18:1-
glycerophosphocholine; DAG, diacylglycerol; FAS, fatty acid synthase; FFA, free fatty acid; 
PPAR?, peroxisome proliferator-activated receptor alpha; RXR, retinoid X receptor; TAG, 
triacylglycerol (triglyceride); VLDL, very low-density lipoprotein.  
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Figure 2. The mouse proximal FAS promoter. Regulatory elements and nuclear factor 
binding site nucleotides are highlighted in yellow. IRE, insulin response element; LXRE, 
liver X receptor element; Nf-Y, nuclear factor Y binding site; Sp1, specificity factor 1 
binding site; SRE, sterol regulatory element. 
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TABLES 
 
Type of post-translational 
modification 
Organism and tissue or cell type Function 
Phosphorylation [142] Pigeon liver FAS inhibition 
Threonine phosphorylation 
[138] 
3T3-L1 adipocytes (mouse) FAS inhibition 
Threonine and serine 
phosphorylation [140] 
NMuMG (mouse mammary epithelial 
cells), T1 (mouse mammary tumor 
cells), SKBr3 (human breast 
carcinoma cells) 
Unknown, 
possibly FAS 
activation 
Tyrosine phosphorylation [140, 
141] 
SKBr3 (human breast carcinoma 
cells) 
FAS activation 
Acetylation [143] Human liver Unknown 
 
Table 1. Post-translational modifications of FAS. 
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Chapter 2: 
 
Differential Subcellular Localization of FAS may be  
Mediated by Interactions with Septin-2 and Septin-7 
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ABSTRACT 
 Fatty acid synthase (FAS) is a lipogenic enzyme functioning both in signaling, by 
promoting synthesis of lipid ligands and signaling molecules, and in energy balance, by 
synthesizing fat for storage of calories. In the liver, FAS exists in two distinct subcellular 
pools: cytoplasmic FAS and membrane FAS. These two pools are differentially regulated and 
appear to be specialized for different physiological functions.  
 Membrane FAS is associated with intracellular membranes through a strong 
peripheral interaction, but the nature of this interaction—whether it is mediated by a lipid 
anchor, by an interaction with another protein, or otherwise—is unknown. We hypothesized 
that hepatic FAS associates with membranes through a protein-protein interaction with a 
membrane-resident protein. To identify candidate proteins for localizing FAS to membranes, 
we used a proteomics approach to comprehensively identify proteins co-precipitating with 
FAS in the cytoplasmic and membrane fractions of two different liver model systems: Hepa1-
6 immortalized hepatocytes and C57/BL6J mouse liver.  
 We identified three proteins—Septin-2, Septin-7, and 40S ribosomal protein S18—
that in two different liver model systems associate with fatty acid synthase exclusively in the 
membrane fraction.  Because the septins are involved in membrane structuring and 
scaffolding, these proteins are possible mediators of FAS membrane localization.  
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INTRODUCTION 
The lipogenic enzyme fatty acid synthase (FAS) is highly expressed in liver and 
involved in several aspects of hepatic metabolism. FAS synthesizes long-chain fatty acids 
that can be incorporated into hepatic lipid droplets or secreted in lipoproteins. Additionally, 
FAS is necessary for generating an endogenous ligand for peroxisome proliferator-activated 
receptor ? (PPAR?) in liver [1]. PPAR? is a nuclear receptor and the primary mediator of the 
fasting response, the adaptive changes in metabolism that occur during fasting or starvation. 
The involvement of FAS in both synthesis of lipids for energy storage as well as the synthesis 
of a lipid ligand to activate the fasting response during energy depletion is paradoxical.  
FAS is localized to both the cytoplasm as well as to the ER and Golgi membranes [2]. 
The involvement of FAS in opposing processes (storage of excess energy and the fasting 
response) is explained by the cytoplasmic FAS and the membrane-associated FAS having 
distinct physiological functions; cytoplasmic FAS is active during starvation to generate 
PPAR? ligand, and membrane-associated FAS is active during feeding, probably to generate 
lipids for incorporation into lipid droplets or VLDL [2].  
The association of FAS with the ER and Golgi is mediated by a strong peripheral 
membrane interaction [2], but the nature of this interaction is unknown. A peripheral 
membrane association can be mediated by lipid anchoring, by ionic or electrostatic 
interactions between the protein and membrane lipids, by an interaction between a 
hydrophobic loop or amphipathic ?-helix and the membrane (the ?-helix being in-plane with 
the membrane with the hydrophilic side facing the cytosol or organelle lumen), or by a 
protein-protein association with another membrane-resident protein.  
Mass spectrometric analysis failed to detect any lipid anchors or other post-
translational modifications of the FAS protein that could act as anchors [2]. There are 
currently no known exposed hydrophobic loops or ?-helices in the FAS protein. Furthermore, 
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if FAS were associated with membranes through a direct protein-membrane interaction, then 
we would expect all FAS molecules to be membrane-associated, or the cytoplasmic FAS 
molecules to have some sort of modification obscuring the membrane association domain. 
However, FAS exists in both cytoplasmic and membrane-associated compartments, and no 
post-translational modifications characteristic of all FAS in a specific compartment could be 
identified [2].  
Instead, we hypothesized that FAS associates with membranes through a protein-
protein interaction with a membrane-resident protein, likely an integral membrane protein 
because of the strength of the interaction between FAS and membranes. If this membrane-
resident protein is less abundant than FAS in the cell, then the membrane-resident protein 
would be saturated with FAS and be the limiting factor determining membrane residence of 
FAS, thus explaining how the two distinct cytoplasmic and membrane pools of FAS can exist 
despite the primary structure of the protein being identical between pools. 
Here, we used a proteomic approach to identify FAS-associated proteins in the 
cytoplasmic and membrane fractions of a liver cell line and of mouse liver. We identified 
three proteins that are FAS-interactors exclusively in the membrane fraction and that were 
found in both model systems. Out of these, two (Septin-2 and Septin-7) are members of the 
septin class of proteins, which is known to be involved in membrane structuring, scaffolding, 
and compartmentalization, marking these FAS-interacting proteins as potential mediators of 
FAS membrane localization.  
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MATERIALS AND METHODS 
 Animals. A six-month old female C57BL/6J mouse was used as a source of liver for 
the mass spectrometric analysis of proteins. 
 Cell culture. Hepa1-6 cells were maintained in DMEM + 10% FBS until switching to 
SILAC (see below) media. The SILAC media contained 10% dialyzed FBS. 
 SILAC labeling. Hepa1-6 cells were differentially labeled using the stable isotope 
labeling with amino acids in cell culture (SILAC) technique  [3, 4] by growing the cells for 6 
passages in SILAC media containing “heavy” 13C6 L-lysine or “light” 12C6 L-lysine (Thermo 
Scientific), ensuring over 99% incorporation of labeled amino acid into the cellular proteome.  
Subcellular fractionation. To fractionate mouse liver, perfused liver from a 
C57BL/6J mouse was homogenized in 20 mM HEPES buffer (pH 7.4) and centrifuged at 
10,000 g for 45 min. The pellet was discarded and the supernatant spun at 179,000 g for 90 
min at 4°C. The resulting supernatant (cytoplasm) was transferred to a fresh tube. Because 
the association of FAS with membranes is resistant to high salt treatment [2], the pellet (crude 
membrane fraction) was then resuspended in 20 mM HEPES buffer containing 1 M NaCl and 
incubated for 30 min in order to dissociate irrelevant proteins from the membrane. After 
spinning the sample again for 90 min, the supernatant was discarded and the pellet (crude 
membrane fraction) was resuspended in a detergent-containing buffer. All spins were done at 
4°C.  
To fractionate Hepa1-6 cells, “light” and “heavy” cells were harvested in 20 mM 
HEPES buffer and centrifuged at 10,000 g for 10 min. The pellets were discarded and the 
supernatants centrifuged at 179,000 g for 2 h. The supernatants (cytoplasm) were removed 
and the pellets (crude membrane fraction) were washed and resuspended.   
 Antibodies and immunoprecipitations. Rabbit polyclonal antibody against FAS 
(ab22759) from Abcam was used to immunoprecipitated FAS. Non-immune rabbit serum 
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from Jackson Immunoresearch was used for control immunoprecipitations. 
For liver, FAS was immunoprecipitated from 1.2 mg of cytoplasmic or membrane 
protein by overnight incubation using a polyclonal rabbit anti-FAS antibody. For Hepa1-6 
cells, equal amounts of cytoplasmic protein from “light” and “heavy” cells and equal amounts 
of membrane protein from “light” and “heavy” cells were used for immunoprecipitation of 
FAS (“light” cells) using a polyclonal rabbit anti-FAS antibody or for a control 
immunoprecipitation (“light” cells) with non-immune rabbit serum. After overnight 
incubations at 4°C with antibodies or non-immune serum, IgG agarose beads were added and 
the samples incubated for another 1 h.  
Mass spectrometry. IP beads were washed, boiled in sample buffer, and subjected to 
SDS-PAGE. The gel was stained with Coomassie, the gel segment corresponding to FAS was 
excised and further cut into small pieces (1 mm2), destained with 50% CH3CN containing 25 
mM NH4HCO3, dehydrated, reduced with 20 mM DTT for 1 h at 55°C, washed and 
dehydrated, alkylated with 100 mM iodoacetamide for 1 h in the dark at room temperature, 
then subjected to cycles of washing and dehydration followed by drying in a centrifugal 
evaporator. In-gel digestion was performed with 0.02 mg/ml trypsin overnight at 37°C. 
Peptides were extracted from the gel pieces using 5% TFA in 50% CH3CN and reconstituted 
in 0.1% FA in 3% CH3CN. 
Samples were then analyzed by LC-MS/MS with a NanoLC-LTQ-Orbitrap mass 
spectrometer (Thermo Fisher Scientific) in data dependent mode. Acquired spectra were 
searched against the Swiss-Prot database through the Mascot server to identify proteins.
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RESULTS 
To identify candidate proteins localizing FAS to membranes, we comprehensively 
surveyed FAS-associated proteins in the cytoplasmic and membrane fractions of mouse liver 
and in a liver cell line by mass spectrometric analysis of proteins pulled down during 
immunoprecipitation of FAS. To narrow the list of candidates, we looked for proteins that 
were 1) exclusively found in the membrane fraction, 2) found in the membrane fractions of 
both model systems, and, preferably, 3) known integral membrane proteins.  
 FAS-associated proteins in mouse liver cytoplasm and membrane. To identify FAS-
associated proteins in mouse liver, perfused liver was fractionated into a crude membrane 
fraction and a cytoplasmic fraction. FAS was immunoprecipitated from both membrane and 
cytoplasmic fractions using an anti-FAS antibody and the peptides pulled down were 
analyzed by mass spectrometry. FAS interactors identified in cytoplasm and membrane of 
mouse liver are listed in Table 1 and Table 2, respectively, along with the number of peptides 
identified for each protein and the protein score (or Mascot score) for each protein. A cut-off 
protein score of 100, reflecting a confidence level over 95% for protein identification, was 
used to determine likely specific interactors. 49 likely FAS interactors were identified in the 
cytoplasmic fraction and 50 likely interactors in the membrane fraction. 
 FAS-associated proteins in Hepa1-6 cell cytoplasm and membrane.  To identify 
FAS-associated proteins in Hepa1-6 cells, a murine immortalized liver cell line, and to 
exclude as many non-specific interactions as possible, we used a combination of stable 
isotope labeling with amino acids in cell culture (SILAC) and mass spectrometry. Hepa1-6 
cells were labeled as “heavy” or “light” using stable isotope labeling with amino acids in cell 
culture (SILAC) [3]. FAS was immunoprecipitated from “heavy” cells, while “light” cells 
were immunoprecipitated using a control antibody. Peptides from both populations were 
mixed and analyzed by mass spectrometry. The most likely FAS-interactors were found using 
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the ratio of the intensity of peptides identified in the “heavy” cells versus the control “light” 
cells, with a minimum ratio of 5 (meaning peak intensity is 5-fold higher for the “heavy” 
peak than the “light” peak) and a minimum number of 2 peptides detected as the cut-off for 
likely specific interactors.  
 FAS interactors in Hepa1-6 cytoplasm and membrane are listed in Table 3 and Table 
4, respectively. Excluding FAS, 54 proteins were identified in the cytoplasmic fraction and 
23 proteins were identified in the membrane fraction.  
 FAS-associated proteins exclusively found in the membrane fractions and in both 
model systems. Three proteins were found that were exclusively present in the membrane 
fraction and present in both Hepa1-6 cells and mouse liver (Table 5): Septin-2 (encoded by 
Sept2), Septin-7 (encoded by Sept7), and 40S ribosomal protein S18 (encoded by Rps18). 
 Integral membrane proteins. None of the three proteins fulfilling the first two criteria 
(exclusively present in the membrane fraction, and present in both model systems) are 
integral membrane proteins; Septin-2 and Septin-7 are soluble cytoskeletal proteins while 
40S ribosomal protein S18 is a component of ribosomes, which are cytoplasmic or associated 
with ER membrane (rough ER).  
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DISCUSSION 
While none of the three candidate FAS-interacting proteins that were identified as 
present exclusively in the membrane fractions in both Hepa1-6 cells and mouse liver were 
integral membrane protein, the nature of the septin protein class marks Septin-2 and Septin-7 
as viable candidates capable of mediating the strong interaction between FAS and 
intracellular membranes.  
The septin proteins are cytoskeletal GTP-binding proteins, forming hexameric and 
octameric complexes that can assemble into filaments (reviewed in [5]). Functions of the 
septins include scaffolding and membrane partitioning [5]. In phospholipid-based liposomes, 
septins tubulate the liposome membrane, creating a membrane “brace” [6]. Septins can 
regulate protein-protein associations [7] and protein-cytoskeleton interactions [8]. 
Unfortunately, there are no published studies to date on the function of Septin-2 or Septin-7 
in liver or liver cells or in interactions with the ER membrane. 
The identification of a ribosomal protein, 40S ribosomal protein S18, in the 
membrane fraction of both model systems could indicate that FAS binds to the rough ER. 
The presence of this protein may be a vestige of the abundance of ribosomes associated with 
the rough ER membrane. 
In conclusion, we have identified three proteins—40S ribosomal protein S18, Septin-2, 
and Septin-7—that in two different liver model systems associate with fatty acid synthase 
exclusively in the membrane fraction.  Rigorous cut-offs for isotope ratio or protein scores 
ensured a high confidence level for the candidate proteins being correctly identified and 
specific interactors of FAS. The association of Septin-2 and Septin-7 with membrane-bound 
FAS and the role of the septins in scaffolding and membrane structuring suggest that these 
proteins could be important for the membrane localization of FAS. If that is true, these 
proteins could potentially be modulated to change the proportion of FAS present in 
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association with membranes and in the cytoplasm, which in turn could affect FAS-mediated 
PPAR? activation and lipid storage/secretion. Studies on FAS localization and function in 
cells deficient in Septin-2 or Septin-7 are needed to elucidate the function of the FAS-septin 
interactions.  
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TABLES 
 
Accession ID Description Protein score 
# of 
peptides
FAS_MOUSE Fatty acid synthase  6979 211 
ACACA_MOUSE Acetyl-CoA carboxylase 1  3551 31 
AL1L1_MOUSE Cytosolic 10-formyltetrahydrofolate dehydrogenase  1469 7 
K2C5_MOUSE Keratin, type II cytoskeletal 5 729 35 
PCCB_MOUSE Propionyl-CoA carboxylase beta chain, mitochondrial  706 2 
K2C6A_MOUSE Keratin, type II cytoskeletal 6A  678 23 
K1C14_MOUSE Keratin, type I cytoskeletal 14  669 34 
ASSY_MOUSE Argininosuccinate synthase  617 7 
BHMT1_MOUSE Betaine--homocysteine S-methyltransferase 1  614 5 
F16P1_MOUSE Fructose-1,6-bisphosphatase 1  612 3 
ALDOB_MOUSE Fructose-bisphosphate aldolase B 596 2 
PYC_MOUSE Pyruvate carboxylase, mitochondrial  560 9 
SAHH_MOUSE Adenosylhomocysteinase  520 5 
K1C17_MOUSE Keratin, type I cytoskeletal 17  515 15 
SBP1_MOUSE Selenium-binding protein 1  512 3 
K1C42_MOUSE Keratin, type I cytoskeletal 42  495 35 
K1C10_MOUSE Keratin, type I cytoskeletal 10  456 8 
K2C75_MOUSE Keratin, type II cytoskeletal 75  448 26 
GSTP1_MOUSE Glutathione S-transferase P 1  418 3 
IGG2B_MOUSE Ig gamma-2B chain C region  397 2 
HSP7C_MOUSE Heat shock cognate 71 kDa protein  370 3 
HPPD_MOUSE 4-hydroxyphenylpyruvate dioxygenase  363 2 
K1C16_MOUSE Keratin, type I cytoskeletal 16  358 16 
K22E_MOUSE Keratin, type II cytoskeletal 2 epidermal  331 8 
K1C15_MOUSE Keratin, type I cytoskeletal 15  327 13 
IGKC_MOUSE Ig kappa chain C region  326 5 
K2C1B_MOUSE Keratin, type II cytoskeletal 1b  306 5 
K22O_MOUSE Keratin, type II cytoskeletal 2 oral  305 11 
K1C13_MOUSE Keratin, type I cytoskeletal 13 301 14 
K2C73_MOUSE Keratin, type II cytoskeletal 73  295 4 
K2C1_MOUSE Keratin, type II cytoskeletal 1  286 10 
TBB4B_MOUSE Tubulin beta-4B chain  282 3 
LDHA_MOUSE L-lactate dehydrogenase A chain  276 3 
K2C8_MOUSE Keratin, type II cytoskeletal 8  221 10 
CAH3_MOUSE Carbonic anhydrase 3  185 3 
K2C79_MOUSE Keratin, type II cytoskeletal 79  154 2 
PLAK_MOUSE Junction plakoglobin  147 2 
K2C72_MOUSE Keratin, type II cytoskeletal 72  142 2 
GSTA3_MOUSE Glutathione S-transferase A3  134 2 
GPX1_MOUSE Glutathione peroxidase 1 113 2 
 
Table 1. FAS-associated proteins in mouse liver cytoplasm. A protein score of 100 
(representing a confidence level over 95%) and a minimum number of two peptides was used 
as the cut-off for likely FAS interactors.  
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Accession ID Description Protein score 
# of 
peptides
FAS_MOUSE Fatty acid synthase  6296 83 
ACACA_MOUSE Acetyl-CoA carboxylase 1  3872 11 
ATPA_MOUSE ATP synthase subunit alpha, mitochondrial  1548 29 
MVP_MOUSE Major vault protein 1339 10 
GRP78_MOUSE 78 kDa glucose-regulated protein  1223 3 
MCCB_MOUSE 
Methylcrotonoyl-CoA carboxylase beta chain, 
mitochondrial  857 4 
K2C5_MOUSE Keratin, type II cytoskeletal 5  807 40 
MCCA_MOUSE 
Methylcrotonoyl-CoA carboxylase subunit alpha, 
mitochondrial  750 3 
K1C14_MOUSE Keratin, type I cytoskeletal 14  715 19 
ENPL_MOUSE Endoplasmin 710 7 
PDIA1_MOUSE Protein disulfide-isomerase  686 7 
S27A2_MOUSE Very long-chain acyl-CoA synthetase  665 6 
K2C6A_MOUSE Keratin, type II cytoskeletal 6A  663 33 
RS4X_MOUSE 40S ribosomal protein S4, X isoform 596 5 
K1C42_MOUSE Keratin, type I cytoskeletal 42  585 19 
TPP2_MOUSE Tripeptidyl-peptidase 2 581 4 
IGG2B_MOUSE Ig gamma-2B chain C region 563 5 
K1C17_MOUSE Keratin, type I cytoskeletal 17  554 9 
FMO5_MOUSE Dimethylaniline monooxygenase [N-oxide-forming] 5 548 3 
CES3_MOUSE Carboxylesterase 3 515 3 
K2C75_MOUSE Keratin, type II cytoskeletal 75  483 31 
ATPB_MOUSE ATP synthase subunit beta, mitochondrial 469 2 
RS3_MOUSE 40S ribosomal protein S3 465 2 
UD11_MOUSE UDP-glucuronosyltransferase 1-1 =2 461 3 
K1C10_MOUSE Keratin, type I cytoskeletal 10  445 15 
K1C16_MOUSE Keratin, type I cytoskeletal 16  433 5 
K22E_MOUSE Keratin, type II cytoskeletal 2 epidermal  419 12 
ACSL5_MOUSE Long-chain-fatty-acid-CoA ligase 5 407 3 
S27A5_MOUSE Bile acyl-CoA synthetase  398 4 
CP2DA_MOUSE Cytochrome P450 2D10 390 2 
CP2DQ_MOUSE Cytochrome P450 2D26  365 4 
SEPT2_MOUSE Septin-2 340 4 
K1C15_MOUSE Keratin, type I cytoskeletal 15  335 9 
K22O_MOUSE Keratin, type II cytoskeletal 2 oral  322 27 
K2C1B_MOUSE Keratin, type II cytoskeletal 1b  318 7 
DHI1_MOUSE Corticosteroid 11-beta-dehydrogenase isozyme 1  306 2 
K1C13_MOUSE Keratin, type I cytoskeletal 13  282 16 
K2C1_MOUSE Keratin, type II cytoskeletal 1  281 5 
K2C73_MOUSE Keratin, type II cytoskeletal 73  266 8 
SEPT7_MOUSE Septin-7  250 3 
CMLO2_MOUSE Probable N-acetyltransferase CML2  240 2 
K2C8_MOUSE Keratin, type II cytoskeletal 8  232 16 
PCCB_MOUSE Propionyl-CoA carboxylase beta chain, mitochondrial 232 4 
K2C79_MOUSE Keratin, type II cytoskeletal 79  224 8 
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K1C19_MOUSE Keratin, type I cytoskeletal 19 219 3 
KRT85_MOUSE Keratin, type II cuticular Hb5 213 2 
ALDOB_MOUSE Fructose-bisphosphate aldolase B  199 2 
RS18_MOUSE 40S ribosomal protein S18  189 2 
K2C7_MOUSE Keratin, type II cytoskeletal 7 133 3 
HVM51_MOUSE Ig heavy chain V region AC38 205.12 108 2 
PYGL_MOUSE Glycogen phosphorylase, liver form  105 2 
 
Table 2. FAS-associated proteins in mouse liver membrane. A protein score of 100 
(representing a confidence level over 95%) and a minimum number of two peptides was used 
as the cut-off for likely FAS interactors. Because the association of FAS with membranes is 
resistant to high salt treatment [2], the pellet containing the crude membrane fraction was 
resuspended in a buffer containing 1 M NaCl and incubated for 30 min in order to dissociate 
irrelevant proteins from the membrane, after which the sample was re-centrifuged and the 
supernatant discarded. 
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Accession ID Description Heavy/light ratio 
# of 
peptides
FAS_MOUSE Fatty acid synthase  32.87 222 
ANR40_MOUSE Ankyrin repeat domain-containing protein 40  25.48 3 
AP2A1_MOUSE AP-2 complex subunit alpha-1  22.59 2 
DTD1_MOUSE D-tyrosyl-tRNA(Tyr) deacylase 1 12.76 2 
SNX5_MOUSE Sorting nexin-5 11.36 2 
GFPT1_MOUSE 
Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1  10.7 15 
TWF1_MOUSE Twinfilin-1  9.94 4 
ARL1_MOUSE ADP-ribosylation factor-like protein 1  9.83 6 
ARF1_MOUSE ADP-ribosylation factor 1  9.79 18 
ARF5_MOUSE ADP-ribosylation factor 5  9.58 13 
ARF4_MOUSE ADP-ribosylation factor 4 9.17 14 
UBC12_MOUSE NEDD8-conjugating enzyme Ubc12 8.76 4 
ATG3_MOUSE Ubiquitin-like-conjugating enzyme ATG3 8.43 2 
MP2K1_MOUSE 
Dual specificity mitogen-activated protein kinase 
kinase 1  8.33 3 
SAR1A_MOUSE GTP-binding protein SAR1a 8.13 4 
CNN3_MOUSE Calponin-3 8.01 27 
KTHY_MOUSE Thymidylate kinase  7.9 2 
UBE2Z_MOUSE Ubiquitin-conjugating enzyme E2 Z  7.88 3 
EF2_MOUSE Elongation factor 2  7.72 80 
CXCR4_MOUSE C-X-C chemokine receptor type 4  7.53 3 
UBE2N_MOUSE Ubiquitin-conjugating enzyme E2 N 7.51 6 
PYRG1_MOUSE CTP synthase 1  7.44 5 
SAR1B_MOUSE GTP-binding protein SAR1b  7.35 7 
SAE2_MOUSE SUMO-activating enzyme subunit 2  7.21 13 
CDK1_MOUSE Cyclin-dependent kinase 1  7.19 8 
PUR6_MOUSE Multifunctional protein ADE2 6.87 26 
RAB5A_MOUSE Ras-related protein Rab-5A  6.84 2 
MOL1A_MOUSE Mps one binder kinase activator-like 1A  6.83 3 
RB11A_MOUSE Ras-related protein Rab-11A  6.83 4 
CDK18_MOUSE Cyclin-dependent kinase 18 6.71 3 
PRS8_MOUSE 26S protease regulatory subunit 8 6.65 3 
BLK_MOUSE Tyrosine-protein kinase Blk  6.45 2 
ATX10_MOUSE Ataxin-10  6.12 10 
PDC6I_MOUSE Programmed cell death 6-interacting protein  6.05 2 
TBB2A_MOUSE Tubulin beta-2A chain  6.05 85 
TBB3_MOUSE Tubulin beta-3 chain 6.03 35 
TBB5_MOUSE Tubulin beta-5 chain 6 104 
TBB2C_MOUSE Tubulin beta-2C chain  5.99 78 
TBB6_MOUSE Tubulin beta-6 chain  5.97 58 
TBAL3_MOUSE Tubulin alpha chain-like 3  5.77 5 
TBA1C_MOUSE Tubulin alpha-1C chain  5.73 134 
TBA1B_MOUSE Tubulin alpha-1B chain 5.72 134 
VILI_MOUSE Villin-1  5.6 7 
G3PT_MOUSE Glyceraldehyde-3-phosphate dehydrogenase, testis- 5.59 15 
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specific  
TBA4A_MOUSE Tubulin alpha-4A chain 5.58 92 
ACTBL_MOUSE Beta-actin-like protein 2  5.54 51 
TBA1A_MOUSE Tubulin alpha-1A chain  5.54 134 
TLN1_MOUSE Talin-1  5.53 3 
KPYM_MOUSE Pyruvate kinase isozymes M1/M2 5.48 61 
CHERP_MOUSE Calcium homeostasis endoplasmic reticulum protein  5.445 2 
IF4A1_MOUSE Eukaryotic initiation factor 4A-I  5.37 28 
EF1A1_MOUSE Elongation factor 1-alpha 1  5.33 24 
G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 5.33 77 
RAB7A_MOUSE Ras-related protein Rab-7a 5.27 3 
 
Table 3. FAS-associated proteins in Hepa1-6 cytoplasm. A minimum heavy/light ratio of 5 
and a minimum of two peptides was used as the cut-off for likely FAS interactors. 
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Accession ID Description Heavy/light ratio 
# of 
peptides
FGF22_MOUSE Fibroblast growth factor 22  73.25 6 
FAS_MOUSE Fatty acid synthase 49.87 533 
RG9D3_MOUSE 
RNA (guanine-9-)-methyltransferase domain-
containing protein 3 48.81 3 
DTD1_MOUSE D-tyrosyl-tRNA(Tyr) deacylase 1 39.4 4 
SEPT2_MOUSE Septin-2  29.2 6 
SEPT9_MOUSE Septin-9 23.41 9 
G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 13.97 47 
SEPT7_MOUSE Septin-7  8.96 2 
TCPH_MOUSE T-complex protein 1 subunit eta 7.24 10 
PCBP1_MOUSE Poly(rC)-binding protein 1  6.5 10 
PCBP2_MOUSE Poly(rC)-binding protein 2  6.48 2 
SC31A_MOUSE Protein transport protein Sec31A 6.41 2 
TCPD_MOUSE T-complex protein 1 subunit delta 6.12 22 
TCPZ_MOUSE T-complex protein 1 subunit zeta  6.1 20 
HAS1_MOUSE Hyaluronan synthase 1  6.08 2 
TCPG_MOUSE T-complex protein 1 subunit gamma 5.99 22 
RS18_MOUSE 40S ribosomal protein S18  5.82 11 
TCPB_MOUSE T-complex protein 1 subunit beta  5.7 19 
EF1A1_MOUSE Elongation factor 1-alpha 1 5.67 49 
NFH_MOUSE Neurofilament heavy polypeptide 5.63 5 
ABCE1_MOUSE ATP-binding cassette sub-family E member 1  5.47 3 
SETB2_MOUSE Histone-lysine N-methyltransferase SETDB2  5.32 2 
UGDH_MOUSE UDP-glucose 6-dehydrogenase 5.29 2 
 
Table 4. FAS-associated proteins in Hepa1-6 membrane. A minimum heavy/light ratio of 
5 and a minimum of two peptides was used as the cut-off for likely FAS interactors. 
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Description Protein score 
# of 
peptides 
Heavy/light 
ratio 
# of 
peptides 
Septin-2  340 4 29.2 6 
Septin-7  250 3 8.96 2 
40S ribosomal protein S18  189 2 5.82 11 
 
Table 5. FAS-associated proteins exclusively present in the membrane fractions and 
present in both mouse liver and Hepa1-6. Excluding FAS.  
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ABSTRACT 
PPAR? is a nuclear receptor that coordinates liver metabolism during fasting. Fatty 
acid synthase (FAS) is an enzyme that stores excess calories as fat during feeding, but also 
activates hepatic PPAR? by promoting synthesis of an endogenous ligand. Here we show that 
the mechanism underlying this paradoxical relationship involves the differential regulation of 
FAS in at least two distinct subcellular pools: cytoplasmic and membrane-associated. In 
mouse liver and cultured hepatoma cells, the ratio of cytoplasmic to membrane FAS specific 
activity was increased with fasting, indicating higher cytoplasmic FAS activity under 
conditions associated with PPAR? activation. This effect was due to a nutrient-dependent and 
compartment-selective covalent modification of FAS. Cytoplasmic FAS was preferentially 
phosphorylated during feeding or insulin treatment at Thr-1029 and Thr-1033, which flank a 
dehydratase domain catalytic residue. Mutating these sites to alanines promoted PPAR? 
target gene expression. Rapamycin-induced inhibition of mTORC1, a mediator of the 
feeding/insulin signal to induce lipogenesis, reduced FAS phosphorylation, increased 
cytoplasmic FAS enzyme activity, and increased PPAR? target gene expression. Rapamycin-
mediated induction of the same gene was abrogated with FAS knockdown. These findings 
suggest that hepatic FAS channels lipid synthesis through specific subcellular compartments 
that allow differential gene expression based on nutritional status. 
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INTRODUCTION 
 PPAR? (peroxisome proliferator-activated receptor ?), one of three known members 
of a nuclear receptor family targeted to treat lipid disorders, diabetes and obesity, is highly 
expressed in the liver. Its induction by fasting promotes lipid uptake, fatty acid ?-oxidation, 
ketogenesis, and gluconeogenesis [1, 2]. Ligand binding to PPAR? causes it to 
heterodimerize with RXR?, allowing activation of gene transcription at PPREs [3, 4]. 
Synthetic PPAR? ligands such as fibrates, used for human lipid disorders [5], have been 
known for decades, but potential endogenous ligands were identified only recently [6, 7]. 
Mice with liver-specific deletion of the lipogenic enzyme fatty acid synthase (FAS) have 
impaired PPAR? activity [8], and FAS activates PPAR? by producing an endogenous 
phospholipid ligand [6]. FAS also activates PPAR? in brain and macrophages [9, 10].  
 Mammalian FAS synthesizes long chain fatty acids, primarily palmitate, through the 
activities of seven functional domains: acyl carrier, acyl transferase, ?-ketoacyl synthase, ?-
ketoacyl reductase, ?-hydroxyacyl dehydratase, enoyl reductase, and thioesterase [11]. Like 
PPAR?, FAS is highly expressed in liver [12]. In times of nutrient excess, hepatic FAS 
converts carbohydrate to lipid that is stored in lipid droplets or secreted in the form of VLDL 
[13]. Nutrient excess is associated with elevated levels of insulin, known to induce FAS 
expression. 
 These accepted physiological roles for PPAR? and FAS appear to conflict with the 
observation that inactivation of FAS impairs PPARα activation. How might FAS activate a 
process stimulated by feeding such as insulin-responsive lipogenesis and yet also activate a 
process stimulated by fasting such as the induction of PPAR?-dependent gene expression?  
  We hypothesized that distinct subcellular pools of FAS mediate these disparate 
effects. Compartmentalization would permit regulation of an FAS pool generating lipids for 
signaling that would be distinct from an FAS pool generating lipids for energy storage. In 
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support of this hypothesis, we demonstrate that FAS at two separate subcellular locations is 
differentially regulated by nutrients and insulin, that this regulation involves preferential 
dehydratase domain phosphorylation for the FAS pool that regulates PPARα, and that the 
effects of the kinase mTORC1 on PPARα activity require FAS.   
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MATERIALS AND METHODS 
Animals. Male C57BL/6J mice at 8 weeks of age were provided ad libitum access to 
chow diet (Purina #5053) or fasted for 18 h. All mice were kept on Aspen bedding and had 
free access to water. Protocols were approved by the Washington University Animal Studies 
Committee. 
FAS enzyme activity assay. Using a modification of a previously described assay 
[14], 20 μl of sample at 1 μg protein/μl was added to 70 μl of assay buffer (0.14 M potassium 
phosphate buffer [pH 7.0], 1.4 mM EDTA [pH 8.0], 1.4  mM DTT, 0.24 mM NADPH, 0.1 
mM acetyl-CoA). The rate of NADPH oxidation was monitored at 340 nm at baseline and 
again after adding 10 μl of 0.85 mg/ml malonyl-CoA (Sigma). The substrate-dependent rate 
was determined by subtracting the baseline NADPH oxidation rate from the rate after 
addition of malonyl-CoA. The rate of NADPH oxidation was normalized to FAS protein 
levels as determined by Western blotting and densitometry to determine specific activity.  
Subcellular fractionation. Perfused liver from C57BL/6J mice was homogenized in 
20 mM HEPES buffer (pH 7.4), centrifuged at 100 g for 30 min, and the pellet was discarded. 
The supernatant was centrifuged at 500 g for 60 min; 1,200 g for 20 min; 10,000 g for 20 
min; 20,000 g for 30 min; 40,000 g for 30 min; 70,000 g for 30 min; 100,000 g for 60 min; 
and 179,000 g for 75 min. After each spin, the pellet was washed and resuspended, while the 
supernatant was centrifuged again. All spins were done at 4°C. To obtain crude membrane 
and cytoplasmic fractions from mouse liver, freshly isolated perfused liver was homogenized 
in HEPES buffer and centrifuged at 10,000 g for 45 min at 4°C. The resulting pellet was 
discarded and the supernatant centrifuged at 179,000 g for 180 min at 4°C. The supernatant 
(cytoplasm) and pellet (crude membrane) were collected, and the pellet was washed and 
resuspended in HEPES buffer. To obtain membrane and cytoplasmic extracts from Hepa1-6 
cells, a Subcellular Protein Fractionation Kit for Cultured Cells (78840) from Thermo Fisher 
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Scientific was used according to the manufacturer’s protocol. 
Antibodies. Rabbit polyclonal antibodies against FAS (ab22759), PMP70 (ab3421), 
and phosphothreonine (ab9337) were from Abcam. Mouse monoclonal antibody against ?-
tubulin (sc-5286) and rabbit polyclonal antibodies against Cav1 (sc-894) and ?-tubulin (sc-
9104, used to control for loading in Western blotting experiments) were from Santa Cruz 
Biotechnology. Rabbit polyclonal antibodies against PDI (226), GM130 (2296), Na+/K+ 
ATPase (3010), Akt (9272), Phospho-Akt (S473) (9271), S6 ribosomal protein (2217), and 
phospho-S6 ribosomal protein (Ser235/236) (2F9/4856) and rabbit monoclonal antibodies 
against p70 S6 Kinase (2708) and CoxIV (4850) were from Cell Signaling Technology. 
FAS solubility. Solubility assays were performed as previously described [15] with 
minor modifications. Membranes were isolated from mouse liver by ultracentrifugation and 
resuspended in buffer containing 20 mM HEPES buffer (pH 7.4), 1 mM EDTA, and 255 mM 
sucrose. The membrane fraction was subjected to treatment with various solvents (1 M NaCl, 
0.1 M Na2CO3 at pH 11.5, 1% SDS or 1% Triton X-100) and then centrifuged once more 
(4°C, 180,000 g, 30 min). The resulting pellets and supernatants were analyzed by Western 
blotting. 
Cell culture. Hepa1-6 and Hek293T cells were maintained in DMEM + 10% FBS. 
Prior to insulin treatment for FAS activity assays, Hepa1-6 cells were cultured in DMEM + 
0.5% FBS for 6 h. All insulin treatments were performed in DMEM + 10% FBS.  
Pulse-chase. Confluent Hepa1-6 cells in 6 cm dishes were incubated in methionine-
free media for 30 min. The cells were then pulsed with 500 μCi of 35S-methionine per dish. 
After 1 h cells for the “0” time point were harvested. For subsequent time points, cells were 
washed with PBS, chased with non-radioactive complete media, and incubated for an 
additional 45, 90, or 180 minutes before harvesting. Cells were fractionated into cytoplasm 
and membrane as described above. FAS was immunoprecipitated from each fraction, samples 
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were subjected to SDS-PAGE, the gel transferred onto PVDF membrane, and the bands 
corresponding to labeled FAS visualized by autoradiography. Autoradiograms were then 
analyzed by densitometry. 
RT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen) and reverse 
transcribed using an iScript™ cDNA synthesis kit  (Invitrogen). Semi-quantitative RT-PCR 
was performed using SYBR® Green reagent (Applied Biosystems) with an ABI Prism 7700 
PCR instrument. 
Mutagenesis and plasmid construction. A retroviral plasmid, pBABE-Puro, 
containing human FAS [16] generated by Max Loda (Dana Farber) was utilized to generate 
FAS phosphosite mutants. A 3.4 kb fragment of FAS/pBABE-Puro including the two 
putative phosphorylation sites (hFAS S1028 and T1032) and two flanking BsrGI sites was 
amplified by PCR and subcloned into an intermediate Topo vector. Site-directed mutagenesis 
of the Topo-FAS plasmid changed the codons corresponding to S1028 and T1032 to alanines, 
yielding two single mutants. The S1028A/T1032A double mutant was made by sequential 
mutagenesis, using the S1028A mutant as a template. Mutated FAS fragments were then 
excised and cloned back into pBabe-Puro using the two BsrGI sites to generate mutant, full 
length FAS cDNAs. Mutations as well as correct orientation of the re-inserted FAS fragments 
were verified by DNA sequencing. 
 GFP-tagged FAS was generated by amplifying the cDNA encoding FAS from 
pBabe-Puro-FAS by RT-PCR, adding restriction sites for XhoI and EcoRI on the 5’ and 3’ 
ends, respectively. The amplified product was cloned into pEGFP-C3 using the XhoI and 
EcoRI sites, yielding an N-terminally GFP-tagged FAS construct.  
 Lentiviral shRNA-mediated knockdown and human FAS expression. A 
plasmid encoding a mouse FAS shRNA (TRCN0000075703) was obtained from Open 
Biosystems. The packaging vector psPAX2 (12260) and envelope vector pMD2.G (12259) 
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were obtained from Addgene. Hek293T cells at 70% confluence in a 15 cm dish were 
transfected using Lipofectamine 2000 with 8 μg psPAX2, 2.25 μg pMD2.G, and 9 μg shRNA. 
After 48 h, media was collected and filtered through 0.45 μm syringe filters. Polybrene was 
added and the media used to treat 50-70% confluent Hepa1-6 cells. After 24 h, the media was 
aspirated and replaced with media containing retroviral particles encoding human FAS (see 
below). Forty-eight h after addition of the retroviral media, cells were selected with 
puromycin. After another 48 h, cells were harvested and knockdown of mouse FAS as well as 
expression of human FAS were assessed. 
 To generate retroviral particles encoding human FAS, Hek293T cells in 10 cm 
dishes were transfected using Lipofectamine 2000 with 3 μg FAS plasmid and 3 μg ?A 
helper plasmid. After 48 h, media were collected, filtered using 0.45 μM syringe filters, 
polybrene was added, and the media was used to treat 50-70% confluent Hepa1-6 cells. After 
48 h, 2 μg/ml puromycin was added, and after an additional 48 h, cells were harvested.  
 In experiments assessing PPAR? target gene expression in cells expressing 
mutant FAS, the endogenous murine FAS of Hepa1-6 cells was knocked down prior to 
retroviral expression of human FAS as described above. 
 PPRE-luciferase reporter assay. Media containing lentiviral particles 
encoding shRNA for murine FAS and media containing retroviral particles encoding wild-
type or S1028A/T1032A double mutant human FAS were prepared as described above. 70% 
confluent Hepa1-6 cells in 10 cm dishes were treated with lentiviral media for 24 h, after 
which the media was aspirated and replaced with retroviral media for either wild type or 
S1028A/T1032A FAS. After another 24 h, the media was again aspirated and replaced with 
fresh media containing puromycin.  
After two days of puromycin selection, the media was aspirated, replaced with 
charcoal-stripped media (which is essentially fatty-acid free, minimizing PPAR activation by 
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lipids in the growth media), and incubated for one hour. For all following steps, charcoal-
stripped media was used. Hepa1-6 cells were transfected with plasmids encoding 3x PPRE-
luciferase and Renilla luciferase by electroporation. The electroporation for each 10 cm dish 
of cells was done as follows: 5 μg of PPRE-luciferase plasmid and 5 μg of Renilla luciferase 
plasmid were added to the bottom of a cuvette. Cells were harvested by trypsinization and 
spun after adding media. The media was aspirated and cells were washed once with PBS. The 
PBS was aspirated and cells resuspended in 0.5 ml PBS and transferred to the cuvette. The 
cuvette containing cells and DNA was electroporated at 360 V and 250 μF (time constant of 
4.5-5 sec-1). 1 ml of media was immediately added to the cuvette. Cells were transferred to a 
15 ml tube and media containing puromycin was added up to 6 ml. Cells were allowed to 
recover for 10 min, then plated.  
One day following transfection, cells were harvested by scraping, washed with room-
temperature PBS three times, resuspended in PBS, and plated on a 96-well plate. 
Luminescence from firefly luciferase and Renilla luciferase was then measured using Dual-
Glo Luciferase Assay System (Promega) according to the manufacturer’s instructions. The 
relative amounts of PPRE-luciferase activity were calculated as the ratio between firefly 
luciferase to Renilla luciferase luminescence. 
Mass spectrometry. To identify post-translational modifications in hepatic FAS, 
perfused C57BL/6J mouse livers were homogenized in lysis buffer containing 1% Triton X-
100. The lysate was spun at 10,000 g for 45 min and the pellet discarded. FAS was 
immunoprecipitated from 10 mg of the lysate by overnight incubation using a polyclonal 
rabbit anti-FAS antibody. IP beads were washed, boiled in sample buffer, and subjected to 
SDS-PAGE. The gel was stained with Coomassie, the gel segment corresponding to FAS was 
excised and further cut into small pieces (1 mm2), destained with 50% CH3CN containing 25 
mM NH4HCO3, dehydrated, reduced with 20 mM DTT for 1 h at 55°C, washed and 
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dehydrated, alkylated with 100 mM iodoacetamide for 1h in the dark at room temperature, 
then subjected to cycles of washing and dehydration followed by drying in a centrifugal 
evaporator. In-gel digestion was performed with 0.02 mg/ml trypsin overnight or 0.02 mg/ml 
chymotrypsin for 6 h at 37°C. Peptides were extracted from the gel pieces using 5% TFA in 
50% CH3CN and reconstituted in 0.1% FA in 3% CH3CN. 
Immobilized metal ion affinity chromatography (IMAC) was used to enrich the 
sample for phosphopeptides. The sample was incubated with IMAC beads for 1 h at room 
temperature. Peptides were eluted from the beads in IMAC buffer and the sample diluted 
with 0.1% FA in 3% CH3CN. Samples were then analyzed by LC-MS/MS with a NanoLC-
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific) in data dependent mode. 
Acquired spectra were searched against Swiss-Prot database through Mascot server to 
identify the protein and its post-translational modification. Non-enriched samples were also 
run to allow a universal search for protein modifications as well as to search for acetyl 
modifications. 
To identify FAS modifications specific to membrane-associated FAS and cytoplasmic 
FAS, membrane and cytoplasmic fractions were isolated from C57BL/6J mice as described 
above. FAS was immunoprecipitated from equal amounts of membrane and cytoplasmic 
lysates (1-10 mg/each) by overnight incubation using a polyclonal rabbit anti-FAS antibody. 
The samples were then subjected to SDS-PAGE and analyzed as described above. 
Statistics. Data are presented as mean ± standard error of the mean. Comparisons 
between two groups were performed using an unpaired, two-tailed t-test. ANOVA was used 
for comparisons involving more than two groups.   
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RESULTS  
Hepatic FAS is present in subcellular compartments.  FAS synthesizes palmitate, and 
FAS deficiency in liver decreases PPAR? target genes. If the effect of FAS deficiency on 
PPAR? simply reflects palmitate availability, then exogenous palmitate should rescue the 
effect. It did not. Treatment of Hepa1-6 cells with 50 μM palmitate failed to rescue 
expression of the PPAR? target gene ACO following FAS knockdown (Figure 1A). Higher 
concentrations of palmitate (125-500 μM) were toxic (data not shown).  
Since the FAS knockdown effect was not rescued with exogenous palmitate, it is 
plausible that not only the product of the FAS reaction but also the location of its synthesis 
mediates downstream effects. Dogma holds that FAS is a cytoplasmic enzyme. To determine 
if FAS is also present at other sites, we fractioned mouse liver FAS by ultracentrifugation 
(Figure 1B). FAS co-fractionated with the cytoplasmic marker S6K, but also with markers for 
several organelles. Immunofluorescent staining for FAS in murine Hepa1-6 liver cells 
demonstrated co-localization of FAS with ER and Golgi markers but not peroxisomal or 
mitochondrial markers (Figure 1C). FAS did not appear in the nucleus (Figure 1C).  
Membrane-associated and cytoplasmic FAS are differentially regulated.  FAS is 
induced by insulin and nutrients [12]. Surprisingly, the specific activity of mouse liver 
cytoplasmic FAS was not increased in the fed state when insulin levels are high (Figure 2A). 
Membrane-associated FAS specific activity was increased with feeding (Figure 2B). The 
cytoplasmic/membrane activity ratio in liver was increased with fasting, when PPARα is 
activated (Figure 2C). In Hepa1-6 cells, a transformed liver cell line, insulin significantly 
decreased cytoplasmic FAS activity (Figure 2D), an effect that was not seen in the membrane 
fraction (Figure 2E). As with mouse liver, the cytoplasmic/membrane activity ratio in Hepa1-
6 cells was increased in the absence of added insulin (Figure 2F), a mimic of fasting.  
To begin to address the possibility that membrane-associated FAS is an artifact of 
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preparation, we treated isolated fractions with different solvents. Membrane-associated FAS 
resisted solubilization by 1 M NaCl, remaining in the pelleted fraction, but was largely 
solubilized by 0.1 M Na2CO3 (Figure 3A). Treatment with detergent (1% SDS or 1% Triton 
X-100) solubilized most FAS protein (Figure 3A). These results suggest [17-19] that FAS 
manifests a strong peripheral membrane interaction.    
A pulse-chase study showed that radiolabelled FAS decreased over time in the 
membrane-associated and cytoplasmic compartments (Figure 3B), suggesting that there is no 
ordered flux of protein from one compartment to another over the time course of this 
experiment. There was no discernible change in the distribution of FAS between membrane 
and cytoplasm when cells were treated with insulin (Figure 3C).   
Given the presence of a putative open reading frame (with a potential alternative start 
codon) 5’ to the published first exon of both mouse and human FAS, we considered the 
possibility that compartmentalized FAS represented differential splicing leading to non-
identical protein isoforms, only one of which is membrane-targeted. However, mass 
spectrometric analysis of FAS in membrane and cytoplasm failed to detect the predicted 
alternative amino acids at the N-terminus, and identified the published FAS protein sequence 
as being N-terminally acetylated (Figure 3D). This modification, which marks the N-terminus 
of most eukaryotic proteins [20], was present in membrane and cytoplasmic fractions of FAS, 
precluding the existence of additional N-terminal sequence. All regions of the FAS protein 
were similarly represented in each fraction, decreasing the possibility that compartment 
location is determined by altered protein sequence due to a process such as exon exclusion 
(data not shown).  
Collectively, these results suggest that the enzyme activities of cytoplasmic and 
membrane-associated FAS are differentially regulated, a phenomenon that does not appear to 
be due to intracellular trafficking of the protein or differences in its primary structure.  
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Cytoplasmic FAS is preferentially phosphorylated.  To address the possibility that 
differential regulation of cytoplasmic and membrane-associated FAS is caused by a covalent 
modification, we immunoprecipitated hepatic FAS from fasting and fed mice then tested 
different fractions for the presence of phosphothreonine by Western blotting. Cytoplasmic 
FAS in fed mice was strongly threonine phosphorylated, a modification that was almost 
undetectable in fasted mice (Figure 4A). Phosphorylation of membrane-associated FAS was 
low under both conditions (Figure 4A). In Hepa1-6 cells, insulin treatment (a mimic of 
feeding) stimulated threonine phosphorylation of cytoplasmic but not membrane-associated 
FAS (Figure 4B).  
Analysis of FAS protein from unfractionated mouse liver by mass spectrometry 
revealed only a single peptide that was threonine phosphorylated. This modification was 
detected at two residues, Thr-1029 and Thr-1033 (a representative spectrum is shown in 
Figure 5A). When liver FAS was separated into cytoplasmic and membrane-associated 
fractions and subjected to the same analysis, the phosphorylated peptide was found 
predominantly in the cytoplasm (Figure 5B) despite similar total amounts of the peptide in 
both fractions (data not shown). These results suggest that the phosphorylated FAS species 
detected in the cytoplasm with feeding or insulin (Figure 4A,B) is modified at Thr-1029 and 
Thr-1033. 
These residues are in the dehydratase domain of FAS. The function of this domain 
requires two catalytic residues, His-878 and Asp-1032, and a third residue, Gln-1036, that 
maintains the orientation of the catalytic residues [21]. The phosphorylated residues we 
identified (denoted by * in Figure 5C) are in close proximity to the catalytic residue D1032 
and the structural residue Q1036 (denoted by # in Figure 5C). Sequence alignment of the 
dehydratase regions from different species revealed that in addition to strict conservation of 
the active site residues D1032 and Q1036 (denoted by #), the phosphoresidues we identified 
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are also conserved as either serines or threonines in humans, mice, rats, D. melanogaster, and 
C. elegans (boxes, Figure 5D).  
Since the evolutionary conservation of these phosphorylation sites suggests 
involvement in FAS function, we mutated S1028 and T1032 in human FAS (corresponding to 
the T1029 and T1033 in murine FAS) to alanines, generating two single mutants (S1028A 
and T1032A) and one double mutant (S1028A/T1032A) (Figure 5E, mutated sites are 
indicated by boxes and the active site residues by #). Wild type or mutant human FAS was 
then expressed in Hepa1-6 cells following knockdown of endogenous mouse FAS. Compared 
to cells expressing wild-type human FAS, cells expressing the S1028A mutation had 
increased levels of the PPAR? target gene CPT1 (Figure 5F), while cells expressing the 
T1032A mutation did not show changes in PPAR? target genes (Figure 5G). However, 
expression of the double mutant S1028A/T1032A was associated with increased levels of 
both ACO and CPT1 (Figure 5H). To test whether this effect could truly be mediated by 
PPAR transcriptional activity, we performed a PPRE-luciferase reporter assay on Hepa1-6 
cells. After expression of wild type or S1028A/T1032A double mutant FAS and knockdown 
of endogenous mouse FAS, cells were transfected with plasmid encoding three tandem 
peroxisome proliferator response elements (PPREs) fused to a firefly luciferase reporter gene. 
Luciferase activity was five-fold increased in cells expressing S1028A/T1032A double 
mutant FAS compared to wild type FAS (Figure 5I), indicating that the effect of FAS mutant 
expression on the PPAR? target genes ACO and CPT1 is indeed likely to be mediated by a 
change in PPAR transcriptional activity. These data suggest that the inability to 
phosphorylate FAS at these two sites disinhibits FAS enzyme activity to promote PPAR? 
target gene expression. 
mTORC1 phosphorylates and inactivates FAS and inhibits PPAR? activity.  mTORC1 
was recently identified as a physiologically important negative regulator of hepatic PPAR? 
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[22]. mTOR, the kinase component of mTORC1, is a serine/threonine kinase that 
preferentially phosphorylates sites with hydrophobic residues at the +1 position [23]. Since 
the phosphorylated residues we identified have the highly hydrophobic phenylalanine 
(F1030) and methionine (M1034) at the +1 positions, we addressed a role for mTORC1 in 
FAS phosphorylation. Treating Hepa1-6 cells with the mTORC1 inhibitor rapamycin for 30 
min abolished the insulin-induced increase in cytoplasmic FAS threonine phosphorylation 
(Figure 6A) and was associated with an increase in cytoplasmic FAS specific activity (Figure 
6B). Treatment of these cells with Torin 1 at 250 nM also abolished insulin-induced FAS 
phosphorylation (data not shown). Treating Hepa1-6 cells with rapamycin for 24 h (a 
sufficient time to reach a new steady state for mRNA levels) decreased expression of the 
PPAR? target gene CPT1 (Figure 6C). These findings confirm those made in a different 
system [22] and extend that work by implicating FAS in the mTORC1-PPARα axis. 
To better define the interaction between mTORC1, FAS, and PPARα, FAS was 
knocked down in Hepa1-6 cells followed by rapamycin treatment. FAS knockdown, 
confirmed in the presence of rapamycin (Figure 6D), decreased CPT1 expression (Figure 6E). 
The induction of CPT1 levels with rapamycin occurring with FAS expression (Figure 6C) 
was lost with FAS knockdown (Figure 6E, solid bar). These results suggest that in this cell 
line under these conditions, the induction of the PPAR? target gene CPT1 caused by 
inhibition of mTORC1 is FAS-dependent. 
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DISCUSSION 
 FAS synthesizes lipid for energy storage and participates in the generation of a lipid 
ligand involved in the activation of fatty acid oxidation. Energy storage occurs with feeding 
and activation of fatty acid oxidation occurs with fasting. To clarify how the same enzyme 
mediates both processes, we pursued the possibility that distinct pools of FAS are 
differentially regulated in the liver.  
We found FAS in the cytosol, but also localized FAS to organelles (Figure 1) through 
a strong peripheral membrane interaction (Figure 3A). FAS specific activity was relatively 
higher with feeding/insulin in membranes and relatively higher with fasting in the cytosol 
(Figure 2). This effect did not appear to involve movement of FAS between compartments or 
primary sequence differences between these pools of FAS. Instead, this activity difference 
was associated with preferential phosphorylation of cytoplasmic (but not membrane) FAS 
with feeding (Figure 4) at conserved sites within a catalytic domain (Figure 5). Mutation of 
these sites increased endogenous PPARα target gene expression as well as activity of a 
PPRE-dependent reporter gene (Figure 5) consistent with disinhibition of FAS in the absence 
of phosphorylation. Inhibition of mTORC1 with rapamycin decreased FAS phosphorylation, 
increased cytosolic FAS enzyme activity, and increased expression of the PPARα target gene 
CPT1, an effect that was FAS-dependent (Figure 6). One interpretation of these findings is 
that hepatic FAS exists in at least two differentially regulated subcellular pools, cytoplasmic 
and membrane-associated (Figure 7). Cytoplasmic FAS is phosphorylated with feeding to 
limit PPAR? activation, and dephosphorylated with fasting to promote PPAR? activation.  
Our findings provide molecular definition and physiological context to an observation 
made nearly four decades ago in birds. Using pigeon liver as a model and exclusively 
studying FAS in the cytoplasm, Qureshi and colleagues found that feeding induced 32P 
incorporation into FAS, which was associated with a loss of enzyme activity [24]. In vitro 
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treatment with phosphatases dephosphorylated FAS and restored enzyme activity. The 
authors of this study did not identify a physiological role for this covalent modification and it 
is not known if the phosphosites we found are conserved in pigeon FAS due to the 
unavailability of sequence data for this species. Regardless, our work suggests that the 
phosphorylation state of cytoplasmic FAS may channel lipid flow to impact phospholipids 
inducing gene expression in the nucleus.   
Physiological, mass spectrometric, and crystal structure data indicate that 
phospholipids interact with nuclear receptors [6, 25-29]. FAS appears to be linked to PPARα 
through phosphatidylcholine synthesis mediated by the Kennedy pathway [6]. Viewed with 
previous studies showing that phosphorylation regulates the CDP-choline branch of the 
Kennedy pathway [30, 31], our identification of functionally relevant FAS phosphorylation 
sites raises the possibility that phosphorylation at several nodes within a cascade of lipid 
signaling from the cytoplasm to the nucleus coordinates FAS-mediated PPARα activation.    
Palmitate is the direct product of the FAS reaction. If the mere availability of 
palmitate were required to activate PPARα, exogenous palmitate would correct FAS 
deficiency. However, the addition of palmitate to liver cells with FAS deficiency does not 
restore defects in PPARα-dependent genes (Figure 1) and elevated serum palmitate levels 
that accompany inactivation of liver FAS in mice does not rescue impaired activation of 
PPARα-dependent genes [8]. Thus, palmitate produced by FAS appears to be 
compartmentalized, a notion supported by our finding of preferential phosphorylation 
depending on cellular location and nutritional state.  
There is precedent for compartmentalization in metabolism. Exogenous 
administration of T3, the active form of thyroid hormone that can be produced locally from 
its precursor T4, does not rescue gene expression defects in the setting of hypothyroidism. 
But administration of T4, which is metabolized to generate T3 locally, restores downstream 
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effects [32]. There is also precedent for compartmentalization in lipid signaling. Phosphatidic 
acid derived from glycerolipid synthesis has effects on mTORC2 that are opposite from those 
induced by phosphatidic acid derived from membrane lipolysis [33]. These observations are 
consistent with our model (Figure 7). In the fed state, cytoplasmic FAS is phosphorylated to 
limit lipid production resulting in PPARα activation, while membrane FAS, less susceptible 
to phosphorylation, likely produces lipids for energy storage or export. Given the rapid 
demands of lipid synthesis prompted by transition from the fasting to the fed state, the 
induction of membrane FAS may be predominantly substrate driven through allosteric 
activation by the glycolytic intermediate fructose-1,6-bisphosphate [34].  
mTORC1 may control the reciprocal activity of FAS in different compartments. 
mTORC1 is activated by insulin and nutrients, prefers substrates like those we identified in 
the dehydratase domain, and is known to suppress PPAR? in the liver [22]. FAS and 
mTORC1 appear to interact in the central nervous system where the physiological effects of 
FAS inhibition are blunted by rapamycin [35], consistent with our model suggesting that 
mTORC1 inhibition would increase FAS activity.  
Our work provides evidence that hepatic FAS is in the cytoplasm as well as 
peripherally associated with membranes. These two pools are differentially regulated by 
nutrients and insulin, and differentially susceptible to phosphorylation, thus providing a 
conceptual framework for understanding how FAS-mediated PPAR? activation is linked to 
the fasting state. Pharmacologically targeting modulators of FAS phosphorylation or 
localization could allow the selective regulation of one pool of FAS. While complete 
inhibition of FAS in liver leads to loss of PPAR? activation and consequently fatty liver, 
specifically targeting FAS-mediated lipid storage and avoiding the undesirable inhibition of 
PPAR? in this manner could, in theory, be an effective treatment for fatty liver and other 
disorders associated with nutrient excess. 
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FIGURES 
 
 
Figure 1. Hepatic FAS is not exclusively cytoplasmic. (A) Expression levels of FAS (left) 
and the PPARα-dependent gene ACO (right) in Hepa1-6 cells. Cells were treated with a 
control (scrambled, sc) shRNA or an FAS shRNA in the presence of exogenous BSA-
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conjugated palmitate or vehicle (BSA alone) for 8 h. *indicates P?0.05. **indicates P?0.005. 
***indicates P?0.0005. (B) Subcellular distribution of FAS protein in mouse liver by 
differential centrifugation followed by Western blotting. Organelle markers: S6K = P70/S6 
kinase (cytoplasmic marker), GM130 = Golgi Matrix protein 130 (Golgi marker), Cav1 = 
Caveolin1 (caveolae marker), PDI = protein disulfide isomerase (endoplasmic reticulum 
marker), Na+/K+ ATPase (plasma membrane marker), PMP70 = Peroxisomal Membrane 
Protein 70 (peroxisomal marker), COXIV = Cytochrome C OXidase IV (mitochondrial 
marker). (C) Immunofluorescent staining of FAS and expression of GFP-tagged organelle 
markers in murine Hepa1-6 cells. Nuclei stained with DAPI are presented on the far left, GFP 
images are presented second from left, FAS images are presented second from right, and 
merged GFP/FAS images are presented on the far right.  
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Figure 2. Differential regulation of the activities of membrane-associated FAS and 
cytoplasmic FAS. (A) Specific activity of FAS in the cytoplasmic fraction of mouse liver. 
Mice were either fed ad lib (fed) or fasted for 18h (fasted). Activity was normalized to FAS 
protein levels as measured by Western blotting. N=9/group. (B) Specific activity of FAS in 
the membrane (Golgi/ER) fraction of mouse liver. Mice were either fed ad lib (fed) or fasted 
for 18h (fasted). Activity was normalized to FAS protein levels as measured by Western 
blotting. N=5/group. **indicates P?0.005. (C) FAS specific activities shown in A and B 
expressed as the ratio of FAS specific activity in cytoplasm to FAS specific activity in 
membrane. *indicates P?0.05. (D) Specific activity of FAS in the cytoplasmic fraction of 
Hepa1-6 cells. Cells were treated with 100 nM insulin for indicated times. Activity was 
normalized to FAS protein levels as measured by Western blotting. N=3/group. *indicates 
P?0.05. (E) Specific activity of FAS in the membrane (Golgi/ER) fraction of Hepa1-6 cells. 
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Cells were treated with 100 nM insulin for indicated times. Activity was normalized to FAS 
protein levels as measured by Western blotting. N=3/group. (F) FAS specific activities shown 
in D and E expressed as the ratio of FAS specific activity in cytoplasm to FAS specific 
activity in membrane.  
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Figure 3. Distinct characteristics of membrane and cytoplasmic FAS. (A) Detection of 
FAS protein by Western blotting in pellets and supernatants of membrane fractions following 
high-salt, carbonate, and detergent treatments. Mouse liver homogenate was fractionated by 
differential centrifugation into cytoplasm (not shown) and membrane pellet (lane 1). The 
pellet was resuspended, exposed to solvents as indicated, and again centrifuged to separate 
pellet (P) from the new supernatant (S). (B) Pulse-chase analysis of FAS protein in 
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membrane and cytoplasm of Hepa1-6 cells. Cells were pulsed with 35S-labeled methionine 
for 1 h, then chased with media containing non-labeled methionine for the indicated times. 
(C) Expression of GFP-tagged human FAS in Hepa1-6 cells treated with insulin for the 
indicated times. Images demonstrate no detectable shifts of FAS between cytoplasmic and 
membrane sites with insulin treatment. (D) Representative spectrum of N-terminally 
acetylated peptide of FAS. N-terminal acetylation effectively marks the initial amino acid of 
the protein, precluding the existence of additional expressed N-terminal exons that might 
constitute distinct FAS isoforms.  
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Figure 4. Cytoplasmic FAS is threonine phosphorylated with feeding or insulin 
treatment. (A) FAS threonine phosphorylation in response to feeding in mouse liver. FAS 
was immunoprecipitated from cytoplasmic and membrane fractions and analyzed for 
phosphothreonine by Western blotting. Mice were either fed ad lib (fed) or fasted for 18 h 
(fasted). Representative blots are shown. Data are averages of two independent experiments. 
*indicates P?0.05. (B) FAS threonine phosphorylation in response to insulin in Hepa1-6 cells. 
FAS was immunoprecipitated from Hepa1-6 cytoplasmic and membrane fractions and 
analyzed for phosphothreonine by Western blotting. Cells were cultured in 0.5% FBS media 
for 4 h prior to harvest (starved), or in 0.5% FBS media for 4 hours, then treated with 1 nM 
insulin in 10% FBS media for 15 min (refed/insulin).  Representative blots are shown. Data 
are averages of two independent experiments. *indicates P?0.05.  
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Figure 5. Phosphorylation of cytoplasmic FAS at the dehydratase domain catalytic site 
controls downstream PPAR? target gene expression. (A) Representative spectrum of the 
FAS P-T1029/P-T1033 phosphopeptide from wild type mouse liver. (B) Distribution of P-
T1029/P-T1033 phosphopeptides identified by mass spectrometry in cytoplasm and 
membrane fractions of mouse liver. While the proportion of phosphorylation differed based 
on fraction, peptide abundances (phosphorylated + non-phosphorylated) were similar for the 
membrane and cytoplasm fractions (not shown). (C) Position of P-T1029 and P-T1033 amino 
acid residues in relation to the FAS dehydratase domain active site residues. D1032 is one of 
two dehydratase domain catalytic residues in FAS. (D) Sequence alignment of the FAS 
putative phospho-amino acids and dehydratase domain active sites in several species. (E) 
Diagram of the FAS phosphosite mutants in human FAS. (F) RT-PCR analyses of PPAR? 
target gene expression in Hepa1-6 cells expressing wild type or S1028A mutant FAS. 
Endogenous FAS was knocked down using lentiviral shRNA for murine FAS. Wild type or 
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mutant human FAS was expressed using retroviruses. Data are averages of three independent 
experiments. *indicates P?0.05. (G) RT-PCR analyses of PPAR? target gene expression in 
Hepa1-6 cells expressing wild type or T1032A mutant FAS. Assay performed as in (F). Data 
are averages of three independent experiments. (H) RT-PCR analyses of PPAR? target gene 
expression in Hepa1-6 cells expressing wild type or S1028A/T1032A mutant FAS. Assay 
performed as in (F). Data are averages of three independent experiments. *indicates P?0.05. 
(I) PPRE-luciferase activity in Hepa1-6 cells expressing wild type or S1028A/T1032A 
mutant FAS. Wild type or mutant human FAS was expressed using retroviruses. Endogenous 
FAS was knocked down using lentiviral shRNA for murine FAS. Cells were co-transfected 
with plasmids encoding 3xPPRE-firefly luciferase and Renilla luciferase. PPRE-luciferase 
activity is reported as the ratio of firefly/Renilla luciferase luminescence. N=3-6/group. 
***indicates P?0.0005. 
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Figure 6. FAS phosphorylation is inhibited by rapamycin and impacts CPT1 expression. 
(A) Cytoplasmic FAS phosphorylation in response to rapamycin in Hepa1-6 cells. Hepa1-6 
cells were treated with vehicle, 100 nM insulin, or 100 nM insulin + 100 nM rapamycin  for 
30 min. The cytoplasmic fractions were isolated, then FAS was immunoprecipitated and 
analyzed for phosphothreonine by Western blotting. *indicates P?0.05. (B) Cytoplasmic FAS 
activity in response to rapamycin in Hepa1-6 cells. Cells were treated with 100 nM insulin 
and vehicle (DMSO) or 100 nM insulin + 100 nM rapamycin for 30 min and FAS enzyme 
activity was assayed. Activity was normalized to FAS protein levels as measured by Western 
blotting. Data are averages of two independent experiments. *indicates P ?0.05. (C) CPT1 
expression levels in response to rapamycin in Hepa1-6 cells. Cells were treated with vehicle 
(DMSO) or 100 nM rapamycin for 24 h. Data are averages of two independent experiments. 
*indicates P?0.05. (D) FAS expression levels following FAS knockdown in Hepa1-6 cells. 
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N=3-5/group. ***indicates P?0.0005. (E) CPT1 expression levels in response to rapamycin 
following FAS knockdown in Hepa1-6 cells. N=3-5/group. *indicates P?0.05. NS indicates 
not significant.   
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Figure 7. Schematic depiction of insulin/feeding-regulated FAS phosphorylation and 
FAS-mediated PPAR? activation. In the fed state, mTORC1 promotes phosphorylation of 
FAS, thus limiting downstream generation of a phosphatidylcholine ligand that activates 
PPARα-dependent gene expression. In the fasting state, dephosphorylated FAS in the 
cytoplasm is permissive for the generation of the ligand activating PPARα-dependent gene 
expression. Abbreviations: PC = phosphatidylcholine, RXR = retinoid X receptor, TAG = 
triacylglycerol.  
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Chapter 4: 
 
Phosphatidylcholine Transfer Protein Activates PPAR? 
in the Liver by Nucleo-Cytoplasmic Ligand Shuttling 
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ABSTRACT 
The nuclear receptor PPAR? is a key regulator of lipid metabolism in the liver and the 
target of the fibrate drugs, used to treat dyslipidemia. Hepatic PPAR? is activated by an 
endogenous phosphatidylcholine (PC) ligand, the production of which is dependent on fatty 
acid synthase (FAS) and choline-ethanolamine phosphotransferase-1 (CEPT1), the latter 
catalyzing the final step in PC synthesis. It is not known how this lipid reaches the nuclear 
PPAR? from the extranuclear CEPT1. Here, we provide evidence that phosphatidylcholine 
transfer protein (PCTP) shuttles PC ligand to PPAR? in liver. 
PCTP knockdown in Hepa1-6 hepatocytes caused dramatic reductions in expression 
of PPAR? target genes, and PCTP co-immunoprecipitated with PPAR?, suggesting this 
effect may be due to a direct interaction. Immunofluorescent imaging showed that PCTP is 
found in both cytoplasm and nucleus, and starvation of cells caused an accumulation of PCTP 
in the nucleus, consistent with a shuttling function controlled by nutrition.  
Using mass spectrometry, we demonstrated that PCTP binds 16:0/18:1-GPC. We 
further showed that the binding of this ligand to PCTP is FAS-dependent: in mice with liver-
specific knockout of FAS, the amount of 16:0/18:1-GPC bound to PCTP in the nucleus was 
significantly reduced. In the cytoplasm, there was no significant difference in binding. In 
mice with whole-body knockout of Pctp, the amount of 16:0/18:1-GPC bound to PPAR? in 
the nucleus may be reduced compared to wild type mice. 
Taken together, these data suggest that PCTP activates PPAR? in the liver by 
promoting delivery of endogenously synthesized lipid ligand to PPAR? in the nucleus.  
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INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease 
in the Western world and a common comorbidity of the metabolic syndrome [1]. In the 
United States, 10–35% of Americans are believed to have fatty liver [2]. While fatty liver in 
itself can be benign, it often progresses into nonalcoholic steatohepatitis (NASH), which in 
turn can lead to liver cirrhosis and hepatocarcinoma. As of 2013, there are no therapies for 
NAFLD that are approved by the FDA in the United States or the EMA in the European 
Union. A pharmacological treatment for fatty liver could thus benefit a large fraction of the 
population.  
One of the major pathways for modulating fat metabolism and transport in the liver is 
through the nuclear receptor peroxisome proliferator-activated receptor ? (PPAR?). In the 
liver, PPAR? is essential for the fasting response and regulates gluconeogenesis, fatty acid 
oxidation, and lipoprotein metabolism in response to changes in nutrient availability [3, 4]. 
Mice lacking PPAR? are fasting-intolerant and develop hepatosteatosis [3, 4]. 
PPAR? is ligand-activated, and in the liver, the phosphatidylcholine (PC) species 
16:0/18:1-glycerophoshocholine (16:0/18:1-GPC) functions as an endogenous ligand 
activating PPAR? during periods of fasting or starvation [5]. Synthesis of this ligand and 
activation of PPAR? is dependent on the presence of fatty acid synthase (FAS) and of 
choline/ethanolamine phosphotransferase-1 (CEPT1), which catalyzes the final step in 
phosphatidylcholine synthesis by the Kennedy pathway [5, 6]. 
How, then, does ligand synthesized by CEPT1 reach PPAR?? CEPT1 is located at the 
ER and the nuclear membranes [7] with the active site facing the cytoplasm [8], precluding a 
direct interaction with the nuclear PPAR?. Because the cytoplasmic movement of 
amphipathic molecules such as phosphatidylcholine is extremely inefficient [9], simple 
diffusion of the ligand is an unlikely mechanism of transport. A more likely possibility is that 
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phosphatidylcholine ligand is transported to PPAR? in association with a protein.   
Phosphatidylcholine transfer protein (PCTP) is a small, soluble lipid-binding protein 
of unclear physiological function. It is also known as StARd2 as it contains a StART (StAR-
related lipid-transfer) domain. PCTP binds phosphatidylcholine exclusively, at a 1:1 ratio 
[10]. It is highly expressed in the liver [11] and found both in cytoplasm and in the nucleus 
[11]. Mice with whole-body knock-out of PCTP have decreased mRNA expression of 
PPAR? target genes in the liver [12]. These characteristics make PCTP an ideal candidate for 
a ligand-delivering chaperone for hepatic PPAR?. 
Here, we present evidence that PCTP activates PPAR? in the liver through the 
endogenous FAS-CEPT1 pathway by promoting ligand delivery to PPAR? in the nucleus. 
Any of the nodes of the FAS-PCTP-CEPT1 pathway of PPAR? activation could potentially 
represent novel targets for treatment of fatty liver. 
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RESULTS 
 Loss of PCTP decreases hepatic PPAR? target gene expression. Gene-chip analysis 
of hepatic mRNA in full-body PCTP knock-out mice (Pctp-/- mice) indicates that the mice 
have decreased PPAR? target gene expression compared to controls [12]. We tested the 
effect of PCTP ablation in Hepa1-6 cells, a murine hepatoma cell line. Following knockdown 
of Pctp with shRNA, expression of the PPAR? targets ACO and CEPT1 was dramatically 
reduced, suggesting a similar role for PCTP with respect to PPAR? in this in vitro system 
(Figure 1A).  If the effect of PCTP on PPAR? is due to PCTP delivering ligand to PPAR?, it 
would be expected that the two proteins physically interact. To test this, we expressed Myc-
tagged PCTP in Hek293T cells and did a pull-down using an anti-Myc antibody. PPAR? co-
immunoprecipitated with Myc (Figure 1B), suggesting a physical interaction between these 
proteins.  
PCTP shuttles between cytoplasm and PPAR? in the nucleus in a nutrient-dependent 
manner. As PPAR? is activated under conditions of low nutrients, we hypothesized that the 
movement of PCTP would be regulated by nutritional stimuli such that there are greater 
amounts of PCTP available to PPAR? in the nucleus during starvation. To test this, we 
imaged Myc-tagged PCTP in Hepa1-6 cells under control or serum-starved conditions using 
an antibody against the Myc epitope. Under control conditions, PCTP was evenly distributed 
throughout the cell (Figure 2A, left). Under serum-starved conditions, the majority of cells 
remained unchanged; however, we found that in a significant proportion of cells, Myc-PCTP 
distinctly accumulated in the nucleus (Figure 2A, right). The reason for the heterogeneous 
PCTP distribution between cells is unclear. 
 To confirm the nuclear localization of PPAR? in this cell line and under these 
conditions, we imaged FLAG-tagged PPAR? in Hepa1-6 cells under control or serum-starved 
conditions. FLAG-PPAR? was exclusively nuclear under either condition (Figure 2B). 
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Nuclear PCTP binds 16:0/18:1-GPC in vivo in liver in a FAS-dependent manner. To 
determine which phosphatidylcholine (PC) species bind to hepatic PCTP in vivo and their 
dependence on FAS, we administrated adenovirus encoding FLAG-tagged PCTP (Ad-PCTP-
FLAG) or, as a control, untagged GFP to wild type or FASKOL mice. Four days after 
adenovirus injection and after fasting the mice for 18 h, the livers were harvested and 
fractionated into cytoplasm and nucleus under conditions unlikely to disturb the 
ligand/protein interaction. We immunoprecipitated FLAG-tagged PCTP using an antibody 
directed at the FLAG epitope. Immunoprecipitate eluates showed a dominant band the size of 
PCTP during immunoblotting with an anti-FLAG antibody (representative blot shown in 
Figure S1).  
Lipids from the eluates were analyzed by mass spectrometry. There was no detectable 
PC signal for eluates from mice injected with GFP adenovirus (data not shown). Several 
peaks corresponding to PC species were detected in wild type Ad-PCTP-FLAG mice 
(representative spectra shown in Figure 3A and 3D), the most abundant being the peaks with 
mass to charge ratio (m/z) of 758.6 and 760.6. M/z 758.6 corresponds to 16:1/18:1-GPC or 
16:0/18:2-GPC, while m/z 760.6 corresponds to the PPAR? ligand 16:0/18:1-GPC. These 
peaks were detected in both the cytoplasmic and the nuclear eluates. As a control, the 
samples were also analyzed for phosphatidylethanolamine (PE). There was no detectable PE 
signal (data not shown), consistent with the highly selective PC-binding by PCTP. 
Since activation of PPAR? by 16:0/18:1-GPC is dependent on the lipogenic pathway 
including FAS and CEPT1 [5], we tested whether the presence of 16:0/18:1-GPC in the 
FLAG-PCTP eluates is dependent on the presence of FAS using mice with liver-specific 
ablation of FAS (FASKOL mice). Representative spectra for PC are shown in Figure 3B and 
3E. In the cytoplasm, there was no difference in the amount of 16:0/18:1-GPC bound to 
FLAG-PCTP (normalized to FLAG protein levels) between wild type and FASKOL mice 
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(Figure 3F). In the nucleus, however, the amount of 16:0/18:1-GPC ligand in the FLAG 
eluate was significantly reduced in mice lacking FAS (Fig. 3E).  M/z 758.6 (corresponding to 
16:1/18:1-GPC or 16:0/18:2-GPC) was likewise reduced in the nucleus of mice lacking FAS 
(see representative spectra in Figure 3A-B; not quantified). 
One interpretation of these data is that FAS participates in the biosynthesis of a lipid 
ligand that is delivered to the nucleus by PCTP. The lack of change in cytoplasmic 16:0/18:1-
GPC levels in the FLAG eluates could reflect participation of cytoplasmic PCTP in additional 
functions that involve its binding to dietary or membrane phosphatidylcholine as well, 
obscuring any difference solely from loss of FAS.  
PPAR? may bind 16:0/18:1-GPC in vivo in liver in a PCTP-dependent manner. To 
test whether the binding of the 16:0/18:1-GPC ligand to PPAR? is dependent on PCTP, we 
administered adenovirus encoding FLAG-tagged PPAR? (Ad-FLAG-PPAR?) to Pctp-/- mice 
or wild type littermates, then analyzed lipids in the FLAG immunoprecipitate eluate as above. 
Immunoblotting with anti-FLAG antibody showed a band the size of PPAR? in the nuclear 
fraction (representative blot shown in Figure S2). There was no detectable FLAG-tagged 
protein in the cytoplasmic fraction, as expected from the nuclear localization of PPAR? (data 
not shown). 
We analyzed FLAG-PPAR? eluates for phospholipids by mass spectrometry. No 
phosphatidylethanolamine or phosphatidylserine was detected (data not shown). Similar to 
PCTP, the dominant peaks for PC were m/z 758.6 and 760.6, corresponding to 16:1/18:1-
GPC/16:0/18:2-GPC and 16:0/18:1-GPC, respectively (Figure 4A). The relative amounts of 
this lipid were over 60% lower in Pctp-/- mice than wild types (representative spectra are 
shown in Figure 4A and 4B); however, this difference was not statistically significant 
(quantification in Figure 4C; p = 0.20).  
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DISCUSSION 
The final enzyme in the biosynthesis of an endogenous ligand for PPAR?, CEPT1, is 
exclusively extranuclear, while hepatic PPAR? is exclusively nuclear. We pursued the 
hypothesis that the phosphatidylcholine-binding protein PCTP functions as a transport protein 
for the 16:0/18:1-GPC PPAR? ligand in the liver, shuttling between the cytoplasm and 
PPAR? in the nucleus to deliver ligand and thereby activate PPAR? during periods of 
starvation. 
We found that PCTP moved between cytoplasm and nucleus in a nutrient-dependent 
manner, tending to accumulate in the nucleus under periods of starvation (Figure 2A). PCTP 
co-precipitated with PPAR? (Figure 1B), suggesting a physical association between the two 
proteins that could serve to transfer lipid. PCTP bound 16:0/18:1-GPC, and in the nucleus, it 
did so in a manner dependent on FAS (Figure 3), indicating that the ligand delivered to the 
nucleus by PCTP is indeed derived from the FAS-catalyzed de novo lipogenic pathway 
previously described [5]. Binding of the 16:0/18:1-GPC ligand to PPAR? may in turn be 
dependent on the presence of PCTP (Figure 4), supporting a role for PCTP in delivering this 
ligand to hepatic PPAR?.  
Because of the capacious ligand-binding domain of PPAR?, there are likely several 
endogenous ligands with varying transactivation capabilities and tissue distribution. It 
follows, then, that there may be several ligand-binding chaperones with varying specificities 
and distributions for transport of lipid ligands with poor solubility, both for PPAR? and for 
the other PPARs. It will be of interest to characterize the transport mechanisms for 
endogenous PPAR ligands in other tissues as well, as this could potentially provide new ways 
of selectively or concomitantly modulating desired sets of PPARs to achieve a therapeutic 
effect. 
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MATERIALS AND METHODS 
Animals. Pctp?/? mice (gift from David Cohen, Brigham and Women’s Hospital, 
generated as described [13]) and littermate control mice were on an FVB/NJ genetic 
background. Pctp?/? mice were genotyped using Klentaq and the following primer sets: 5’-
CCCTTCTTGCCGTCACTC-3’ and 5’- TACGTCTACACCCGCCAG-3’ resulting in a 162 
bp PCTP fragment and 5’-TGTCAAGACCGACCTGTCCG-3’ and 5’-TATTCGGCAAGC-
AGGCATCG-3’ resulting in a 447 bp fragment of the Neomycin resistance gene replacing 
the Pctp gene in knock-out alleles. Liver-specific FAS knock-out mice (FASKOL mice) and 
littermate controls were on a C57BL/6J background and were genotyped using previously 
described primer sets [6].  
Mice were provided ad libitum access to chow diet (Purina #5053) or fasted for 18 h. 
All mice were kept on Aspen bedding during fasting/feeding experiments and had free access 
to water. Protocols were approved by the Washington University Animal Studies Committee. 
Antibodies. Rabbit monoclonal antibody against p70 S6 Kinase (2708) was from Cell 
Signaling Technology (Danvers, MA). Rabbit polyclonal antibody against Myc (sc789) and 
rabbit polyclonal antibody against PPAR? (sc9000) were from Santa Cruz Biotechnology 
(Santa Cruz, CA). Mouse monoclonal antibody against FLAG (F1804) was from Sigma (St. 
Louis, MO). 
Cell culture. Hepa1-6 cells, Hek293, and Hek293T cells were maintained in DMEM 
+ 10% FBS. 
Lentiviral shRNA-mediated knockdown. Plasmid encoding shRNA for mouse 
PCTP (TRCN0000105217) was obtained from Open Biosystems (Huntsville, AL). Packaging 
vector psPAX2 (12260) and envelope vector pMD2.G (12259) were obtained from Addgene 
(Cambridge, MA). 70% confluent Hek293T cells in a 15 cm dish were transfected using 
Lipofectamine 2000 with 8 μg psPAX2, 2.25 μg pMD2.G, and 3 μg mouse PCTP shRNA. 
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After 48 h, media was collected and filtered through 0.45 μm syringe filters. Polybrene was 
added and the media was used to treat 50-70% confluent Hepa1-6 cells. After 24 h, the media 
was aspirated and replaced with fresh media. 48 h after addition of retroviral media, cells 
were selected with puromycin. After another 48 h, cells were harvested and knockdown of 
PCTP was assessed. 
RT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) 
and reverse transcribed using iScript™ cDNA synthesis kit  (Invitrogen). Quantitative RT-
PCR was performed using SYBR® Green reagent (Applied Biosystems, Carlsbad, CA) with 
an ABI Prism 7700 PCR instrument. 
Plasmid constructs. Plasmid encoding Myc-tagged PCTP was a gift from David 
Cohen (Brigham and Women’s Hospital).  
Transfection. Hepa1-6 cells were transfected by electroporation. 25 μg plasmid DNA 
was used per confluent 10 cm dish of Hepa1-6 cells (or ~1x107 cells). Plasmid DNA was 
added to the bottom of a cuvette. Cells were trypsinized and spun down after adding regular 
media. Media was aspirated and the cells washed in PBS and spun again. PBS was aspirated 
and cells were resuspended in 0.5 ml PBS and transferred to the cuvette. The cuvette with 
cells and DNA was electroporated at 360 V and 250 μF (time constant of 4.5-5 sec-1) and 1 
ml of media was immediately added to the cuvette. Cells were transferred to a 15 ml tube and 
media was added up to 5-10 ml. Cells were allowed to recover for 10 min after which they 
were plated. For immunofluorescent imaging, cells were plated directly onto fibronectin-
covered glass coverslips (BD Biosciences) in 6-well dishes and imaged 2 days following 
transfection. 
Hek293T cells were transfected using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions. 10 μg of plasmid was used per 10 cm dish of ~90% confluent 
Hek293T cells. Cells were harvested for immunoprecipitation the following day. 
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Myc immunoprecipitation. 0.5 mg protein lysate from Hek293T cells in 1 ml of 
buffer containing 0.5% NP-40 was incubated with 20 μl anti-Myc antibody on a rocker at 
4°C overnight. 50 μl agarose beads were then added and the sample incubated for another 1 h 
on a rocker at 4°C. The beads were spun down, the supernatant aspirated, and the beads were 
washed with HNTG buffer 3 times before boiling the beads in 2X loading buffer for Western 
blotting and loading the entire volume onto a protein gel. 
Adenoviruses. Adenovirus encoding FLAG-tagged wild type mouse PPAR? and 
adenovirus encoding a GFP marker only were gifts from T. C. Leone and D. P. Kelly. To 
make adenovirus encoding FLAG-tagged wild type mouse PCTP, murine Hepa1-6 cell 
cDNA was used as template to amplify full-length Pctp by PCR with primers adding a 5’ 
BamHI site followed by a FLAG tag on the 5’ side and an XhoI site on the 3’ side:  
5’-ACAACAGGATCCACCATGGATTACAAGGATGACG- 3’ and 5’-ACAACACTC-
GAGTTAGGTTTTCTTGTGGTAGTTC-3’. The amplified Pctp was cut using BamHI and 
XhoI, ligated with pAdTrack-CMV vector (encoding a GFP marker) that had been cut with 
BglII and XhoI, and recombined with Ad-Easy1 vector.  
Adenoviruses were packaged in Hek293 cells and purified with cesium chloride 
ultracentrifugation. Optimal dosing of the adenoviruses was determined by assaying for 
adenoviral protein expression by Western blotting and the survival of mice injected with 
varying doses of adenovirus. Adenovirus was injected in 100 μl total volume. Livers were  
harvested four days following injection for nuclear extraction and FLAG 
immunoprecipitation for mass spectrometry. 
Nuclear extraction. Perfused liver from Pctp?/? mice, FASKOL mice, or appropriate 
control mice was harvested and ~100 mg liver was added directly into a glass homogenizing 
tube on ice containing 1 ml of cold non-detergent-containing hypotonic buffer (10 mM 
HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, protease and phosphatase 
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inhibitors). After 5 min incubation on ice, the liver was manually homogenized using a glass 
pestle. After an additional 10 min incubation, the homogenate was centrifuged at 8000 g at 
4°C for 20 min. The supernatant (cytoplasmic fraction) was removed to a fresh tube. The 
pellet was resuspended in nuclear extraction buffer (10 mM HEPES, 0.42 M NaCl, 25% 
glycerol, 1.5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, protease and phosphatase inhibitors), 
placed on a rotating shaker at 4°C for 1 h, then centrifuged at 18,000 g for 10 min. The 
supernatant (nuclear fraction) was removed to a fresh tube.  
FLAG immunoprecipitation. Cytoplasmic or nuclear extract (~3 mg of cytoplasmic 
protein or ~600 μg nuclear protein in a total volume of 750 μl) was incubated with 50 μl anti-
FLAG M2-Agarose affinity gel beads (A2220, Sigma) overnight at 4°C on a rotating shaker. 
Five washes (wash buffer: 50 mM Tris HCl [pH 7.4], 100 mM NaCl, protease and 
phosphatase inhibitor cocktail) were followed by elution by competition with excess 3x 
FLAG peptide (F4799, Sigma; 150 ng/ml). A 25 μl aliquot of the eluted sample was 
processed for immunoblotting. The remainder was transferred to glass tubes along with 1 ml 
of chloroform per sample and processed for mass spectrometry. 
Mass spectrometry. Lipids were extracted from the samples, mixed with 14:0/14:0-
GPC as an internal standard for PC, and analyzed as [M+H]+ ions by positive ion ESI/MS.  
Statistics. Data are shown as mean ± SEM. Comparisons between two groups were 
performed using un unpaired, two-tailed t-test. Comparisons between more than two groups 
were performed using ANOVA.  
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FIGURES 
 
Figure 1. PCTP promotes hepatic PPAR? target gene expression and physically 
associates with PPAR?. (A) mRNA expression of Pctp, Aco, and Cpt1 as measured by real-
time RT-PCR in Hepa1-6 cells with or without knock-down of Pctp using shRNA. 
Expression levels are normalized to the ribosomal gene L32. *indicates P?0.05. (B) Co-
immunoprecipitation of PPAR? and Myc-tagged PCTP. Myc-PCTP was overexpressed in 
Hek293T cells and immunoprecipitated using anti-Myc antibody. The immunoprecipitate 
eluates were analyzed by Western blotting as shown for PPAR? and Myc (PCTP).  
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Figure 2. PCTP shuttles between cytoplasm and the nucleus in a nutrient-dependent 
manner. (A) Representative images of immunofluorescent staining of Myc-tagged PCTP in 
Hepa1-6 cells during control or serum-starved conditions. Hepa1-6 cells were transfected 
with Myc-PCTP by electroporation two days prior to experiment. Cells pictured on the left 
were kept in media containing 10% FBS (fresh at 6 h prior to fixation). Cells pictured on the 
right were starved in media containing 0.5% FBS for 6 h prior to fixation. BF denotes bright-
field. Insets show cells stained with secondary antibody only. (B) Representative images of 
immunofluorescent staining of FLAG-tagged PPAR? in Hepa1-6 cells under control or 
serum-starved conditions (as described for panel A). Cells were treated with FLAG- PPAR? 
adenovirus two days prior to harvest. There were no cells under either condition where extra-
nuclear PPAR? staining was visible. 
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Figure 3. Nuclear PCTP binds 16:0/18:1-GPC in vivo in liver in a FAS-dependent 
manner. (A-B) and (D-E) Representative mass spectra of phosphatidylcholine bound to 
FLAG-PCTP immunoprecipitated from nuclear and cytoplasmic fractions of liver from 
FASKOL mice or wild type littermates. The insets show magnification of peaks including 
that corresponding to 16:0/18:1-GPC. (C) Quantification of 16:0/18:1-GPC abundance in 
nuclear PCTP expressed as percentage of wild type, as measured by mass spectrometry. 
*indicates P?0.05. (F) Quantification of 16:0/18:1-GPC abundance in cytoplasmic PCTP 
expressed as percentage of wild type, as measured by mass spectrometry. 
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Figure 4. PPAR? binds 16:0/18:1-GPC in vivo in liver in a PCTP-dependent manner. 
(A-B) Representative mass spectra of phosphatidylcholine bound to FLAG-PPAR? 
immunoprecipitated from nuclear fractions of liver from Pctp-/- mice and wild type 
littermates. The insets show magnification of peaks including that corresponding to 
16:0/18:1-GPC. (C) Quantification of 16:0/18:1-GPC abundance in nuclear PPAR? 
expressed as percentage of wild type, as measured by mass spectrometry.  
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Figure 5. Proposed model of PCTP-mediated ligand delivery to PPAR?. In the fasting 
state, FAS is active and promotes synthesis of an endogenous PC ligand for PCTP, which can 
then enter the nucleus and deliver the ligand to PPAR?.  PPAR? then promotes transcription 
of genes involved in fatty acid oxidation and ketogenesis. Abbreviations: CEPT1, 
choline/ethanolamine phosphotransferase 1; FAS, fatty acid synthase; PC, 
phosphatidylcholine; PCTP, phosphatidylcholine transfer protein, PPAR?, peroxisome 
proliferator-activated receptor alpha; RXR = retinoid X receptor. 
  
 107 
 
 
Figure S1. FLAG protein levels in liver from mice injected with PCTP-FLAG or GFP 
adenovirus. “KO” refers to FASKOL mice. “Wt” refers to wild type, FAS lox+/+ mice not 
expressing Cre. 
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Figure S2. FLAG protein levels in liver from mice injected with PPAR?-FLAG 
adenovirus. “KO” refers to a Pctp-/- mouse. “Wt” refers to a wild type littermate. 
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Chapter 5: 
 
Conclusions 
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The studies presented in this dissertation demonstrate how the post-translational 
regulation of a signaling lipid—16:0/18:1-glycerophosphocholine—ensures appropriate 
metabolic responses to changes in nutrient and hormone levels.  
This lipid activates the hepatic fasting response via PPAR?, and we have shown that 
its activity is regulated both at the level of its synthesis and by its subcellular location. In 
Chapter 2 and 3, we demonstrated that PPAR? activation by 16:0/18:1-GPC is controlled by 
multiple modes of post-translational regulation of its biosynthesis by fatty acid synthase 
(FAS). In Chapter 4, we demonstrated that the nucleo-cytoplasmic transport of 16:0/18:1-
GPC by phosphatidylcholine transfer protein (PCTP) regulates PPAR? activation.  
 Here, I will briefly discuss these findings in the context of four things I learned from 
my graduate research. 
 
1.  The cytoplasm is a big place 
 In Chapter 3, I presented evidence that FAS protein in the liver is compartmentalized 
into two separate subcellular locations, each with its own distinct pattern of regulation and 
physiological function. In Chapter 2, a possible mechanism for the membrane localization of 
FAS was provided by identifying two cytoskeletal proteins, Septin-2 and Septin-7, that 
associate with FAS exclusively in the membrane fraction. 
 The dual location of FAS was surprising, as FAS is a cytoplasmic protein according 
to textbooks (the term “cytosolic FAS” is used to distinguish it from mitochondrial type II 
FAS in some sources [1]). The discovery that liver FAS concentrates at the ER and Golgi was 
a chance observation. But the textbooks are correct: FAS is not a membrane-spanning protein 
or a secreted protein and does not exist within any intracellular organelles. “Cytoplasmic” is 
simply too broad a term to be useful in describing location. As exemplified by FAS, a protein 
freely floating in the cytoplasm can be very different in function and regulation from the 
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same protein peripherally associated with the cytoplasmic side of a membrane—even though 
they are both, technically, cytoplasmic proteins. 
 
2.  Some things are not new, just forgotten  
 Even more surprising was the discovery that cytoplasmic FAS is active during fasting, 
while membrane FAS is active during feeding; our hypothesis for months had been that the 
unexpected membrane-bound FAS would be responsible for the correspondingly unexpected 
role of FAS in PPAR? activation. Actually measuring FAS activity in mouse liver after ad lib 
feeding or fasting, however, disrupted this hypothesis (Chapter 3, Figure 2).  
 I found it worrisome that the “classical,” cytoplasmic pool of FAS was regulated in 
the opposite direction of how it was supposed to be regulated—let alone that the changes in 
specific activity by necessity involved post-translational regulation, another feature that FAS 
was not thought to possess. However, a careful literature search revealed that we were not the 
first to observe feeding-induced inhibition of FAS activity nor post-translational regulation of 
FAS activity. In fact, some of the earliest studies on FAS demonstrated changes in FAS 
specific activity, allosteric regulation, and post-translational modifications of FAS. In 1968, 
Salih Wakil’s group demonstrated allosteric regulation of FAS specific activity by 1,6-
fructose-bisphosphate, a glycolytic intermediate [2], and in 1975, John Porter’s group 
published an account of inhibitory phosphorylation of FAS during feeding in pigeon liver [3].  
 These were rigorously performed studies on the biochemistry of the FAS protein, 
something of a rarity today when FAS mRNA levels are far easier to measure and so a 
common proxy for FAS activation. They also provided completely novel and, in the case of 
the Porter study, unexpected information about the regulation of FAS. In spite of this, neither 
study had ever been cited in a review article; rather, reviews on FAS tend to focus on the 
studies showing induction of FAS mRNA by re-feeding following starvation and to define 
FAS regulation as transcriptional and feeding-induced [4-6]. The lack of impact of these 
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studies can in part be attributed to their age; they used the term “fatty acid synthetase” which 
has become less common, and may so be missed during literature searches for “fatty acid 
synthase.” But it also emphasizes the importance of reading primary literature, even (or 
especially) when it is relatively old. As a side note, I was delighted to find the 1975 article on 
inhibition of FAS by phosphorylation; it set my mind at ease that our results were real, yet the 
study was old enough that our work would still be considered novel. Sometimes old is new 
again.  
 
3.  Housekeeping gene ? unregulated gene 
  
In Chapter 3, we demonstrated rapid, post-translational regulation of FAS, a 
housekeeping gene. FAS enzymatic activity was controlled through two phosphorylations on 
threonines 1029 and 1033 of murine FAS, flanking a crucial catalytic residue. These 
phosphorylations were found exclusively in cytoplasmic FAS, where insulin or feeding 
induced phosphorylation of FAS by mTORC1 leading to an inhibition of FAS-mediated 
PPAR? activation. 
In the textbook Molecular Biology of the Cell,  a housekeeping gene is defined as a 
“[g]ene serving a function required in all the cell types of an organism, regardless of their 
specialized role” [7]. These include genes involved in transcription and translation (such as 
ribosomal proteins and heat shock proteins), metabolism (such as genes involved in in lipid 
and glucose metabolism), and cell structure (such as actin and myosin). The term is useful 
and accurate to indicate genes and proteins that are ubiquitous and necessary for life, but 
becomes problematic when it is assumed that “constitutive” expression is equivalent to 
“unregulated” expression. If a protein is necessary for life, would that diminish the likelihood 
of its regulation by physiological or pathophysiological stimuli, or, by extension, of its 
involvement in signaling cascades requiring some manner of regulation? There is no reason 
to believe that to be the case. 
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An example of this misconception is the use of certain housekeeping genes as internal 
standards or loading controls for protein or mRNA levels, such as the the glycolytic enzyme 
GAPDH, when the levels of many housekeeping genes and proteins are in fact regulated in 
response to various drugs, experimental conditions, cell cycle stages, age etc. (reviewed and 
studied in [8]). But more importantly, this misconception puts a damper on interest in 
research on housekeeping proteins. A gene assumed not to be regulated is simply not as 
interesting for studying dynamic signaling processes.  
The “housekeeping” attribute of a protein or gene does make it difficult to study: 
unless compensatory mechanisms are at play, a mouse with full-body knock-out of a 
housekeeping gene by definition cannot be generated, as the housekeeping protein fulfills a 
function required for life. The embryonic lethality resulting from knock-out of many 
housekeeping genes obscures more subtle functions and any physiological or 
pathophysiological regulation that would occur in adult mice. In the case of FAS, whole-body 
knock-out causes early embryonic lethality (probably due to an inability to synthesize cell 
membranes), but tissue-specific knock-outs have revealed a number of signaling functions of 
FAS specific for different tissues that are sometimes finely regulated [9-14]. How many other 
important signaling roles and levels of regulation of housekeeping proteins are unexplored 
simply because they are assumed not to exist, or too difficult to study? 
 
4. Not all lipids are the same 
Just like not all proteins are the same, there is a staggering variety of lipids in nature 
and not all lipids are functionally equivalent. Rather, different lipids (or the same lipid in 
different places) play a variety of roles in cell signaling, structure, and energy storage, such as 
the function of 16:0/18:1-GPC in activating PPAR? (and not just 16:0/18:1-GPC, but FAS-
derived 16:0/18:1-GPC specifically). While the variety of functions of such a diverse class of 
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biomolecules shouldn’t come as a big surprise, the importance of lipids in signaling has only 
gained attention in the past fifteen years. As an illustration of this, the phrases “lipid signaling” 
and “signaling lipid” appeared 584 times in articles in the PubMed database over the past 
fifteen years (as of 6/20/2013), and prior to that only 44 times since the first usage of “lipid 
signaling” in the literature in 1988. 
The increasing interest in signaling lipids partly results from improvements in mass 
spectrometry, allowing for rapid identification of low-abundance lipid molecules. It also 
represents a recognition that the abundance of distinct lipid species may reflect a 
corresponding variety in functions. To me, this recognition ties in with the third point in 
emphasizing just how much we still do not know about cell biology, even in research fields 
that have been studied for decades, such as lipids and housekeeping genes. Thanks to the 
enormous increase in our knowledge of biology over the past century, a textbook in 
molecular biology may make it seem as if most cell biology has already been worked out. 
The challenge lies in seeing the gaps in our knowledge.  
The most important classes of larger biomolecules in living organisms are proteins, 
nucleic acids, lipids and polysaccharides. It would be easy to dismiss any of the latter classes 
as simply “fats” and “sugars” meant for storing and transporting energy, yet the sheer number 
of unique lipid species and polysaccharide modifications suggest that there is much we do not 
yet know. Developments in mass spectrometry have improved our ability to fill these gaps in 
knowledge.  
Establishing lipid-protein relationships for signaling lipids will be crucial, as the 
existence of protein targets facilitate pharmacological and genetic manipulation for research 
or therapeutic purposes. For all the lipid species of yet unknown function, there will be 
known and novel proteins involved in their synthesis, transport, and catabolism. Identification 
of signaling lipids may provide novel pathways that can be targeted to treat human disease, 
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and knowledge of these proteins would provide feasible pharmacological targets to treat 
metabolic disease. 
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Fatty acid synthase (FAS) catalyzes the de novo synthesis of fatty acids. In the liver, FAS has long been cate-
gorized as a housekeeping protein, producing fat for storage of energy when nutrients are present in excess.
Most previous studies of FAS regulation have focused on the control of gene expression. However, recent
findings suggest that hepatic FAS may also be involved in signaling processes that include activation of peroxi-
some proliferator-activated receptor α (PPARα). Moreover, reports of rapid alterations in FAS activity as well
as findings of post-translational modifications of the FAS protein support the notion that dynamic events in ad-
dition to transcription impact FAS regulation. These results indicate that FAS enzyme activity can impact liver
physiology through signaling as well as energy storage and that its regulation may be complex. This article is
part of a Special Issue entitled Triglyceride Metabolism and Disease.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
The liver is involved in the uptake, synthesis, storage, secretion,
and catabolism of fatty acids and triglycerides. Fatty acid synthase
(FAS), the enzyme catalyzing de novo synthesis of fatty acids, is tradi-
tionally thought of as a housekeeping protein, producing fatty acids
that can be used for energy storage, membrane assembly and repair,
and secretion in the form of lipoprotein triglycerides. However, the
contribution by FAS to secreted triglycerides appears to be negligible
compared to other sources of fat under common dietary conditions.
An unexpected role for FAS as a signaling enzyme emerged with the
finding that FAS can affect fatty acid oxidation through PPARα, the
main mediator of the fasting response in the liver.
The possibility that FAS may be involved in promoting fat catabo-
lism in addition to its known function of synthesizing fat raises new
questions regarding the regulation of FAS. Are there multiple pools
of FAS with distinct functions, allowing separate control of FAS-
mediated signaling and FAS-mediated energy storage? How is FAS-
PPARα signaling regulated in response to nutritional and hormonal
stimuli, and how is it possible for FAS to be activated or inhibited rapid-
ly? FAS has been thought to be regulated mostly at the transcriptional
level, which might preclude an immediate response by FAS to changes
in nutritional or hormonal stimuli since FAS mRNA is fairly stable. A
role for FAS in signaling suggests the presence of rapid, post-
translational mechanisms of FAS regulation. This review will address
physiological functions of hepatic FAS, its regulation by nutrients and
hormones, and mechanisms of regulation.
FAS may be a therapeutic target for treating fatty liver and dyslipi-
demia [1]. Both are common features of the metabolic syndrome
[2,3], which affects ~1 in 4 Americans [4]. Both are also independent
risk factors for coronary artery disease [5–7], the most common
cause of death worldwide. Identification of regulatory proteins and
pathways distinguishing housekeeping FAS from signaling FAS could
potentially lead to novel therapeutics that selectively target FAS
function.
1.1. Hepatic triglyceride metabolism
Under nutrient-replete conditions, the primary fuel of the liver is
glucose rather than fat. Fatty acids are not subjected to β-oxidation
and instead are incorporated into triglycerides for storage in lipid
droplets or secretion in very low-density lipoproteins (VLDL). Dietary
fat in the form of chylomicron remnants is taken up by the liver; de
novo synthesis of fatty acids by FAS may make a modest contribution
to storing energy as fat when nutrients are present in excess.
During fasting, lipolysis in peripheral tissues (primarily adipose
tissue) increases the levels of plasma free fatty acids (FFAs), which
are taken up by the liver. Activation of the transcription factor peroxi-
some proliferator-activated receptor α (PPARα) mediates the adaptive
response to fasting by promoting the transcription of genes involved in
the uptake and catabolism of fatty acids [8–11]. Fatty acids derived from
peripheral tissues or intrahepatic lipid droplets are catabolized through
β-oxidation to produce ketone bodies, which are used as fuel when glu-
cose is scarce.
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In insulin resistance, insulin fails to suppress lipolysis in peripheral
tissues even when nutrients are abundant, resulting in high circulating
levels of FFAs that are taken up by the liver. Increased FFA uptake and
perhaps increased de novo synthesis of fat in the liver overwhelms
the capacity for fatty acid oxidation, leading to fat accumulation and
eventually the development of hepatosteatosis or fatty liver.
There are thus three main sources of FFAs that contribute to liver
triglyceride: plasma, de novo synthesis, and dietary fat delivered by
chylomicron remnants. Triglycerides are secreted in VLDL, stored in
lipid droplets, or catabolized through the action of lipases and β-
oxidation. Fatty acid synthase appears to participate in liver triglyceride
metabolism both by contributing de novo synthesized lipids for storage
and secretion under nutrient-replete conditions and by promoting β-
oxidation of fatty acids through activation of PPARα under nutrient-
deficient conditions.
1.2. Fatty acid synthase
Fatty acid synthase (FAS, encoded by Fasn) catalyzes the biosyn-
thesis of saturated fatty acids from simple precursors (de novo lipo-
genesis). The primary product of the FAS reaction is palmitate
(C16:0), but stearate (C18:0) and shorter fatty acids may also be pro-
duced. FAS substrates are acetyl-CoA, malonyl-CoA, and NADPH.
Acetyl-CoA functions as a primer for the reaction, while NADPH pro-
vides reducing equivalents. The fatty acid is elongated from the initial
acetyl-CoA by repeated condensations with malonyl-CoA, which do-
nates two carbons in each cycle of condensation. Palmitate synthesis
thus requires seven cycles of malonyl-CoA addition to an acetyl-CoA
primer to yield a saturated, 16-carbon fatty acid.
The FAS protein exists as a homodimer of 273 kDa subunits. Each
monomer contains seven protein domains required for fatty acid syn-
thesis: acyl carrier, acyl transferase, β-ketoacyl synthase, β-ketoacyl
reductase, β-hydroxylacyl dehydratase, enoyl reductase, and thioes-
terase [12] (reviewed in Refs. [13–15]). However, FAS is only enzy-
matically active in the dimeric form [12]. The monomers were
initially thought to be oriented head-to-tail to form the dimer
[16,17], but recent structural data demonstrate a head-to-head orien-
tation of the monomers that are intertwined at their middle to form
an X-shape [18–21]. Mammalian FAS is a type I FAS complex with
the domains consolidated in a single peptide; prokaryotes and yeast
have a type II FAS with separate proteins catalyzing the individual re-
actions. Type II FAS complexes capable of synthesizing short-chain
(up to 14 carbons) fatty acids are also found in mammalian mito-
chondria [22].
FAS is a soluble protein and thought to be localized in the cyto-
plasm, although the specifics of its subcellular localization are largely
unexplored. Its tissue distribution is broad with highest levels in the
liver, adipose tissue, and lungs [23,24]. Whole-body knockout of FAS
causes embryonic lethality in mice, suggesting that de novo lipogenesis
is necessary early during development [25]. A likely possibility is that
FAS is required to provide lipids for cell membranes of the growing em-
bryo. Viable tissue-specific FAS knockout mice have been generated, in-
cluding a liver-specific knockout (discussed below).
2. Function of FAS in hepatic lipid metabolism
2.1. Contribution of de novo synthesized lipids to stored and secreted
hepatic triglycerides
Hepatic FAS synthesizes lipids that are stored as lipid droplets or
secreted in VLDL in the fed state. In mice, the contribution of liver
FAS to secreted VLDL is minor. Ob/obmice have 10-fold increased he-
patic de novo lipogenesis compared to lean mice, but no significant
differences in serum triglycerides [26]. In mice with liver-specific
knockout of FAS (FASKOL mice), serum triglycerides are normal on
a chow diet [27].
The contribution of de novo lipogenesis to secreted triglycerides
has been studied in humans in the setting of various diets. On diets
low in fat and high in carbohydrate (10% of calories as fat and 75%
as carbohydrate), de novo lipogenesis makes a significant contribu-
tion to circulating lipids as almost half of VLDL triglyceride is derived
from de novo lipogenesis under these conditions [28]. However, a
typical Western diet is high in fat as well as carbohydrates. In similar
studies using diets higher in fat (30% fat, 55% carbohydrate or 40% fat,
45% carbohydrate), the contribution of de novo lipogenesis to VLDL
triglycerides is undetectable or minor, at 0–10% [28,29]. These diets
are more representative of the high fat, high carbohydrate content
of a typical Western diet, indicating that under common dietary con-
ditions, de novo lipogenesis is not a significant contributor to VLDL
triglycerides. Substituting starch for sugar in a high-carbohydrate
diet also decreases the contribution of de novo lipogenesis to 0–1%
or 5% [30,31]. Obese individuals do not appear to have increased
FAS-derived VLDL triglycerides compared to lean individuals [29].
Under the high-fat, high-carbohydrate dietary conditions common
in the Western world today, hepatic FAS thus appears to be a minor
contributor to VLDL triglycerides.
FAS may contribute to triglycerides stored in hepatic lipid drop-
lets. In rats fed a chow diet, 11±1% of hepatic triglycerides are de-
rived from de novo lipogenesis [32]. On a high-fat diet, de novo
lipogenesis is suppressed and only 1.0±0.2% of hepatic triglycerides
are derived from FAS [32]. FASKOL mice on a chow diet have normal,
rather than decreased, liver triglyceride content [27]. It thus appears
that the contribution of de novo lipogenesis to stored triglycerides
is small in healthy liver.
In fatty liver, the contribution of FAS to intrahepatic triglycerides
may be greater. Ob/ob mice have increased hepatic FAS activity and
fatty liver [33], but a mechanistic link between the two has not
been established. In humans with non-alcoholic fatty liver disease,
one group has reported that 26±7% of hepatic triglycerides are de-
rived from de novo lipogenesis [34]. It is unknown how this compares
to the triglyceride content of healthy human liver. However, even in
the setting of hepatic over-accumulation of fat, the contribution of
FAS appears to be less than that of fats derived from peripheral tissues
or dietary fat.
2.2. Regulation of triglyceride metabolism through signaling lipids: ligand
activation of PPARα
PPARα is a member of a family of ligand-activated nuclear recep-
tors important for modulating metabolism and inflammation. During
fasting, PPARα promotes lipid uptake and catabolism of fatty acids
through β-oxidation to produce ketone bodies [9–11].
When liver-specific fatty acid synthase knockout (FASKOL) mice
were generated, they were surprisingly not protected against hepatic
lipid accumulation, but instead developed severe hepatic steatosis
when on a zero-fat diet or with prolonged fasting [35]. The phenotype
of fasted or zero-fat diet-fed FASKOL mice is similar to that of PPARα
null mice: hypoglycemia, low serum ketone levels, marked hepatic
steatosis, and deficient hepatic fatty acid oxidation [10,35]. Much of
this phenotype was corrected by administration of a known PPARα li-
gand. The deficient PPARα activation in the absence of both FAS and
dietary fat led to the hypothesis that “new” fat, derived from de
novo lipogenesis or dietary fat, can activate PPARα, whereas “old”
fat, derived from peripheral tissues or stored in the liver, cannot. Hy-
drolysis of hepatic triglycerides has also been shown to mediate
PPARα activation [36], suggesting that triglycerides of different ori-
gins (de novo synthesis vs. free fatty acids entering the liver following
lipolysis in peripheral tissues) may occupy separate compartments in
the hepatocyte. In addition to activating PPARα in liver, FAS has been
shown to regulate PPARα in macrophages [37] and hypothalamus
[38] as well.
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Further study of the FASKOL mouse led to the identification of an
endogenous ligand for hepatic PPARα: the phosphatidylcholine spe-
cies 16:0/18:1-glycerophosphocholine [27]. The interaction of this
species with PPARα is dependent on the activity of FAS, and inactiva-
tion of choline/ethanolamine phosphotransferase 1 (CEPT1), an en-
zyme catalyzing the final step in phosphatidylcholine biosynthesis,
mimics the FASKOL phenotype [27]. FAS thus appears to contribute
to PPARα activity by promoting the synthesis of one of its ligands.
A summary of the impact of FAS on hepatic triglyceride metabo-
lism is presented in Fig. 1.
2.3. Modulating hepatic FAS to treat disease
Ob/obmice have increased hepatic FAS gene expression as well as
increased hepatic FAS activity compared to lean mice [33]. Knock-
down of the transcription factor carbohydrate response element
binding protein (ChREBP), which promotes the expression of FAS as
well as other genes, in ob/ob liver decreases hepatic lipid accumula-
tion and decreases hepatic lipogenesis, suggesting a link between de
novo lipogenesis by FAS and fatty liver [39]. However, in a gene ex-
pression profiling study of ob/ob animals separated into high glucose
and lower glucose groups, mice with lower sugars (and thus likely to
be more insulin sensitive) had higher hepatic expression levels of
genes encoding lipogenic enzymes, including FAS, as compared to
mice with higher sugars [40]. This finding suggests that while activa-
tion of lipogenic enzymes in the liver is associated with obesity, this
effect is unlikely to be mechanistically linked to insulin resistance.
FAS inhibitors have been tested in mouse models of obesity and
diabetes. Treatment of lean or obese mice with the FAS inhibitor
C75 causes dramatic weight loss and improvement of hepatic steato-
sis in obese mice. However, the effect is primarily mediated by re-
duced food intake through inhibition of hypothalamic FAS (in
addition to possible effects of this particular agent that are indepen-
dent of FAS), obscuring the potential effects of inhibiting hepatic
FAS [41].
The FAS inhibitor platensimycin is concentrated in the liver when
administered orally and does not affect food intake [1]. Treatment of
high-fructose diet-fed db/dbmice with platensimycin reduces hepatic
FAS activity, hepatic lipid accumulation, and hepatic fatty acid oxida-
tion [1]. These data are consistent with roles for hepatic FAS both as a
producer of fat that may accumulate in liver, and as a generator of
lipid signals to nuclear receptors such as PPARα.
These data also highlight a caveat when considering FAS inhibitors
as therapy for hepatic steatosis: inhibition of FAS can affect both lipid
storage and lipid catabolism, and under conditions where baseline
FAS activity is not particularly high, loss of FAS activity might aggra-
vate rather than ameliorate hepatic steatosis, as seen in the liver-
specific FAS knockout mice [35].
3. Regulation of FAS activity
Transcriptional regulation of FAS has been well characterized, but
little is known about the post-translational regulation of FAS activity.
Similarly, long-term effects of hormones and nutrients on FAS expres-
sion are clear but their immediate effects are poorly understood.
3.1. Hormonal and nutritional regulation of FAS
Hepatic FAS is known to be regulated by insulin, glucagon, cyclic
AMP, fructose, glucose, and dietary fat.
Re-feeding mice or rats a high-carbohydrate diet following a pro-
longed fast causes a robust induction of FAS expression as compared
to the fasted or the ad lib-fed state [42–45]. The effect of carbohydrate
re-feeding is mediated by both insulin and glucose. Insulin regulates
FAS through transcriptional and non-transcriptional mechanisms.
Under nutrient-replete conditions, de novo lipogenesis may promote
storage of excess energy in the form of hepatic triglycerides. Insulin
promotes FAS expression through activation of the transcription fac-
tors sterol regulatory element binding protein 1c (SREBP-1c) [46]
and upstream stimulatory factors 1 and 2 (USF1 and USF2) [47,48].
Fig. 1. The role of FAS in hepatic triglyceride metabolism. Fatty acid synthase controls fatty acid catabolism through the synthesis of a ligand for PPARα, which activates fatty acid
oxidation genes. FAS makes a minor contribution of lipids to stored and secreted triglycerides, with the major contributions coming from plasma free fatty acids and dietary fats
from chylomicron remnants. 16:0/18:1 GPC, 16:0/18:1-glycerophosphocholine; DAG, diacylglycerol; FAS, fatty acid synthase; FFA, free fatty acid; PPARα, peroxisome
proliferator-activated receptor alpha; RXR, retinoid X receptor; TAG, triacylglycerol (triglyceride); VLDL, very low-density lipoprotein.
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Conversely, glucagon and cyclic AMP inhibit the increase in FAS activity
induced by carbohydrate re-feeding in rats [42,49,50].
The effect of fasting compared to ad lib feeding on the activity of
hepatic FAS is less clear. In mice, a 6 hour fast reduces FAS expression
levels by 60% compared to ad lib feeding [44], and in rats, a 24 hour
fast reduces FAS expression by over 90% compared to ad lib feeding
[45]. However, a 14 hour fast in mice produces no change in FAS ac-
tivity compared to ad lib-fed mice [51]. One potential explanation
for the lack of change in FAS activity in some circumstances could
be a relatively long half-life for the FAS protein. It is possible that
changes in FAS gene expression might have little effect on FAS en-
zyme activity in response to certain physiologically relevant periods
of fasting as compared to the ad lib fed condition.
While insulin promotes the expression of FAS, insulin also acutely
inhibits the enzymatic activity of hepatic FAS, causing a decrease in
FAS activity within minutes [51]. This inhibition is dependent on the
presence of the carcinoembryonic antigen-related cell adhesion mole-
cule 1 (CEACAM1), which is phosphorylated in response to insulin
and subsequently associates with FAS [51]. This acute inhibition of
FAS by insulin is blunted in hyperinsulinemic ob/obmice [51]. While a
clear physiological role for this acute inhibition of FAS activity has not
been determined, it is possible that the acute effect on FAS by insulin
primarily affects FAS lipid signals that impact PPARα. Acute inhibition
of FAS in response to insulin could then serve to halt the fasting re-
sponse by PPARα and decrease fatty acid oxidation when nutrients
are abundant. Because this acute change alters the specific activity
of FAS, the effect is likely post-translationally mediated. In contrast,
the long-term effect of insulin on FAS is transcriptionally mediated
and promotes FAS expression, enabling increased storage of energy
as fat.
Carbohydrates directly promote the expression of hepatic FAS in
the liver in addition to having an indirect effect by stimulating insulin
secretion. Feeding mice a high-glucose or high-fructose diet for
1 week leads to 3-fold and 8-fold, respectively, increases in FAS pro-
tein [52]. The effect of glucose on FAS expression is mediated by
ChREBP [53–56]. Hepatic metabolism of glucose by glucokinase (GK)
is necessary for the glucose-mediated induction of FAS by ChREBP [57].
The insulin-induced activation of SREBP-1c and the glucose-induced ac-
tivation of ChREBP act synergistically to promote FAS expression [57]. A
connection between lipid/carbohydrate sensing and metabolism is sug-
gested by the finding that stearoyl-CoA desaturase (SCD1), an enzyme
catalyzing the synthesis of oleate, is involved in the carbohydrate-
induced induction of FAS and other lipogenic enzymes [52].
Dietary fats inhibit FAS expression to decrease de novo lipogenesis
when fats are already abundant. Polyunsaturated fatty acids (PUFAs)
may decrease FAS expression through inhibition of SREBP-1c [58] and
ChREBP [59] activity. Diets consisting of 10% oil inhibit hepatic FAS ac-
tivity when fed to rats of over the course of 4 weeks, with the greatest
reduction in rats fed fish oil [60]. Re-feeding rats a carbohydrate-free,
high-fat diet following fasting suppresses FAS gene expression to
levels as low as those seen in rats fasted for 24 h [45].
3.2. Transcription and the FAS promoter
Much of the work on transcriptional regulation of FAS has been
done in rats, but the FAS promoter is highly conserved between species
suggesting that studies of the rat FAS promoter are likely to be relevant
to mice and humans. Regulatory elements and transcription factor
binding sites in the proximal mouse FAS promoter are shown in Fig. 2.
As noted above, SREBP-1c is activated by insulin and under appro-
priate conditions promotes expression of lipogenic genes, including
FAS. The FAS promoter contains a sterol regulatory element (SRE) at
−150 as well as tandem SREs at positions−72 and−62 that are re-
quired for optimal SREBP-1c-mediated activation of FAS expression in
rats [61–63].
An inverted CCAAT box at−94 is a binding site for nuclear factor Y
(NF-Y) and is necessary for inhibition of FAS expression by cyclic AMP
[64,65]. A binding site for the transcription factor specificity factor 1
(Sp1) is located nearby at −91 [63]. NF-Y and Sp1 proteins interact
[66] and mediate sterol-induced FAS expression synergistically with
SREBP-1c [63,67]. Another transcription factor, X-box binding protein
1 (XBP1), increases FAS promoter activity indirectly via SREBP-1c [68].
Also as noted above, ChREBP plays a central role in the glucose-
induced transcriptional regulation of FAS as well as other lipogenic
and glycolytic genes in the liver [53–56]. Glucose promotes the nuclear
translocation and activation of ChREBP, while polyunsaturated fatty
acids and cyclic AMP inhibit ChREBP activity [59,69]. ChREBP binds to
a carbohydrate response element (ChRE) located at−7214 in the distal
FAS promoter in rats to activate FAS transcription [70]. ChREBP appears
to be the main regulator of glucose-induced FAS expression, as glucose
fails to induce an increase in FAS expression in ChREBP-null hepatocytes
[53]. Mice fed a high-fructose diet have similar amounts of nuclear
ChREBP protein and ChRE-bound ChREBP protein compared to mice
fed a high-glucose diet, suggesting that dietary fructose and glucose
have comparable effects on ChREBP [71].
In addition to the ChRE, a direct repeat-1 (DR-1) element located
between−7110 and−7090 in the distal promoter of rat FAS is neces-
sary for full glucose activation of FAS expression [72]. Hepatic nuclear
factor-4α (HNF-4α) binds to the DR-1 element and interacts with
ChREBP. Ablation of HNF-4α produces a corresponding decrease in
glucose-induced FAS expression [72].
Liver X receptor (LXR), a transcription factor activated by oxysterols,
upregulates FAS expression through direct and indirect mechanisms.
Indirectly, LXR can promote FAS expression by binding to liver X recep-
tor elements (LXREs) in the promoters of the SREBP [73] and ChREBP
[74] genes to promote their transcription. SREBP and ChREBP in turn ac-
tivate FAS transcription. The LXR-mediated activation of SREBP-1c is the
primarymechanismof insulin-induced SREBP activation [73]. The phys-
iological relevance of LXR-mediated transcriptional regulation of
ChREBP is debated, as LXR is not necessary for the glucose-induced ac-
tivation of ChREBP [56]. LXR can also bind directly to LXREs located at
positions −686 to −672 of the mouse FAS promoter to activate FAS
transcription [75].
Fig. 2. The mouse proximal FAS promoter. Regulatory elements and nuclear factor binding site nucleotides are highlighted in yellow. IRE, insulin response element; LXRE, liver X
receptor element; Nf-Y, nuclear factor Y binding site; Sp1, specificity factor 1 binding site; SRE, sterol regulatory element.
750 A.P.L. Jensen-Urstad, C.F. Semenkovich / Biochimica et Biophysica Acta 1821 (2012) 747–753
An insulin response element (IRE) containing an E-box DNA binding
motif is located at positions−71 to−50 of the FAS promoter, overlap-
ping two tandem SREs. The IRE is necessary for insulin-induced FAS ex-
pression [76]. USF1 andUSF2 bind to the IRE [48]. Mutation of the E-box
prevents USF binding and abolishes insulin-induced FAS expression.
However, the importance of USFs in insulin-stimulated FAS expression
remains unclear, because mutation of the E-box also prevented
SREBP-1c binding [47].
3.3. Post-translational regulation of FAS
Transcriptional regulation of FASmay require hours to affect protein
levels since both FAS mRNA and protein are fairly stable, buffering sud-
den changes due to increased transcription and subsequent translation.
There are several reports of FAS protein being activated or inhibited
in far shorter time frames, as well as reports of changes in FAS activity
that do not correlate with changes in FAS protein levels. Insulin acutely
decreases FAS enzyme activity. In hepatoma cells, FAS activity decreases
linearly from 2 to 15 min after insulin treatment, followed by an in-
crease in FAS activity for 75 min [51]. Peroxynitrate inhibits FAS activity
in adipocytes within 10 min, without any effect on FAS protein levels
[77]. Activation and inhibition of FAS without corresponding changes
in FAS protein levels have been reported in a variety of cancer cell
lines [78–80]. These data suggest the presence of post-translational regu-
lation of FAS.
Phosphorylation has been proposed as a mechanism of FAS regu-
lation in cancer cells, adipocytes, and liver. In livers from pigeons
that were fasted and then re-fed, radiolabeled phosphate was incor-
porated into FAS in the cytosolic fraction. The phosphorylation
event was associated with low FAS activity, and dephosphorylation
of FAS by incubation with phosphatases caused a 20-fold increase in
FAS activity [81]. Another inhibitory phosphorylation was demon-
strated in 3T3-L1 adipocytes, where FAS threonine phosphorylation
was associated with inhibition of FAS activity [77]. This phosphoryla-
tion event was shown to require AMP-activated kinase (AMPK), likely
through indirect effects since in vitro kinase assays failed to demon-
strate any incorporation of labeled phosphate into FAS in the presence
of AMPK [77]. Thesefindings suggest the presence of an unidentified in-
termediate kinase step.
In human and mouse breast cancer cell lines, the finding that large
differences in FAS activity between cell lines did not correlate with
FAS protein levels prompted an exploration of FAS phosphorylation
as an alternative mechanism of FAS regulation [79]. Phosphoserine
and phosphothreonine residues were detected in FAS in cell lines
from both species, while FAS phosphotyrosine residues were detected
in human cells only. Phosphorylation of FAS in these cell lines was as-
sociated with greater FAS activity [79]. Recently, tyrosine phosphory-
lation of FAS was noted in two different human breast cancer cell
lines. Both FAS tyrosine phosphorylation and FAS activity were in-
duced by overexpression of human epidermal growth factor receptor
2 (HER2) and decreased by HER2 inhibition, and FAS was phosphory-
lated when complexed with HER2 [80].
In addition to phosphorylation, FAS was one of a large number of
hepatic metabolic enzymes recently found to be lysine acetylated
[82]. Acetylation was linked with diverse effects on metabolic en-
zymes, including protein destabilization, activation, and inhibition,
suggesting that acetylation may play a major role in metabolic regu-
lation. Acetylation of FAS could represent a novel mechanism for con-
trolling its activity.
Known examples of post-translational regulation of FAS are sum-
marized in Table 1.
4. Conclusions and future directions
Hepatic FAS is generally thought to be a housekeeping protein,
synthesizing fatty acids for the partitioning and storage of excess
energy. However, the contribution of FAS to stored and secreted tri-
glycerides is minor under most physiological conditions. Studies of
mice deficient in hepatic FAS have demonstrated that FAS also serves
as a signaling protein, controlling the activation of PPARα under
nutrient-deficient conditions to promote the adaptive response to
fasting.
FAS is regulated in part through effects on gene expression.However,
rapid changes in enzyme activity associated with alterations in nutri-
tional status suggest that post-translational mechanisms underlie enzy-
matic responses to external stimuli. An approach to understanding
these dynamic effects might include identifying post-translational
modifications of FAS, characterizing FAS subcellular localization,
searching for FAS-interacting proteins, and pursuing other mecha-
nisms that enable immediate control of FAS activity.
The existence of separate physiological functions for FAS implies
that it might be possible to develop function-specific therapies. Exclu-
sively modulating the cellular FAS pool that promotes fatty acid oxi-
dation or exclusively modulating the pool that promotes synthesis
of lipids for storage could provide new treatment options for fatty
liver and other serious obesity-related conditions.
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SUMMARY
De novo lipogenesis in adipocytes, especially with
high fat feeding, is poorly understood. We demon-
strate that an adipocyte lipogenic pathway encom-
passing fatty acid synthase (FAS) and PexRAP
(peroxisomal reductase activating PPARg) modu-
lates endogenous PPARg activation and adiposity.
Mice lacking FAS in adult adipose tissue manifested
increased energy expenditure, increased brown fat-
like adipocytes in subcutaneous adipose tissue,
and resistance to diet-induced obesity. FAS knock-
down in embryonic fibroblasts decreased PPARg
transcriptional activity and adipogenesis. FAS-
dependent alkyl ether phosphatidylcholine species
were associated with PPARg and treatment of
3T3-L1 cells with one such ether lipid increased
PPARg transcriptional activity. PexRAP, a protein
required for alkyl ether lipid synthesis, was associ-
ated with peroxisomes and induced during adi-
pogenesis. PexRAP knockdown in cells decreased
PPARg transcriptional activity and adipogenesis.
PexRAPknockdown inmicedecreasedexpressionof
PPARg-dependent genes and reduced diet-induced
adiposity. These findings suggest that inhibiting
PexRAP or related lipogenic enzymes could treat
obesity and diabetes.
INTRODUCTION
A relentless increase in mean global body weight since 1980
has resulted in an estimated 1.5 billion overweight people world-
wide, of which a half billion are obese (Finucane et al., 2011).
Obesity leads to diabetes, which is associated with premature
death from many causes (Seshasai et al., 2011). Obesity is
caused by positive energy balance leading to expansion of
adipocyte mass. However, adipocytes possess functional path-
ways that might be targeted to complement therapies altering
energy balance. De novo lipogenesis, an adipocyte function
that requires the multifunctional enzyme fatty acid synthase
(FAS) (Semenkovich, 1997), is one such potential target since
adipose tissue FAS has been implicated in obesity and insulin
resistance in humans (Moreno-Navarrete et al., 2009; Roberts
et al., 2009; Schleinitz et al., 2010).
Fatty acid synthase catalyzes the first committed step in
de novo lipogenesis. The magnitude of de novo lipogenesis is
different in rodents and people. Lipogenesis is thought to be
a relatively minor contributor to whole body lipid stores in
a present-day human consuming a typical high fat diet (Aarsland
et al., 1996; Letexier et al., 2003; McDevitt et al., 2001). However,
pharmacologic or genetic manipulation of enzymes in the lipo-
genic pathway can have profound metabolic consequences
(Postic and Girard, 2008), suggesting that de novo lipogenesis
might serve a signaling function independent of the generation
of lipid stores (Lodhi et al., 2011). Consistent with this concept,
FAS in liver is part of a lipogenic pathway involved in the gener-
ation of a ligand for peroxisome proliferator-activated receptor
a (PPARa) (Chakravarthy et al., 2009), a key transcriptional regu-
lator of fatty acid oxidation.
PPARs, consisting of PPARa, PPARd and PPARg, are ligand
activated transcription factors that form obligate heterodimers
with the retinoid X receptor (RXR) and regulate metabolism
(Wang, 2010). Ligand binding results in a conformational change
in the receptor, promoting dissociation of repressors, recruit-
ment of coactivators, and subsequent activation of target gene
expression. This nuclear receptor family was identified and
named based on activation by chemicals that promote prolifera-
tion of peroxisomes (Dreyer et al., 1992; Issemann and Green,
1990).
Peroxisomes participate in the oxidation of certain fatty acids
as well as the synthesis of bile acids and ether lipids (Wanders
and Waterham, 2006). These single membrane-enclosed organ-
elles are present in virtually all eukaryotic cells. In adipocytes
they tend to be small and were referred to as microperoxisomes
by Novikoff and colleagues, who documented a large increase in
peroxisome number during the differentiation of 3T3-L1 adipo-
cytes (Novikoff and Novikoff, 1982; Novikoff et al., 1980).
We sought to evaluate the role of de novo lipogenesis in adipo-
cyte function and metabolism. Here we show that a lipogenic
pathway encompassing FAS and PexRAP (peroxisomal reduc-
tase activating PPARg), an enzyme localized to peroxisomes
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and encoded by a previously unidentified mammalian gene,
contributes to the endogenous activation of PPARg and modu-
lates adiposity with high fat feeding.
RESULTS
Targeted Deletion of Adipose Tissue FAS
We generated FAS knocked out in fat (FASKOF) mice by
crossing FASlox/lox mice (Chakravarthy et al., 2005) with adipo-
nectin-Cre transgenic mice (Eguchi et al., 2011). FASKOF
mice, born at the expected Mendelian frequency, were overtly
normal. FAS protein was decreased in white and brown adipose
tissue of FASKOF relative to Cre only (without lox sites) and lox/
lox (without Cre) control mice (Figures 1A and 1B). FAS protein
content was not decreased in whole brain extracts of FASKOF
mice (Figure 1B). FAS mRNA assayed by quantitative RT-PCR
was the same in the hypothalamus of FASKOF and lox/lox
mice (not shown), suggesting that phenotypes are not likely to
be due to CNS effects (Lu et al., 2011; Ryan et al., 2011). FAS
enzyme activity was decreased in fat but not liver of FASKOF
mice (Figure 1C). Hepatic FAS enzyme activity was not signifi-
cantly increased in the setting of decreased adipose tissue
FAS activity (Figure 1C).
Chow-fed FASKOF and control mice weighed the same.
However, feeding a high fat diet (HFD) elicited a phenotypic
difference. HFD-fed FASKOF mice weighed less (Figure 1D)
and had less adiposity as well as more lean tissue compared
to controls (Figure 1E). The adiposity effect was seen in both
sexes and also in the setting of high carbohydrate/zero fat diet
feeding (Table S1). Epididymal fat pads (white adipose tissue,
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Figure 1. Targeted Deletion of Adipose Tissue FAS Decreases Adiposity
(A) FAS protein by western blot in brown (BAT) and white (WAT) adipose tissue of Lox/Lox control (without Cre), adiponectin-Cre control (without floxed alleles),
and FASKOF mice.
(B) Tissue distribution of FAS protein by western blot. An apparent increased expression of hepatic FAS protein in FASKOF mice was not consistently observed.
(C) FAS enzyme activity assay. *p = 0.031. N = 4/genotype.
(D) Body weight of HFD-fed control and FASKOF male mice. Similar results were also obtained in two additional feeding experiments with different cohorts of
male mice. *p = 0.03. **p = 0.0068 at 16 weeks, 0.0028 at 20 weeks. N = 6-8/genotype. Additional data including females are provided in Table S1.
(E) MRI analysis of body composition in HFD-fed mice. **p < 0.0001. N = 6/genotype.
(F) Tissue weights of HFD-fed control and FASKOF mice. **p = 0.005. N = 6/genotype.
(G) Histologic appearance of WAT harvested from chow-fed or HFD-fed mice.
(H) Adipocyte size distribution determined with the NIH Image J program. Error bars in (C)–(F) represent SEM.
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WAT), but not other tissues, from HFD-fed FASKOF mice
weighed less than those from control mice (Figure 1F). White
adipocytes isolated from FASKOFmicewere smaller than adipo-
cytes from control mice with HFD feeding (Figures 1G and 1H),
but there was no effect with chow feeding. Genotype and diet
had no effect on adipocyte cell number (not shown), perhaps
reflecting induction of adiponectin-Cre expression following adi-
pose tissue development.
The weight of brown adipose tissue (BAT) was not different in
mice fed HFD. However, when adult mice were fed a high carbo-
hydrate/zero fat diet, which maximizes effects due to FAS defi-
ciency, the BAT depot in FASKOF mice weighed significantly
less than that of control mice (Figure S1A). The histologic
appearance of BAT was not different between genotypes in
mice fed HFD, but lipid stores were depleted (Figure S1B) and
the PPARg target genes CD36, HSL, and ATGL were decreased
(Figure S1C) in the BAT depot from FASKOF mice fed a high
carbohydrate/zero fat diet.
Hepatic histologic appearance (Figure S1D) and lipid content
(Figure S1E) were not different between control and FASKOF
animals.
Altered Thermogenesis in FASKOF Mice
Food intake was not different between FASKOF and control
mice on any diet (Table S1). When studied on a HFD prior to de-
velopment of statistically significant differences in body weight,
FASKOF mice had increased energy expenditure compared to
controls (Figure 2A). Systemic glucose tolerance and insulin
sensitivity were enhanced in HFD-fed FASKOF mice (notable
for less adiposity) compared to controls (Figures 2B and 2C),
but with chow feeding (a condition associated with similar
degrees of adiposity in each genotype) there was no difference
in glucose tolerance between FASKOF and control mice (Fig-
ure S1F). Consistent with the observation that decreased
adiposity improves insulin sensitivity in numerous animal models
(Elchebly et al., 1999; Masuzaki et al., 2001; Yang et al., 2005;
Yuan et al., 2001), levels of phospho-Akt relative to total Akt
were increased in skeletal muscle of HFD-fed FASKOF mice
(data not shown). Serum leptin was lower (perhaps reflecting
decreased adiposity) but adiponectin was unaffected in HFD-
fed FASKOF mice (Table S1). Given effects of FAS deletion on
other PPARg genes (see below), it is possible that not all targets
of PPARg, including adiponectin, are affected by FAS deletion.
Monitored physical activity was not increased in FASKOF ani-
mals (Figure S1G).
Body temperature was not different between control and
FASKOF mice at room temperature, there were no apparent
brown fat-like adipocytes in the epididymal fat of FASKOF
mice, and FASKOF epididymal fat did not have increased
expression of the brown fat gene UCP1 (not shown). However,
UCP1 expression was strikingly increased in inguinal fat from
HFD-fed FASKOF mice as compared to controls (Figure 2D).
Expression of PRDM16, a transcriptional coregulator involved
in the development of classic BAT as well as brown fat-like
adipocytes in subcutaneous white adipose tissue (WAT) (Seale
et al., 2011), was also increased as were levels of the brown
fat genes Cidea and PGC1a (Figure 2D). PPARa is known to
induce UCP1 expression (Barbera et al., 2001), andmRNA levels
for PPARa as well as the PPARa-dependent genes CPT1 and
ACO were increased in inguinal fat (Figure 2D). Since PPARa
promotes fatty acid oxidation, we assayed this process in
homogenates of WAT as the release of CO2 from radiolabelled
palmitate. In HFD-fed mice, fatty acid oxidation was increased
in FASKOF as compared to control mice in inguinal but not
epididymal WAT (Figure 2E). To maximize effects due to
FAS deficiency, we fed mice a high carbohydrate/zero fat diet
and analyzed inguinal fat. Under these conditions, inguinal fat
mRNA levels for UCP1, Cidea, and PGC1a were increased (Fig-
ure S1H). UCP1 protein was increased in inguinal fat from
FASKOF as compared to control mice by both western blotting
(Figure 2F) and immunocytochemistry (Figure 2G). With cold
exposure, FASKOF mice maintained their body temperature at
a significantly higher level than control mice (Figure 2H), suggest-
ing that increased brown fat-like cells in subcutaneous WAT of
FASKOF are physiologically relevant.
FAS Promotes PPARg Activation and Adipogenesis
PPARg is necessary and sufficient for adipogenesis (Tontonoz
and Spiegelman, 2008) but also mediates HFD-induced hyper-
trophy of adipocytes (Hosooka et al., 2008; Kubota et al., 1999).
Moreover, PPARg is thought to promote fat development at
the expense of myogenesis (Hu et al., 1995; Seale et al., 2008).
Previous studies suggested that lipogenic pathways may be
required for activating PPARg by generating its endogenous
ligand (Kim and Spiegelman, 1996; Kim et al., 1998) and influ-
encing adipogenesis (Schmid et al., 2005).
Since HFD-fed FASKOF mice have decreased adiposity and
reduced adipocyte hypertrophy (Figure 1), we explored the pos-
sibility that FAS is involved in PPARg activation and adipogene-
sis using mouse embryonic fibroblasts (MEFs) from FASlox/lox
animals. Expression of Cre using an adenovirus (Ad-Cre) in these
cells decreased FAS protein and impaired adipogenesis (Figures
3A and 3B). Defective adipogenesis induced by FAS deficiency
was rescued by treatment with the PPARg activator rosiglitazone
(Figure 3B, bottom panels), likely due to induction of processes
(involving CD36, LPL, and other proteins) that facilitate uptake
of lipids from the culture media.
We next transfected HEK293 cells with cDNAs for PPARg
and a PPAR-dependent luciferase reporter in the presence
or absence of FAS knockdown. FAS deficiency decreased
luciferase reporter activity, an effect that was rescued with
rosiglitazone, suggesting that FAS regulates PPARg transcrip-
tional activity (Figure 3C). To address possible contributions of
ligand-independent effects of FAS knockdown on PPARg trans-
activation, we performed luciferase reporter assays using cells
transfected with constitutively active PPARg (VP16-PPARg) or
wild-type PPARg. FAS knockdown reduced luciferase reporter
activity in cells transfected with WT PPARg, and the effect was
significantly greater than in cells transfected with VP16-PPARg
(Figure 3D). Knockdown of FAS in primary MEFs decreased
expression of the PPARg target genes aP2 and CD36 but
increased expression of the early myogenesis markers MyoD
andmyogenin, effects that were reversed with rosiglitazone (Fig-
ure 3E). Consistent with induction of myogenic markers, FAS
inactivation was associated with myotube formation under
promyogenic culture conditions (Figure 3F). FAS knockdown
decreased levels of proteins regulated by PPARg in 3T3-L1
adipocytes (Figure 3G). PPARg target gene expression was
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restored in these murine cells with FAS knockdown by express-
ing human FAS (Figure 3H). PPARg target genes were also
decreased in the adipose tissue of FASKOF mice (Figure 3I).
To determine if FAS deficiency is affecting PPARg expression
as opposed to its transcriptional activity, we fed mice a high
carbohydrate/zero fat diet to maximize effects due to FAS defi-
ciency and subjected gonadal WAT to western blotting. There
was no effect on PPARg protein mass while protein levels of
the PPARg target aP2 were decreased in FASKOF as compared
to control mice (Figure 3J). One plausible interpretation of these
results is that FAS is part of a lipogenic pathway that regulates
adipogenesis at the expense of myogenesis by generating
endogenous ligands for PPARg that promote its transcriptional
activity.
Identification of FAS-Dependent Diacyl and Alkyl Ether
Lipid Species Bound to PPARg
There are probably numerous PPARg endogenous ligands that
may be generated under conditions requiring alterations in
adipocyte function, but ligands are initially produced early during
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Figure 2. Altered Metabolism in Mice with Adipose-Specific Knockout of FAS
(A) Oxygen consumption (VO2) by indirect calorimetry in HFD-fed mice. Indicated p value by ANOVA. N = 8–10/genotype.
(B) Glucose tolerance testing in HFD-fed mice. p = 0.0477 at 0 min, 0.0415 at 60 min. N = 6–8/genotype. Serum insulin values at 30 min point shown in the inset.
(C) Insulin tolerance testing in the mice of (B). *p = 0.039.
(D) RT-PCR analysis of gene expression in inguinal WAT of HFD-fed control and FASKOFmalemice. Gene expression analysis in inguinalWAT of ZFD-fedmice is
presented in Figure S1H. **p = < 0.0001 for UCP1, 0.0017 for Cidea, 0.0001 for PRDM16, 0.0008 for PGC1a, 0.0012 for PPARa, and 0.0001 for CPT1; *p = 0.042
for ACO.
(E) Measurement of fatty acid oxidation in epididymal (eWAT) and inguinal (iWAT) fat of control and FASKOF mice fed HFD. *p = 0.0355 for HFD iWAT. N = 3
animals/genotype for each diet.
(F) Western blot analysis in inguinal WAT of ZFD-fed control and FASKOF male mice. Each lane represents a separate mouse.
(G) Immunocytochemical analysis of UCP1 expression in inguinal WAT of ZFD-fed control and FASKOF mice. Images are from two separate mice per genotype.
(H) Rectal temperature of ZFD-fed control and FASKOF mice at room temperature (23C) and after 1 hr exposure to 4C. N = 6–8 animals/genotype. *p = 0.011.
Error bars in (A)–(E) and (H) represent SEM.
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adipocyte differentiation (Tzameli et al., 2004). To isolate such
putative FAS-dependent ligands, we used mass spectrometry
after infecting MEFs with an adenovirus encoding FLAG-tagged
PPARg and inducing differentiation (Figure 4A). PPARg was iso-
lated by affinity from cells in the presence or absence of FAS
knockdown (Figure 4B) and associated lipids were analyzed by
mass spectrometry (Figure 4C). We identified several phospha-
tidylcholine species with diacyl (ester bond-linked) or 1-O-alkyl
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Figure 3. FAS Is Required for Adipogenesis and PPARg Activation
(A) Western blot analysis of FAS knockdown in primaryMEFs from FASlox/lox mice treatedwith an adenovirus expressing GFP or Cre at the indicatedmultiplicity of
infection (moi).
(B) Oil red O staining of FASlox/lox MEFs treated with Ad-GFP or Ad-Cre and differentiated to adipocytes in the presence or absence of rosiglitazone.
(C) HEK293 cells treated with control or FAS siRNA were transfected with plasmids encoding PPRE-luciferase, Renilla luciferase and wild-type PPARg in the
presence or absence of rosiglitazone. **p < 0.0001 versus control, #p < 0.0001 versus FAS siRNA basal. N = 3/condition.
(D) HEK293 cells treated with control or FAS siRNA were transfected with plasmids encoding PPRE-luciferase, Renilla luciferase and wild-type PPARg or VP16-
PPARg DBD (an N-terminal fragment of PPARg encompassing the DNA binding domain fused to the VP16 transactivation domain). **p < 0.0001 versus control,
#p < 0.0001 versus FAS siRNA/WT PPARg. N = 3/condition.
(E) RT-PCR analysis of gene expression in FAS-deficient (Ad-Cre-treated) or control (Ad-GFP-treated)MEFs subjected to the adipogenesis protocol. **versus Ad-
GFP, p = 0.0060 for aP2, 0.0010 for CD36, 0.0051 for MyoD, 0.0007 for Myogenin. #versus Ad-Cre, p = 0.0015 for aP2, 0.0013 for CD36, 0.0099 for MyoD, 0.0019
for Myogenin.
(F) FAS-deficient (Ad-Cre-treated) or control (Ad-GFP-treated) MEFs cultured to promote myogenesis and stained with a skeletal muscle myosin heavy chain
antibody.
(G) Detection of proteins induced by PPARg in 3T3-L1 fibroblasts and adipocytes treated with control or FAS shRNA.
(H) Restoration of PPARg target gene expression with human FAS using 3T3-L1 adipocytes with endogenous knockdown of FAS. 3T3-L1 cells stably expressing
retrovirally encoded human FAS were infected with a lentivirus expressing scrambled control (SC) or mouse FAS shRNA. The cells were induced to differentiate
into adipocytes. The upper panel shows real-time PCR analysis of aP2 expression and the bottom panel shows a western blot with antibodies against FAS, HA,
and actin. *p = 0.0224 (versus SC shRNA, empty vector). #p < 0.0001 (versus FAS shRNA, empty vector).
(I) RT-PCR analysis of gene expression in control and FASKOF gonadal WAT. **p = 0.007. *p = 0.0493 for C/EBPa, 0.010 for LPL, 0.039 for CD36. N = 4/genotype.
(J) Western blot analysis in gonadal WAT of ZFD-fed control and FASKOF female mice. Each lane represents a separate mouse. Error bars in (C)–(E), (H), and (I)
represent SEM.
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(ether bond-linked) side chains associated with PPARg that were
competitively displaced by rosiglitazone (not shown). Alkyl ether
lipids were particularly enriched in PPARg samples compared to
controls (Table S2). The species at m/z 752 [M+Li]+ was most
frequently associated with PPARg and tandem mass spectrom-
etry identified it as 1-O-octadecenyl-2-palmitoyl-3-glycerophos-
phocholine (18:1e/16:0-GPC) (Figure S2). We synthesized this
alkyl ether lipid and used it to treat cultured cells. 18:1e/16:0-
GPC increased PPARg-dependent luciferase reporter activity
in a dose-dependent fashion (Figure 4D) but was less potent
than rosiglitazone. We found that 20 mM 18:1e/16:0-GPC signif-
icantly increased the expression of PPARg target genes in differ-
entiating 3T3-L1 adipocytes (Figure 4E).
In order to provide insight into the interaction between
18:1e/16:0-GPC and the PPARg ligand binding domain (LBD),
we developed a GST-pulldown assay of PPARg ligand bind-
ing based on the ligand-dependent interaction between an
N-terminal region of CBP1 and the PPARg LBD (Gelman et al.,
A C
B
D
E
Figure 4. Isolation of FAS-Dependent Diacyl and 1-O-alkyl Ether Phosphatidylcholine Species Associated with PPARg
(A) Strategy for detection of PPARg-associated lipids.
(B) Detection of FLAG-PPARg protein immunoprecipitated from adipocytes treated with control or FAS shRNA.
(C) Mass spectrometric analyses of [M+Li]+ ions of glycerophosphocholine (GPC) lipids bound to FLAG-PPARg or control protein (GFP) immunoprecipitated from
control and FAS knockdown adipocytes. Ions of m/z 752 and 780 represent 1-O-alkyl GPC species.
(D) CV-1 cells were transfected with plasmids encoding UAS-luciferase, Renilla luciferase and Gal4-PPARg LBD (a C-terminal fragment of PPARg encompassing
the ligand binding domain fused to the Gal4 DNA binding domain) or Gal4 alone. The cells were treated with 18:1e/16:0-GPC (corresponding to m/z 752 in C),
rosiglitazone, or DMSO. After 48 hr, UAS-luciferase reporter activity was measured and normalized to Renilla luciferase reporter activity. **p = 0.0001. *p = 0.018
(10 mM), 0.024 (20 mM), 0.019 (80 mM).
(E) 3T3-L1 cells were induced to differentiate in DMEM+10%FBSwith supplemental dexamethasone, insulin and IBMX in the presence of 20 mM18:1e/16:0-GPC
or DMSO. After 3 days, the cells were retreated with the GPC in media containing supplemental insulin alone. The next day, the cells were harvested for RNA
extraction and real-time PCR analysis. The data are representative of 3 separate experiments. *p = 0.0147 (aP2), 0.0006 (LPL), 0.0102 (CD36). Error bars in (D) and
(E) represent SEM.
Cell Metabolism
Lipogenesis and Adipose Programming
6 Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc.
Please cite this article in press as: Lodhi et al., Inhibiting Adipose Tissue Lipogenesis Reprograms Thermogenesis and PPARg Activation to Decrease
Diet-Induced Obesity, Cell Metabolism (2012), http://dx.doi.org/10.1016/j.cmet.2012.06.013
1999). 18:1e/16:0-GPC increased the interaction between the
GST-tagged PPARg LBD and the myc-tagged CBP1 N terminus
in a dose-dependent manner (Figure S3A). However, 18:1e/16:0-
GPC did not increase the interaction between the GST-tagged
LBD of a different nuclear receptor, PPARa, and the myc-tagged
CBP1 N terminus (Figure S3B). To provide additional evidence
that this ether lipid enhances PPARg transcription due to ago-
nism, we added 18:1e/16:0-GPC to terminally differentiated
3T3-L1 adipocytes. Both 18:1e/16:0-GPC and rosiglitazone
increased LPL gene expression in differentiated adipocytes
that were treatedwith a control shRNAprior to induction of differ-
entiation (Figure S3C). In cells prevented from differentiating into
adipocytes by FAS knockdown, treatment with either 18:1e/
16:0-GPC or rosiglitazone after completion of the differentiation
protocol (with dexamethasone, IBMX, and insulin followed by
additional insulin treatment) did not restore full LPL expression
(Figure S3C). FAS deficiency decreased expression of PPARg-
dependent genes (Figure 3I) while increasing expression of
PPARa-dependent genes (Figure 2D). When FAS expression
was knocked down in 3T3-L1 cells that were subsequently
induced to differentiate into adipocytes, the FAS-deficiency-
associated increase in ACO gene expression was significantly
decreased when cells were differentiated in the presence of
the selective PPARa antagonist GW6471 (Figure S3D). These
results suggest that an FAS-dependent ether lipid interacts
with PPARg but not PPARa and that FAS deficiency is associ-
ated with decreased activation of PPARg and increased activa-
tion of PPARa.
Cloning and Characterization of PexRAP
Ether lipid synthesis in mammals occurs through the peroxi-
somal acyl dihydroxyacetone phosphate (DHAP) pathway, al-
lowing synthesis of lysophosphatidic acid as an alternative to
direct acylation of glycerol 3-phosphate. This pathway is obliga-
tory for synthesis of ether lipids including platelet activating
factors and plasmalogens (Hajra and Das, 1996; Hajra et al.,
2000; McIntyre et al., 2008) (Figure 5A). The terminal enzyme
activity in this pathway, acyl/alkyl DHAP reductase, was purified
and characterized from guinea pig liver (LaBelle and Hajra,
1974), but the gene encoding this protein has not been identified
inmammals (McIntyre et al., 2008). Since a yeast enzyme (Ayr1p)
(Athenstaedt and Daum, 2000) that catalyzes this reaction has
been cloned and characterized, we used this sequence to iden-
tify DHRS7b, a protein of unknown function, as a mammalian or-
tholog (Figure 5B). We renamed this protein PexRAP. Gradient
fractionation of 3T3-L1 adipocytes showed that PexRAP is
enriched in fractions containing peroxisomal markers, such as
PMP70 and catalase (Figure 5C). Myc-tagged PexRAP coimmu-
noprecipitated with Pex19 (peroxisomal biogenesis factor 19, an
import receptor for peroxisomal membrane proteins) (Figure 5D),
and this interaction was confirmed in pulldown experiments
using GST-PexRAP (Figure 5E).
To demonstrate that PexRAP mediates its predicted enzyme
activity, we knocked down PexRAP expression in MEFs (Fig-
ure 5F) and found decreased levels of 1-O-alkyl ether phospho-
lipids as well as certain diacyl phospholipids (Figure 5G), some of
which also arise from the DHAP pathway. 18:1e/16:0-GPC was
detected in these experiments as m/z 746 [M+H]+ since these
experiments were performed with protonated species; 18:1e/
16:0-GPC was detected as m/z 752 using lithiated species in
Figure 4C. PexRAP protein was detected in multiple tissues,
but levels were low in skeletal muscle (Figure 5H). The overall
expression of PexRAP in BAT was relatively low and BAT
primarily expressed a shorter isoform (which lacks 9 amino
acid residues at the N terminus), suggesting that PexRAP may
have a different role in BAT compared to WAT. Both PexRAP
and FAS proteins markedly increase early during differentia-
tion of 3T3-L1 adipocytes, prior to similar increases in proteins
such as C/EBPa and aP2 known to be induced by PPARg acti-
vation (Figure 5I). Thus, PexRAP is peroxisomal, its inactivation
decreases lipids associated with PPARg, and its temporal rela-
tionship during differentiation with other adipocyte proteins
suggests that it could be involved in adipogenesis.
PexRAP Is Required for Adipogenesis
To address the role of PexRAP in adipogenesis, we knocked
down its expression in 3T3-L1 cells. Adipogenesis (assessed
by both Nile red staining and triglyceride content) was abro-
gated with PexRAP knockdown and rescued with rosiglitazone
(Figures 6A and 6B), suggesting that PexRAP, like FAS (Fig-
ure 3B), affects PPARg activation. Knockdown of PexRAP or
DHAP acyltransferase (DHAPAT, the enzyme immediately up-
stream of PexRAP, Figure 5A) in 3T3-L1 adipocytes decreased
expression of PPARg target genes (Figure 6C). Rosiglitazone
treatment rescued the effect of PexRAP or DHAPAT knockdown
on PPARg target genes (Figure 6D).
PexRAP Knockdown in Mice Alters Body Composition
and Metabolism
We translated these observations to HFD-fed C57BL/6J mice,
characterized by increased adiposity and insulin resistance.
A series of PexRAP antisense oligonucleotides (ASOs) were
screened for effectiveness (not shown) and results of PexRAP
knockdown for two of themost promising are shown in Figure 7A
using Hepa1-6 cells. ASO2 was selected for use in mice. Intra-
peritoneal administration of ASO2 at up to 20 mg/kg twice
a week for three weeks resulted in a dose-dependent decrease
in PexRAP protein in WAT and liver (but not in brain or skeletal
muscle, Figures 7B and S4A). Mice were fed a HFD for four
weeks to increase adiposity and then animals were injected
twice a week with 20 mg/kg of ASO2 or the control ASO for
24 days while HFD was continued. ASO treatment had no
effect on liver function tests or liver histology (not shown). Liver
fat content was nearly significantly lower (p = 0.072) with ASO
treatment. Food intake was unaffected (Table S3). However,
this intervention decreased expression of PexRAP as well as
PPARg target genes (including PPARg itself) in WAT (Figure 7C).
PexRAP knockdown in HFD-fed mice also decreased adiposity,
increased leanness, and decreased fasting glucose (Figure 7D
and Table S3). Glucose tolerance was improved and insulin
levels were lower in HFD-fed mice treated with the PexRAP
ASO (Figures 7E and 7F).
DISCUSSION
These studies suggest that depletion of FAS in adipose tissue
suppresses HFD-induced obesity. FAS is a minor contributor
to cellular lipid stores with high fat feeding (Aarsland et al.,
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1996; Letexier et al., 2003; McDevitt et al., 2001); HFD feeding
decreases FAS expression (Coupe et al., 1990; Kersten, 2001).
Thus, it is unlikely that the reduced adiposity observed in the
HFD-fed FASKOF mice was due to the inability to synthesize
fatty acids per se. Rather, our results suggest that inhibiting
a lipogenic pathway initiated by FAS increases thermogenesis
and reduces activation of PPARg. Increased energy expenditure
comes not from effects on classic BAT but instead by inducing
the formation of brown fat-like (‘‘brite’’) cells in subcutaneous
adipose tissue (Seale et al., 2011).
In addition to inducing brown fat-like cells in subcutaneous
fat, FAS deletion decreased PPARg transcriptional activity. It is
possible that these transcriptional effects are unrelated or only
partially related to the phenotype of resistance to diet-induced
obesity caused by increased brite cells. PPARg agonism can
induce UCP1 gene expression and produce small adipocytes in
A B
D EC
F G H
I
Figure 5. Cloning and Characterization of the Terminal Component in the Mammalian Peroxisomal Ether Lipid Synthetic Pathway
(A) The peroxisomal acyl-DHAP pathway of lipid synthesis. FAS, fatty acid synthase; ACS, acyl CoA synthase; G3PDH, glycerol 3-phosphate dehydrogenase;
DHAP, dihydroxyacetone phosphate; DHAPAT, DHAP acyltransferase; FAR1, fatty acyl CoA reductase 1; ADHAPS, alkyl DHAP synthase; ADHAP Reductase,
acyl/alkyl DHAP reductase activity; LPA, lysophosphatidic acid; AGP, 1-O-alkyl glycerol 3-phosphate.
(B) Mouse DHRS7b is homologous to yeast acyl DHAP reductase, Ayr1p. TMD, transmembrane domain; Adh_short, short chain dehydrogenase/reductase
domain.
(C) PexRAP (peroxisomal reductase activating PPARg, detected using anti-DHRS7b antibody) is enriched in peroxisomal fractions isolated from 3T3-L1
adipocytes. S, supernatant; P, pellet after sedimentation.
(D) Pex19 coimmunoprecipitates with Myc-tagged PexRAP. WCL, whole cell lysates.
(E) Pex19 interacts with PexRAP in GST pull-down experiments using 3T3-L1 adipocytes.
(F) RT-PCR analysis of PexRAP expression with PexRAP knockdown in MEFs. **p = 0.0084.
(G) Mass spectrometric analyses of [M+H]+ ions of GPC lipids in MEFs after PexRAP knockdown. Quantification of the 1-O-alkyl ether GPC lipid peak atm/z 746
[M+H]+ (identical to the lithium adduct at m/z 752 in Figure 4C) is shown in the inset. **p = 0.0009.
(H) Mouse tissue distribution of PexRAP protein by western blotting.
(I) Protein abundances of PexRAP and FAS increase prior to increases in C/EBPa and aP2 during differentiation of 3T3-L1 adipocytes. Error bars in (F) and (G)
(inset) represent SEM.
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WAT (de Souza et al., 2001; Fukui et al., 2000; Tiraby et al., 2003),
similar to the FASKOF mouse phenotype, and yet FASKOF mice
have decreased PPARg activation. However, pharmacologic
agonism of PPARg promotes adiposity, while FASKOF mice
have less adiposity. Effects on PPARa with FAS deletion could
provide a plausible explanation. PPARa and its targets are
induced in FASKOF adipose tissue (Figure 2D). PPARa inhibition
decreases induction of the PPARa target gene ACO with FAS
knockdown in 3T3-L1 cells (Figure S3D). PPARa agonism can
also induce UCP1 gene expression (Barbera et al., 2001) as
well as decrease adipocyte size (Tsuchida et al., 2005), and the
acute effects of PPARa activation on UCP1 gene expression
may exceed those of PPARg (Pedraza et al., 2001). Decreased
PPARg transcriptional activity could reflect the lack of an FAS-
associated lipid ligand, allowing increased PPARa activity and
induction of UCP1. In support of this notion, induction of UCP1
and the development of brown fat-like cells by FNDC5 (cleaved
to form irisin) occurs in part throughPPARa (Bostro¨met al., 2012).
Our data point to a pathway (Figure 7G, left) in which lipids
synthesized by FAS serve as substrate for PexRAP, which
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Figure 6. PexRAP Is Required for Adipogenesis and PPARg Activation
(A) Nile red staining of 3T3-L1 adipocytes treated with control or PexRAP shRNA in the presence or absence of rosiglitazone.
(B) Triglyceride content for the cells of (A). **p = 0.0066 versus control, #p = 0.0071 versus PexRAP shRNA vehicle. N = 3/condition.
(C) RT-PCR analysis of gene expression following PexRAP or DHAPAT knockdown. P versus control: DHAPAT, *0.0278, **0.007; PexRAP, *0.040; aP2, **0.0060
for PexRAP shRNA and 0.0058 for DHAPAT shRNA; C/EBPa, *0.0160 for PexRAP shRNA and 0.0165 for DHAPAT shRNA; LPL, **0.0014, *0.0450; CD36, *0.0113
for PexRAP shRNA and 0.0132 for DHAPAT shRNA. N = 3–5/condition.
(D) Rosiglitazone treatment rescues the effect of PexRAP or DHAPAT knockdown on PPARg target gene expression. 3T3-L1 cells infected with lentivirus ex-
pressing control, PexRAP, or DHAPAT shRNA were induced to differentiate into adipocytes and then treated with 2.5 mM rosiglitazone. Expression of PPARg
target genes was analyzed by quantitative RT-PCR. For aP2, exact p values from left to right = 0.0038, 0.0119, 0.0024, 0.0032. For CD36, p values = 0.0022,
0.0015, 0.0110, < 0.0001.
Error bars in (B)–(D) represent SEM.
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generates alkyl ether lipids that are potential endogenous
PPARg ligands. Disruption of FAS (Figure 7G, right) decreases
these ether lipids, altering the coactivator milieu to favor
PPARa-dependent gene expression.
Several lines of evidence support the concept that a lipogenic
pathway localized to peroxisomes is important for endogenous
activation of PPARg. The PPAR family was named because of
the ability to be activated by agents that increase the number
of peroxisomes (Dreyer et al., 1992; Issemann and Green,
1990). The number of peroxisomes is dramatically increased
during differentiation of 3T3-L1 adipocytes (Novikoff and Novik-
off, 1982; Novikoff et al., 1980), a PPARg-dependent process.
Consistent with our observation that PexRAP expression is
induced during adipogenesis, previous studies suggest that
the activities of various enzymes in the peroxisomal ether lipid
synthetic pathway increase during differentiation of 3T3-L1 adi-
pocytes (Hajra et al., 2000).
There is precedent for PPARg activation by alkyl ether lipids.
Azelaoyl PAF (1-O-hexadecyl-2-O-(9-carboxyoctanoyl)-sn-glyc-
eryl-3-phosphocholine), reported to be equipotent to rosiglita-
zone (Davies et al., 2001), and 1-O-alkyl glycerol 3-phosphate
(McIntyre et al., 2003; Tsukahara et al., 2006), synthesized
directly by PexRAP (see Figure 5A), are thought to be PPARg
ligands. Because PPARg has a capacious ligand binding pocket
(Schupp and Lazar, 2010), it is possible that instead of a single
authentic endogenous ligand, multiple lipids are recruited to
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Figure 7. Knockdown of PexRAP in Mice Alters Body Composition and Metabolism
(A) PexRAP knockdown using antisense oligonucleotides (ASOs) in Hepa1-6 cells.
(B) Western blot analysis using epididymal WAT of C57BL/6J mice treated intraperitoneally with the indicated doses of control or PexRAP ASO twice a week for
3 weeks.
(C) RT-PCR analysis of epididymal WAT expression following ASO treatment. P versus control: PexRAP **0.0078; PPARg **0.0051; CD36 *0.0420; LPL **0.0030.
N = 4/condition.
(D) Body composition byMRI following 4weeks of HFD feeding (baseline) and after 3.5 weeks of ASO treatment while still eating aHFD. **p = 0.0098 for fat, 0.0071
for lean. N = 4/condition.
(E) Glucose tolerance testing in HFD-fed mice following ASO treatment. *p = 0.0220 at 15 min and 0.0434 at 120 min. **p = 0.0019.
(F) Insulin levels at the 30 min point from (E). *p = 0.0363.
(G) Models of PPARg and PPARa gene expression in WT and FAS-deficient adipocytes. Error bars in (C)–(F) represent SEM.
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the receptor depending on the physiological context, with vari-
able effects on transcriptional activity (Lodhi et al., 2011; Schupp
and Lazar, 2010).
ASO-mediated inhibition of PexRAP decreased adiposity and
improved glucose metabolism, probably by activating thermo-
genesis in subcutaneous WAT. In studies to be reported else-
where, we have observed that PexRAP deficiency in adipose
tissue achieved by crossing adiponectin-Cre mice with floxed
PexRAP animals robustly induces UCP1 expression in subcuta-
neous but not epididymal WAT.
Adipose-specific knockout of PPARg in mice has yielded
conflicting results: one group reported lipodystrophy and insulin
resistance (He et al., 2003), while another found enhanced insu-
lin sensitivity (Jones et al., 2005). Certain human PPARg muta-
tions cause lipodystrophy and insulin resistance, likely through
a dominant-negative effect to disrupt interaction with coactiva-
tors (Agostini et al., 2006). In our studies, neither ASO-mediated
PexRAP knockdown in mice nor Cre-mediated adipose-specific
FAS knockout in mice produced lipodystrophy. Both decreased
adiposity and improved glucose metabolism. PPARg haploin-
sufficiency in mice (Kubota et al., 1999; Miles et al., 2000) also
decreases adiposity and increases insulin sensitivity, but this
genetic effect is not limited to adipose tissue. A Pro12Ala
PPARg mutation in mice (Heikkinen et al., 2009) and humans
(Huguenin and Rosa, 2010) decreases (but does not abolish)
PPARg transcriptional activity and results in decreased adiposity
and increased insulin sensitivity, although this mutation is not
adipose-specific.
Inhibiting FAS or the peroxisomal enzyme PexRAP in adipose
tissue alters body composition and improves glucose metabo-
lism in the setting of a high fat diet. Both represent attractive
targets for novel diabetes and obesity therapies.
EXPERIMENTAL PROCEDURES
Animals
Mice with a floxed FAS locus (FASlox/lox) (Chakravarthy et al., 2005) were
crossed with transgenic mice (a gift from Evan Rosen, BI Deaconess) express-
ing Cre recombinase under the control of the adiponectin promoter (Eguchi
et al., 2011) to obtain FASKOF mice that were studied after backcrossing
R7 times with pure C57BL/6J mice. Genotyping was performed using previ-
ously described primer sets and diets included Purina 4043 control chow,
Harlan Teklad TD 88137 high fat diet, and Harlan Teklad TD03314 high carbo-
hydrate/zero fat diet. Unless indicated otherwise, male FASKOF mice and
control littermates at 8–12 weeks of age were used for experiments. For
antisense oligonucleotide studies, 8-week-old C57BL/6J mice were used.
All protocols were approved by the Washington University Animal Studies
Committee.
Cell Culture
Primary mouse embryonic fibroblasts (MEFs) were isolated at 13.5 days post
conception from FASlox/lox embryos as previously described (Razani et al.,
2001) andmaintained in DMEM+10% FBS. MEFs were differentiated to adipo-
cytes by treatment with 1 mM dexamethasone, 5 mg/ml insulin and 0.5 mM
IBMX for 14 days, followed by supplemental 5 mg/ml insulin alone for an addi-
tional 4 days. 3T3-L1 cells were maintained in DMEM+10% NCS and differen-
tiated to adipocytes as previously described (Lodhi et al., 2007). CV-1, HEK293
and HEK293T cells were maintained in DMEM+10% FBS.
Lentiviral shRNA-Mediated Knockdown
Plasmids encoding shRNA for mouse FAS (TRCN0000075703), PexRAP
(TRCN0000181732 and 0000198546), and DHAPAT (TRCN0000193539)
were obtained from Open Biosystems (Huntsville, AL). Packaging vector
psPAX2 (12260), envelope vector pMD2.G (12259), and scrambled shRNA
plasmid (1864) were obtained from Addgene. 293T cells in 10 cm dishes
were transfected using Fugene 6 with 2.66 mg psPAX2, 0.75 mg pMD2.G,
and 3 mg shRNA plasmid. After 48 hr, media were collected, filtered using
0.45 um syringe filters, and used to treat cells. After 36 hr, cells were selected
with puromycin and knockdown was assessed after an additional 48 hr.
Identification of Alkyl Ether GPC Lipids Associated with PPARg
The strategy for detecting endogenous lipids associated with PPARg involved
adenovirus-mediated expression of FLAG-tagged PPARg or GFP (as control)
in cells induced to differentiate into adipocytes. Nuclear fractions, prepared
from cell lysates and subjected to hypotonic lysis as described (Chakravarthy
et al., 2009), were incubated with an antibody recognizing the FLAG epitope to
capture the PPARg construct and any associated lipids under conditions (no
detergent or high salt elution buffers) unlikely to disrupt potential ligand/
nuclear factor interaction.
Affinity matrix eluates (with equal protein content) of nuclear fractions from
cells treated with Ad-GFP (as a control) or Ad-PPARg were subjected to lipid
extraction. These extracts were mixed with an internal standard [(14:0/14:0)-
GPC] and analyzed as [M+Li]+, [M+H]+, or [M+Na]+ ions by positive ion
ESI/MS or as [M+CH3CO2]
- ions by negative ion ESI/MS (Hsu and Turk,
2007; Hsu et al., 2003). To determine the identity of the lithiated lipid species
of m/z 752, we performed multigenerational tandem MS on a linear ion
trap instrument. Collisionally activated dissociation (CAD) was employed to
deduce structures of R1 and R2 substituents. Additional details are provided
in Figure S3.
GST-PexRAP Pull-Down Assays
3T3-L1 adipocytes were lysed using a buffer containing 50 mM HEPES
(pH 7.4), 4 mM EDTA, 2 mM EGTA, 2 mM sodium pyrophosphate, 1% Triton
X-100, 10 mMNaF, and protease inhibitors. Lysates were mixed with an equal
volume of the same buffer lacking Triton X-100, then 5 mg of GST or GST-
PexRAP was added and samples were rocked at 4C. After 2 hr, samples
were centrifuged at 2500 3 g for 1 min, beads were washed 5 times with
1 ml of the lysis buffer containing Triton X-100, then 2X SDS-PAGE sample
buffer was added and samples were subjected to SDS-PAGE.
Antisense Oligonucleotides
ASOs were synthesized by TriLink Biotechnologies (San Diego, CA). The first 5
and last 5 nucleotides were substituted with 20 O-methyl RNA bases; all of the
bases had phosphorothioate linkages. The PexRAP ASO (RNA bases under-
lined) is: 50 GGUUGGTGTGTCTGTCCCUG 30. The control oligonucleotide is:
50 CCUUCCCTGAAGGTTCCUCC 30. Both were purified by anion exchange
HPLC, lyophilized, reconstituted with 0.9% normal saline, and then injected
intraperitoneally.
Statistical Analysis
Data are expressed as mean ± SEM. Comparisons between two groups were
performed using an unpaired, two-tailed t test. ANOVAwas used for more than
two groups and post testing was performed using Tukey’s post test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, three tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.06.013.
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targeted to treat lipid disorders, diabetes, and obesity, is 
highly expressed in the liver. Its induction by fasting pro-
motes lipid uptake, fatty acid   -oxidation, ketogenesis, 
and gluconeogenesis ( 1, 2 ). Ligand binding to PPAR  
causes it to heterodimerize with retinoid X receptor 
(RXR)  , allowing activation of gene transcription at 
peroxisome proliferator response elements (PPRE) ( 3, 4 ). 
Synthetic PPAR  ligands, such as fi brates, used for human 
lipid disorders ( 5 ) have been known for decades, but po-
tential endogenous ligands were identifi ed only recently 
( 6, 7 ). Mice with liver-specifi c deletion of the lipogenic 
enzyme fatty acid synthase (FAS) have impaired PPAR  
activity ( 8 ), and FAS activates PPAR  by producing an 
endogenous phospholipid ligand ( 6 ). FAS also activates 
PPAR  in brain and macrophages ( 9, 10 ). 
 Mammalian FAS synthesizes long-chain fatty acids, primar-
ily palmitate, through the activities of seven functional do-
mains: acyl carrier, acyl transferase,   -ketoacyl synthase, 
  -ketoacyl reductase,   -hydroxyacyl dehydratase, enoyl re-
ductase, and thioesterase ( 11 ). Like PPAR  , FAS is highly 
expressed in liver ( 12 ). In times of nutrient excess, hepatic 
FAS converts carbohydrate to lipid that is stored in lipid drop-
lets or secreted in the form of VLDL ( 13 ). Nutrient excess is 
associated with elevated levels of insulin, known to induce 
FAS expression. 
 These accepted physiological roles for PPAR  and FAS ap-
pear to confl ict with the observation that inactivation of FAS 
impairs PPAR  activation. How might FAS activate a process 
stimulated by feeding such as insulin-responsive lipogenesis 
and also activate a process stimulated by fasting such as the 
induction of PPAR  -dependent gene expression? 
 We hypothesized that distinct subcellular pools of FAS 
mediate these disparate effects. Compartmentalization 
would permit regulation of an FAS pool generating lipids 
for signaling that would be distinct from an FAS pool gener-
ating lipids for energy storage. In support of this hypothesis, 
 Abstract  Peroxisome proliferator-activated receptor 
(PPAR)  is a nuclear receptor that coordinates liver metab-
olism during fasting. Fatty acid synthase (FAS) is an enzyme 
that stores excess calories as fat during feeding, but it also 
activates hepatic PPAR  by promoting synthesis of an en-
dogenous ligand. Here we show that the mechanism under-
lying this paradoxical relationship involves the differential 
regulation of FAS in at least two distinct subcellular pools: 
cytoplasmic and membrane-associated. In mouse liver and 
cultured hepatoma cells, the ratio of cytoplasmic to mem-
brane FAS-specifi c activity was increased with fasting, in-
dicating higher cytoplasmic FAS activity under conditions 
associated with PPAR  activation. This effect was due to 
a nutrient-dependent and compartment-selective cova-
lent modifi cation of FAS. Cytoplasmic FAS was preferen-
tially phosphorylated during feeding or insulin treatment at 
Thr-1029 and Thr-1033, which fl ank a dehydratase domain 
catalytic residue. Mutating these sites to alanines pro-
moted PPAR  target gene expression. Rapamycin-induced 
inhibition of mammalian/mechanistic target of rapamycin 
complex 1 (mTORC1), a mediator of the feeding/insulin 
signal to induce lipogenesis, reduced FAS phosphorylation, 
increased cytoplasmic FAS enzyme activity, and increased 
PPAR  target gene expression. Rapamycin-mediated induc-
tion of the same gene was abrogated with FAS knockdown.  
These fi ndings suggest that hepatic FAS channels lipid syn-
thesis through specifi c subcellular compartments that allow 
differential gene expression based on nutritional status. —
Jensen-Urstad, A. P. L., H. Song, I. J. Lodhi, K. Funai, L. Yin, 
T. Coleman, and C. F. Semenkovich.  Nutrient-dependent 
phosphorylation channels lipid synthesis to regulate PPAR  . 
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 FAS solubility 
 Solubility assays were performed as previously described ( 15 ) with 
minor modifi cations. Membranes were isolated from mouse liver by 
ultracentrifugation and resuspended in buffer containing 20 mM 
HEPES buffer (pH 7.4), 1 mM EDTA, and 255 mM sucrose. The 
membrane fraction was subjected to treatment with various solvents 
(1 M NaCl, 0.1 M Na 2 CO 3 at pH 11.5, 1% SDS or 1% Triton X-100) 
and then centrifuged once more (4°C, 180,000  g , 30 min). The re-
sulting pellets and supernatants were analyzed by western blotting. 
 Cell culture 
 Hepa1-6 and Hek293T cells were maintained in DMEM + 10% 
FBS. Prior to insulin treatment for FAS activity assays, Hepa1-6 
cells were cultured in DMEM + 0.5% FBS for 6 h. All insulin treat-
ments were performed in DMEM + 10% FBS. 
 Pulse-chase study 
 Confl uent Hepa1-6 cells in 6 cm dishes were incubated in methi-
onine-free media for 30 min. The cells were then pulsed with 500 
μCi of  35 S-methionine per dish. After 1 h, cells for the “0” time point 
were harvested. For subsequent time points, cells were washed with 
PBS, chased with nonradioactive complete media, and incubated 
for an additional 45, 90, or 180 min before harvesting. Cells were 
fractionated into cytoplasm and membrane as described above. FAS 
was immunoprecipitated from each fraction, samples were subjected 
to SDS-PAGE, the gel was transferred onto PVDF membrane, and 
the bands corresponding to labeled FAS were visualized by autora-
diography. Autoradiograms were then analyzed by densitometry. 
 RT-PCR 
 Total RNA was extracted with TRIzol reagent (Invitrogen) and 
reverse transcribed using an iScript™ cDNA synthesis kit (Invit-
rogen). Semiquantitative RT-PCR was performed using SYBR® 
Green reagent (Applied Biosystems) with an ABI Prism 7700 PCR 
instrument. 
 Mutagenesis and plasmid construction 
 A retroviral plasmid, pBABE-Puro, containing human FAS 
( 16 ) generated by Max Loda (Dana Farber) was utilized to gener-
ate FAS phosphosite mutants. A 3.4 kb fragment of FAS/pBABE-
Puro, including the two putative phosphorylation sites (hFAS 
S1028 and T1032) and two fl anking BsrGI sites, was amplifi ed by 
PCR and subcloned into an intermediate Topo vector. Site-di-
rected mutagenesis of the Topo-FAS plasmid changed the codons 
corresponding to S1028 and T1032 to alanines, yielding two sin-
gle mutants. The S1028A/T1032A double mutant was made by 
sequential mutagenesis, using the S1028A mutant as a template. 
Mutated FAS fragments were then excised and cloned back into 
pBabe-Puro using the two BsrGI sites to generate mutant, full-
length FAS cDNAs. Mutations as well as correct orientation of the 
reinserted FAS fragments were verifi ed by DNA sequencing. 
 Green fl uorescent protein (GFP)-tagged FAS was generated by 
amplifying the cDNA encoding FAS from pBabe-Puro-FAS by 
RT-PCR, adding restriction sites for XhoI and EcoRI on the 
5 ′ and 3 ′ ends, respectively. The amplifi ed product was cloned 
into pEGFP-C3 using the XhoI and EcoRI sites, yielding an 
N-terminal GFP-tagged FAS construct. 
 Lentiviral shRNA-mediated knockdown and human FAS 
expression 
 A plasmid encoding a mouse FAS shRNA (TRCN0000075703) 
was obtained from Open Biosystems. The packaging vector 
psPAX2 (12260) and envelope vector pMD2.G (12259) were 
obtained from Addgene. Hek293T cells at 70% confl uence in a 
15 cm dish were transfected using Lipofectamine 2000 with 8 μg 
we demonstrate that FAS at two separate subcellular loca-
tions is differentially regulated by nutrients and insulin, 
that this regulation involves preferential dehydratase do-
main phosphorylation for the FAS pool that regulates 
PPAR  , and that the effects of the kinase mammalian/mech-
anistic target of rapamycin complex 1 (mTORC1) on PPAR  
activity require FAS. 
 MATERIALS AND METHODS 
 Animals 
 Male C57BL/6J mice at eight weeks of age were provided ad 
libitum access to chow diet (Purina #5053) or fasted for 18 h. All 
mice were kept on Aspen bedding and had free access to water. 
Protocols were approved by the Washington University Animal 
Studies Committee. 
 FAS enzyme activity assay 
 Using a modifi cation of a previously described assay ( 14 ), 20 μl 
of sample at 1 μg protein/μl was added to 70 μl of assay buffer 
[0.14 M potassium phosphate buffer (pH 7.0), 1.4 mM EDTA 
(pH 8.0), 1.4 mM DTT, 0.24 mM NADPH, 0.1 mM acetyl-CoA]. 
The rate of NADPH oxidation was monitored at 340 nm at base-
line and again after adding 10 μl of 0.85 mg/ml malonyl-CoA 
(Sigma). The substrate-dependent rate was determined by sub-
tracting the baseline NADPH oxidation rate from the rate after 
addition of malonyl-CoA. The rate of NADPH oxidation was nor-
malized to FAS protein levels as determined by western blotting 
and densitometry to determine specifi c activity. 
 Subcellular fractionation 
 Perfused liver from C57BL/6J mice was homogenized in 20 mM 
HEPES buffer (pH 7.4) and centrifuged at 100  g for 30 min, and 
then the pellet was discarded. The supernatant was centrifuged at 
500  g for 60 min; 1,200  g for 20 min; 10,000  g for 20 min; 20,000  g 
for 30 min; 40,000  g for 30 min; 70,000  g for 30 min; 100,000  g for 
60 min; and 179,000  g for 75 min. After each spin, the pellet was 
washed and resuspended, while the supernatant was centrifuged 
again. All spins were done at 4°C. To obtain crude membrane and 
cytoplasmic fractions from mouse liver, freshly isolated perfused 
liver was homogenized in HEPES buffer and centrifuged at 10,000  g 
for 45 min at 4°C. The resulting pellet was discarded, and the su-
pernatant centrifuged at 179,000  g for 180 min at 4°C. The super-
natant (cytoplasm) and pellet (crude membrane) were collected, 
and the pellet was washed and resuspended in HEPES buffer. To 
obtain membrane and cytoplasmic extracts from Hepa1-6 cells, a 
Subcellular Protein Fractionation Kit for Cultured Cells (78840) 
from Thermo Fisher Scientifi c was used according to the manufac-
turer’s protocol. 
 Antibodies 
 Rabbit polyclonal antibodies against FAS (ab22759), PMP70 
(ab3421), and phosphothreonine (ab9337) were from Abcam. 
Mouse monoclonal antibody against   -tubulin (sc-5286) and rab-
bit polyclonal antibodies against Cav1 (sc-894) and   -tubulin (sc-
9104, used to control for loading in western blotting experiments) 
were from Santa Cruz Biotechnology. Rabbit polyclonal antibod-
ies against PDI (226), GM130 (2296), Na + /K + ATPase (3010), Akt 
(9272), phospho-Akt (S473) (9271), S6 ribosomal protein (2217), 
and phospho-S6 ribosomal protein (Ser235/236) (2F9/4856), 
and rabbit monoclonal antibodies against p70 S6 kinase (2708) 
and CoxIV (4850) were from Cell Signaling Technology. 
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was excised and further cut into small pieces (1 mm 2 ), destained 
with 50% CH 3 CN containing 25 mM NH 4 HCO 3 , dehydrated, re-
duced with 20 mM DTT for 1 h at 55°C, washed and dehydrated, 
alkylated with 100 mM iodoacetamide for 1 h in the dark at room 
temperature, then subjected to cycles of washing and dehydra-
tion followed by drying in a centrifugal evaporator. In-gel diges-
tion was performed with 0.02 mg/ml trypsin overnight or 0.02 
mg/ml chymotrypsin for 6 h at 37°C. Peptides were extracted 
from the gel pieces using 5% TFA in 50% CH 3 CN and reconsti-
tuted in 0.1% FA in 3% CH 3 CN. 
 Immobilized metal ion affi nity chromatography (IMAC) was 
used to enrich the sample for phosphopeptides. The sample was 
incubated with IMAC beads for 1 h at room temperature. Pep-
tides were eluted from the beads in IMAC buffer, and the sample 
was diluted with 0.1% FA in 3% CH 3 CN. Samples were then ana-
lyzed by LC-MS/MS with a NanoLC-LTQ-Orbitrap mass spec-
trometer (Thermo Fisher Scientifi c) in data-dependent mode. 
Acquired spectra were searched against Swiss-Prot database 
through Mascot server to identify the protein and its posttransla-
tional modifi cations. Nonenriched samples were also run to al-
low a universal search for protein modifi cations as well as to 
search for acetyl modifi cations. 
 To identify FAS modifi cations specifi c to membrane-associ-
ated FAS and cytoplasmic FAS, membrane and cytoplasmic 
fractions were isolated from C57BL/6J mice as described 
above. FAS was immunoprecipitated from equal amounts of 
membrane and cytoplasmic lysates (1–10 mg/each) by over-
night incubation using a polyclonal rabbit anti-FAS antibody. 
The samples were then subjected to SDS-PAGE and analyzed as 
described above. 
 Statistics 
 Data are presented as mean ± standard error of the mean. 
Comparisons between two groups were performed using an un-
paired, two-tailed  t -test. ANOVA was used for comparisons involv-
ing more than two groups. 
 RESULTS 
 Hepatic FAS is present in subcellular compartments 
 FAS synthesizes palmitate, and FAS defi ciency in liver 
decreases PPAR  target genes. If the effect of FAS defi -
ciency on PPAR  simply refl ects palmitate availability, 
then exogenous palmitate should rescue the effect. It did 
not. Treatment of Hepa1-6 cells with 50 μM palmitate 
failed to rescue expression of the PPAR  target gene 
ACO following FAS knockdown ( Fig. 1A ).  Higher con-
centrations of palmitate (125–500 μM) were toxic (data 
not shown). 
 Since the FAS knockdown effect was not rescued with 
exogenous palmitate, it is plausible that not only the prod-
uct of the FAS reaction but also the location of its synthesis 
mediates downstream effects. Dogma holds that FAS is a 
cytoplasmic enzyme. To determine whether FAS is also 
present at other sites, we fractioned mouse liver FAS by 
ultracentrifugation ( Fig. 1B ). FAS cofractionated with the 
cytoplasmic marker S6K but also with markers for several 
organelles. Immunofl uorescent staining for FAS in mu-
rine Hepa1-6 liver cells demonstrated colocalization of 
FAS with endoplasmic reticulum (ER) and Golgi markers 
psPAX2, 2.25 μg pMD2.G, and 9 μg shRNA. After 48 h, media was 
collected and fi ltered through 0.45 μm syringe fi lters. Polybrene 
was added and the media used to treat 50–70% confl uent He-
pa1-6 cells. After 24 h, the media was aspirated and replaced with 
media containing retroviral particles encoding human FAS (see 
below). Forty-eight hours after addition of the retroviral media, 
cells were selected with puromycin. After another 48 h, cells were 
harvested and knockdown of mouse FAS as well as expression of 
human FAS were assessed. 
 To generate retroviral particles encoding human FAS, Hek293T 
cells in 10 cm dishes were transfected using Lipofectamine 2000 
with 3 μg FAS plasmid and 3 μg   A helper plasmid. After 48 h, 
media were collected, fi ltered using 0.45 μM syringe fi lters, then 
polybrene was added, and the media was used to treat 50–70% 
confl uent Hepa1-6 cells. After 48 h, 2 μg/ml puromycin was added, 
and after an additional 48 h, cells were harvested. 
 In experiments assessing PPAR  target gene expression in 
cells expressing mutant FAS, the endogenous murine FAS of 
Hepa1-6 cells was knocked down prior to retroviral expression of 
human FAS as described above. 
 PPRE-luciferase reporter assay 
 Media containing lentiviral particles encoding shRNA for mu-
rine FAS and media containing retroviral particles encoding 
wild-type or S1028A/T1032A double-mutant human FAS were 
prepared as described above. Seventy percent confl uent Hepa1-6 
cells in 10 cm dishes were treated with retroviral media for either 
wild-type or S1028A/T1032A FAS for 24 h, after which the media 
was aspirated and replaced with lentiviral media. After another 
24 h, the media was again aspirated and replaced with fresh me-
dia containing puromycin. 
 After two days of puromycin selection, the media was aspi-
rated, replaced with charcoal-stripped media, and incubated for 
1 h. Charcoal-stripped media was also used for subsequent steps. 
Hepa1-6 cells were transfected with plasmids encoding 3× PPRE-
luciferase and  Renilla luciferase by electroporation. The elec-
troporation for each 10 cm dish of cells was done as follows: 5 μg 
of PPRE-luciferase plasmid and 5 μg of  Renilla luciferase plasmid 
were added to the bottom of a cuvette. Cells were harvested by 
trypsinization and spun after adding media. The media was aspi-
rated, and cells were washed once with PBS. The PBS was aspi-
rated, and cells were resuspended in 0.5 ml PBS and transferred 
to the cuvette followed by electroporation at 360 V and 250 μF 
(time constant of 4.5–5 s   1 ). One milliliter of media was added to 
the cuvette, cells were transferred to a 15 ml tube, and media 
containing puromycin was added up to 6 ml. Cells were allowed 
to recover for 10 min, then plated. 
 One day following transfection, cells were harvested by scrap-
ing, washed with room-temperature PBS three times, resus-
pended in PBS, and plated on a 96-well plate. Luminescence 
from fi refl y luciferase and  Renilla luciferase was then measured 
using the Dual-Glo Luciferase Assay System (Promega) according 
to the manufacturer’s instructions. PPRE-luciferase activity was 
calculated as the ratio of fi refl y luciferase to  Renilla luciferase 
luminescence. 
 Mass spectrometry 
 To identify posttranslational modifi cations in hepatic FAS, 
perfused C57BL/6J mouse livers were homogenized in lysis buf-
fer containing 1% Triton X-100. The lysate was spun at 10,000  g 
for 45 min, and the pellet was discarded. FAS was immunopre-
cipitated from 10 mg of the lysate by overnight incubation using 
a polyclonal rabbit anti-FAS antibody. IP beads were washed, 
boiled in sample buffer, and subjected to SDS-PAGE. The gel was 
stained with Coomassie, the gel segment corresponding to FAS 
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 Fig.  1. Hepatic FAS is not exclusively cytoplasmic. (A) Expression levels of FAS (left) and the PPAR  -dependent gene ACO (right) in 
Hepa1-6 cells. Cells were treated with a control (scrambled, sc) shRNA or an FAS shRNA in the presence of exogenous BSA-conjugated 
palmitate or vehicle (BSA alone) for 8 h. * P   0.05, ** P   0.005, *** P   0.0005. NS, not signifi cant. (B) Subcellular distribution of FAS 
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sequence due to a process such as exon exclusion (data 
not shown). 
 Collectively, these results suggest that the enzyme activi-
ties of cytoplasmic and membrane-associated FAS are dif-
ferentially regulated, a phenomenon that does not appear 
to be due to intracellular traffi cking of the protein or dif-
ferences in its primary structure. 
 Cytoplasmic FAS is preferentially phosphorylated 
 To address the possibility that differential regulation of 
cytoplasmic and membrane-associated FAS is caused by a 
covalent modifi cation, we immunoprecipitated hepatic 
FAS from fasting and fed mice, and then tested different 
fractions for the presence of phosphothreonine by west-
ern blotting. Cytoplasmic FAS in fed mice was strongly 
threonine phosphorylated, a modifi cation that was almost 
undetectable in fasted mice ( Fig. 4A ).  Phosphorylation of 
membrane-associated FAS was low under both conditions 
( Fig. 4A ). In Hepa1-6 cells, insulin treatment (a mimic of 
feeding) stimulated threonine phosphorylation of cyto-
plasmic but not membrane-associated FAS ( Fig. 4B ). 
 Analysis of FAS protein from unfractionated mouse liver 
by mass spectrometry revealed only a single peptide that 
was threonine phosphorylated. This modifi cation was de-
tected at two residues, Thr-1029 and Thr-1033 (a representa-
tive spectrum is shown in  Fig. 5A ).  When liver FAS was 
separated into cytoplasmic and membrane-associated frac-
tions and subjected to the same analysis, the phosphorylated 
peptide was found predominantly in the cytoplasm ( Fig. 5B ) 
despite similar total amounts of the peptide in both fractions 
(data not shown). These results suggest that the phosphory-
lated FAS species detected in the cytoplasm with feeding or 
insulin ( Fig. 4A, B ) is modifi ed at Thr-1029 and Thr-1033. 
 These residues are in the dehydratase domain of FAS. 
The function of this domain requires two catalytic residues, 
His-878 and Asp-1032, and a third residue, Gln-1036, that 
maintains the orientation of the catalytic residues ( 21 ). The 
phosphorylated residues we identifi ed (denoted by * in  Fig. 
5C ) are in close proximity to the catalytic residue D1032 
and the structural residue Q1036 (denoted by # in  Fig. 5C ). 
Sequence alignment of the dehydratase regions from differ-
ent species revealed that in addition to strict conservation of 
the active site residues D1032 and Q1036 (denoted by #), 
the phosphoresidues we identifi ed are also conserved as ei-
ther serines or threonines in humans, mice, rats,  D. melano-
gaster , and  C. elegans (boxes in  Fig. 5D ). 
 Since the evolutionary conservation of these phosphory-
lation sites suggests involvement in FAS function, we mu-
tated S1028 and T1032 in human FAS (corresponding to 
the T1029 and T1033 in murine FAS) to alanines, generat-
ing two single mutants (S1028A and T1032A) and one 
double mutant (S1028A/T1032A) ( Fig. 5E , mutated sites 
but not peroxisomal or mitochondrial markers ( Fig. 1C ). 
FAS did not appear in the nucleus ( Fig. 1C ). 
 Membrane-associated and cytoplasmic FAS are 
differentially regulated 
 FAS is induced by insulin and nutrients ( 12 ). Surpris-
ingly, the specifi c activity of mouse liver cytoplasmic FAS 
was not increased in the fed state when insulin levels are 
high ( Fig. 2A ).  Membrane-associated, FAS-specifi c activity 
was increased with feeding ( Fig. 2B ). The cytoplasmic/
membrane activity ratio in liver was increased with fasting, 
when PPAR  is activated ( Fig. 2C ). In Hepa1-6 cells, a 
transformed liver cell line, insulin signifi cantly decreased 
cytoplasmic FAS activity ( Fig. 2D ), an effect that was not 
seen in the membrane fraction ( Fig. 2E ). As with mouse 
liver, the cytoplasmic/membrane activity ratio in Hepa1-6 
cells was increased in the absence of added insulin ( Fig. 2F ), 
a mimic of fasting. 
 To begin to address the possibility that membrane-asso-
ciated FAS is an artifact of preparation, we treated isolated 
fractions with different solvents. Membrane-associated 
FAS resisted solubilization by 1 M NaCl, remaining in the 
pelleted fraction, but it was largely solubilized by 0.1 M 
Na 2 CO 3 ( Fig. 3A ).  Treatment with detergent (1% SDS or 
1% Triton X-100) solubilized most FAS protein ( Fig. 3A ). 
These results suggest ( 17–19 ) that FAS manifests a strong 
peripheral membrane interaction. 
 A pulse-chase study showed that radiolabeled FAS de-
creased over time in the membrane-associated and cytoplas-
mic compartments ( Fig. 3B ), suggesting that there was no 
ordered fl ux of protein from one compartment to another 
over the time course of this experiment. There was no dis-
cernible change in the distribution of FAS between mem-
brane and cytoplasm when cells were treated with insulin 
( Fig. 3C ). 
 Given the presence of a putative open reading frame 
(with a potential alternative start codon) 5 ′ to the pub-
lished fi rst exon of both mouse and human FAS, we 
considered the possibility that compartmentalized FAS 
represented differential splicing leading to nonidentical 
protein isoforms, only one of which is membrane-targeted. 
However, mass spectrometric analysis of FAS in membrane 
and cytoplasm failed to detect the predicted alternative 
amino acids at the N-terminus, and it identified the 
published FAS protein sequence as being N-terminally 
acetylated ( Fig. 3D ). This modifi cation, which marks the 
N-terminus of most eukaryotic proteins ( 20 ), was present 
in membrane and cytoplasmic fractions of FAS, preclud-
ing the existence of an additional N-terminal sequence. 
All regions of the FAS protein were similarly repre-
sented in each fraction, decreasing the possibility that 
compartment location was determined by altered protein 
protein in mouse liver by differential centrifugation followed by western blotting. Organelle markers: S6K = P70/S6 kinase (cytoplasmic 
marker), GM130 = Golgi Matrix protein 130 (Golgi marker), Cav1 = Caveolin1 (caveolae marker), PDI = protein disulfi de isomerase (en-
doplasmic reticulum marker), Na + /K + ATPase (plasma membrane marker), PMP70 = peroxisomal membrane protein 70 (peroxisomal 
marker), and COXIV = cytochrome C oxidase IV (mitochondrial marker). (C) Immunofl uorescent staining of FAS and expression of GFP-
tagged organelle markers in murine Hepa1-6 cells. Nuclei stained with DAPI are presented on the far left, GFP images are presented sec-
ond from left, FAS images are presented second from right, and merged GFP/FAS images are presented on the far right. 
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compared with wild-type FAS ( Fig. 5I ), suggesting that 
effects of the FAS mutant on PPAR  target genes are 
mediated by PPAR  transcriptional activity. One interpre-
tation of these data is that the inability to phosphorylate 
FAS disinhibits FAS enzyme activity to promote PPAR  
transcription. 
 mTORC1 phosphorylates and inactivates FAS and 
inhibits PPAR  activity 
 mTORC1 was recently identifi ed as a physiologically 
important negative regulator of hepatic PPAR  ( 22 ). 
mTOR, the kinase component of mTORC1, is a serine/
threonine kinase that preferentially phosphorylates sites 
with hydrophobic residues at the +1 position ( 23 ). Since 
the phosphorylated residues we identifi ed have the 
highly hydrophobic phenylalanine (F1030) and methion-
ine (M1034) at the +1 positions, we addressed a role for 
are indicated by boxes and the active site residues by #). 
Wild-type or mutant human FAS was then expressed in 
Hepa1-6 cells following knockdown of endogenous mouse 
FAS. Compared with cells expressing wild-type human 
FAS, cells expressing the S1028A mutation had increased 
levels of the PPAR  target gene CPT1 ( Fig. 5F ), whereas 
cells expressing the T1032A mutation did not show changes 
in PPAR  target genes ( Fig. 5G ). However, expression of 
the double-mutant S1028A/T1032A was associated with 
increased levels of both ACO and CPT1 ( Fig. 5H ). To im-
plicate PPAR transcriptional activity in this effect, we per-
formed a PPRE-luciferase reporter assay. After expression of 
wild-type or S1028A/T1032A double-mutant FAS and knock-
down of endogenous mouse FAS, cells were transfected with 
a plasmid encoding three tandem PPREs fused to a fi refl y 
luciferase reporter gene. Luciferase activity was increased in 
cells expressing the S1028A/T1032A double-mutant FAS 
 Fig.  2. Differential regulation of the activities of membrane-associated FAS and cytoplasmic FAS. (A) Spe-
cifi c activity of FAS in the cytoplasmic fraction of mouse liver. Mice were fed ad lib (fed) or fasted for 18 h 
(fasted). Activity was normalized to FAS protein levels as measured by western blotting. N = 9/group. (B) 
Specifi c activity of FAS in the membrane (Golgi/ER) fraction of mouse liver. Mice were fed ad lib (fed) or 
fasted for 18 h (fasted). Activity was normalized to FAS protein levels as measured by western blotting. N = 
5/group. ** P   0.005. (C) FAS-specifi c activities in (A) and (B) expressed as the ratio of FAS-specifi c activity 
in cytoplasm to FAS-specifi c activity in membrane. * P   0.05. (D) Specifi c activity of FAS in the cytoplasmic 
fraction of Hepa1-6 cells. Cells were treated with 100 nM insulin for indicated times. Activity was normalized 
to FAS protein levels as measured by western blotting. N = 3/group. * P   0.05. (E) Specifi c activity of FAS in 
the membrane (Golgi/ER) fraction of Hepa1-6 cells. Cells were treated with 100 nM insulin for indicated 
times. Activity was normalized to FAS protein levels as measured by western blotting. N = 3/group. (F) FAS-
specifi c activities in (D) and (E) expressed as the ratio of FAS-specifi c activity in cytoplasm to FAS-specifi c 
activity in membrane. * P   0.05. 
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 Fig.  3. Distinct characteristics of membrane and cytoplasmic FAS. (A) Detection of FAS protein by western blotting in pellets and super-
natants of membrane fractions following high-salt, carbonate, and detergent treatments. Mouse liver homogenate was fractionated by dif-
ferential centrifugation into cytoplasm (not shown) and membrane pellet (lane 1). The pellet was resuspended, exposed to solvents as 
indicated, and again centrifuged to separate pellet (P) from the new supernatant (S). (B) Pulse-chase analysis of FAS protein in membrane 
and cytoplasm of Hepa1-6 cells. Cells were pulsed with  35 S-labeled methionine for 1 h, then chased with media containing nonlabeled 
methionine for the indicated times. (C) Expression of GFP-tagged human FAS in Hepa1-6 cells treated with insulin for the indicated times. 
Images demonstrate no detectable shifts of FAS between cytoplasmic and membrane sites with insulin treatment. (D) Representative spec-
trum of N-terminally acetylated peptide of FAS. N-terminal acetylation effectively marks the initial amino acid of the protein, precluding 
the existence of additional expressed N-terminal exons that might constitute distinct FAS isoforms. 
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 DISCUSSION 
 FAS synthesizes lipid for energy storage and participates 
in the generation of a lipid ligand involved in the activa-
tion of fatty acid oxidation. Energy storage occurs with 
feeding, and activation of fatty acid oxidation occurs with 
fasting. To clarify how the same enzyme mediates both 
processes, we pursued the possibility that distinct pools of 
FAS are differentially regulated in the liver. 
 We found FAS in the cytosol, but we also localized FAS 
to organelles ( Fig. 1 ) through a strong peripheral mem-
brane interaction ( Fig. 3A ). FAS-specifi c activity was rela-
tively higher with feeding/insulin in membranes and 
relatively higher with fasting in the cytosol ( Fig. 2 ). This 
effect did not appear to involve movement of FAS between 
compartments or primary sequence differences between 
these pools of FAS. Instead, this activity difference was as-
sociated with preferential phosphorylation of cytoplasmic 
(but not membrane) FAS with feeding ( Fig. 4 ) at con-
served sites within a catalytic domain ( Fig. 5 ). Mutation of 
these sites increased endogenous PPAR  target gene ex-
pression as well as activity of a PPRE-dependent reporter 
gene ( Fig. 5 ), consistent with disinhibition of FAS in the 
mTORC1 in FAS phosphorylation. Treating Hepa1-6 cells 
with the mTORC1 inhibitor rapamycin for 30 min abol-
ished the insulin-induced increase in cytoplasmic FAS 
threonine phosphorylation ( Fig. 6A )  and was associated 
with an increase in cytoplasmic FAS-specific activity 
( Fig. 6B ). Treatment of these cells with Torin 1 at 250 nM 
also abolished insulin-induced FAS phosphorylation (data 
not shown). Treating Hepa1-6 cells with rapamycin for 
24 h (a suffi cient time to reach a new steady state for mRNA 
levels) increased expression of the PPAR  target gene 
CPT1 ( Fig. 6C ). These fi ndings confi rm those made in a 
different system ( 22 ) and extend that work by implicating 
FAS in the mTORC1-PPAR  axis. 
 To better defi ne the interaction between mTORC1, 
FAS, and PPAR  , FAS was knocked down in Hepa1-6 cells 
followed by rapamycin treatment. FAS knockdown, con-
fi rmed in the presence of rapamycin ( Fig. 6D ), decreased 
CPT1 expression ( Fig. 6E ). The induction of CPT1 levels 
with rapamycin occurring with FAS expression ( Fig. 6C ) 
was lost with FAS knockdown ( Fig. 6E , solid bar). These 
results suggest that in this cell line under these conditions, 
the induction of the PPAR  target gene CPT1 caused by 
inhibition of mTORC1 is FAS-dependent. 
 Fig.  4. Cytoplasmic FAS is threonine phosphorylated with feeding or insulin treatment. (A) FAS threonine 
phosphorylation in response to feeding in mouse liver. FAS was immunoprecipitated from cytoplasmic and 
membrane fractions and analyzed for phosphothreonine by western blotting. Mice were fed ad lib (fed) or 
fasted for 18 h (fasted). Representative blots are shown. Data are averages of two independent experiments. 
* P   0.05. (B) FAS threonine phosphorylation in response to insulin in Hepa1-6 cells. FAS was immunopre-
cipitated from Hepa1-6 cytoplasmic and membrane fractions and analyzed for phosphothreonine by western 
blotting. Cells were cultured in 0.5% FBS media for 4 h prior to harvest (starved) or in 0.5% FBS media for 
4 h, then treated with 1 nM insulin in 10% FBS media for 15 min (refed/insulin). Representative blots are 
shown. Data are averages of two independent experiments. * P   0.05. 
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birds. Using pigeon liver as a model and exclusively studying 
FAS in the cytoplasm, Qureshi and colleagues found that 
feeding induced  32 P incorporation into FAS, which was associ-
ated with a loss of enzyme activity ( 24 ). In vitro treatment with 
phosphatases dephosphorylated FAS and restored enzyme 
activity. The authors of this study did not identify a physiologi-
cal role for this covalent modifi cation, and it is not known 
whether the phosphosites we found are conserved in pigeon 
FAS due to the unavailability of sequence data for this species. 
Regardless, our work suggests that the phosphorylation state 
of cytoplasmic FAS may channel lipid fl ow to impact phos-
pholipids inducing gene expression in the nucleus. 
absence of phosphorylation. Inhibition of mTORC1 with 
rapamycin decreased FAS phosphorylation, increased cy-
tosolic FAS enzyme activity, and increased expression of 
the PPAR  target gene CPT1, an effect that was FAS-de-
pendent ( Fig. 6 ). One interpretation of these fi ndings is 
that hepatic FAS exists in at least two differentially regu-
lated subcellular pools, cytoplasmic and membrane-associ-
ated ( Fig. 7 ).  Cytoplasmic FAS is phosphorylated with 
feeding to limit PPAR  activation, and it is dephosphory-
lated with fasting to promote PPAR  activation. 
 Our fi ndings provide molecular defi nition and physiologi-
cal context to an observation made nearly four decades ago in 
 Fig.  5. Phosphorylation of cytoplasmic FAS at the dehydratase domain catalytic site controls downstream PPAR  target gene expression. 
(A) Representative spectrum of the FAS P-T1029/P-T1033 phosphopeptide from wild-type mouse liver. (B) Distribution of P-T1029/P-T1033 
phosphopeptides identifi ed by mass spectrometry in cytoplasm and membrane fractions of mouse liver. Although the proportion of phos-
phorylation differed based on fraction, peptide abundances (phosphorylated + nonphosphorylated) were similar for the membrane and 
cytoplasm fractions (not shown). (C) Position of P-T1029 and P-T1033 amino acid residues in relation to the FAS dehydratase domain ac-
tive site residues. D1032 is one of two dehydratase domain catalytic residues in FAS. (D) Sequence alignment of the FAS putative phospho-
amino acids and dehydratase domain active sites in several species. (E) FAS phosphosite mutants in human FAS. (F) RT-PCR analyses of 
PPAR  target gene expression in Hepa1-6 cells expressing wild-type or S1028A mutant FAS. Endogenous FAS was knocked down using 
lentiviral shRNA for murine FAS. Wild-type or mutant human FAS was expressed using retroviruses. Data are averages of three independent 
experiments . * P   0.05. (G) RT-PCR analyses of PPAR  target gene expression in Hepa1-6 cells expressing wild-type or T1032A mutant 
FAS. Assay performed as in (F). Data are averages of three independent experiments. (H) RT-PCR analyses of PPAR  target gene expres-
sion in Hepa1-6 cells expressing wild-type or S1028A/T1032A mutant FAS. Assay performed as in (F). Data are averages of three indepen-
dent experiments. * P   0.05. (I) PPRE-luciferase activity in Hepa1-6 cells expressing wild-type or S1028A/T1032A mutant FAS. Wild-type 
or mutant human FAS was expressed using retroviruses. Endogenous FAS was knocked down using lentiviral shRNA for murine FAS. Cells 
were cotransfected with plasmids encoding 3× PPRE-fi refl y luciferase and  Renilla luciferase. PPRE-luciferase activity is reported as the ratio 
of fi refl y/ Renilla luciferase luminescence. N = 3–6/group. *** P   0.0005. 
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preferential phosphorylation depending on cellular loca-
tion and nutritional state. 
 There is precedent for compartmentalization in me-
tabolism. Exogenous administration of T3, the active form 
of thyroid hormone that can be produced locally from its 
precursor T4, does not rescue gene expression defects in 
the setting of hypothyroidism. But administration of T4, 
which is metabolized to generate T3 locally, restores 
downstream effects ( 32 ). There is also precedent for com-
partmentalization in lipid signaling. Phosphatidic acid 
derived from glycerolipid synthesis has effects on mTORC2 
that are opposite from those induced by phosphatidic 
acid derived from membrane lipolysis ( 33 ). These obser-
vations are consistent with our model ( Fig. 7 ). In the fed 
state, cytoplasmic FAS is phosphorylated to limit lipid pro-
duction resulting in PPAR  activation, while membrane 
FAS, less susceptible to phosphorylation, likely produces 
lipids for energy storage or export. Given the rapid de-
mands of lipid synthesis prompted by transition from the 
fasting to the fed state, the induction of membrane FAS 
may be predominantly substrate-driven through allosteric 
 Physiological, mass spectrometric, and crystal structure 
data indicate that phospholipids interact with nuclear re-
ceptors ( 6, 25–29 ). FAS appears to be linked to PPAR  
through phosphatidylcholine synthesis mediated by the 
Kennedy pathway ( 6 ). Viewed with previous studies show-
ing that phosphorylation regulates the CDP-choline branch 
of the Kennedy pathway ( 30, 31 ), our identification of 
functionally relevant FAS phosphorylation sites raises the 
possibility that phosphorylation at several nodes within a 
cascade of lipid signaling from the cytoplasm to the nucleus 
coordinates FAS-mediated PPAR  activation. 
 Palmitate is the direct product of the FAS reaction. If 
the mere availability of palmitate were required to activate 
PPAR  , exogenous palmitate would correct FAS defi -
ciency. However, the addition of palmitate to liver cells 
with FAS defi ciency does not restore defects in PPAR  -
dependent genes ( Fig. 1 ), and elevated serum palmitate 
levels that accompany inactivation of liver FAS in mice 
does not rescue impaired activation of PPAR  -dependent 
genes ( 8 ). Thus, palmitate produced by FAS appears to be 
compartmentalized, a notion supported by our fi nding of 
 Fig.  6. FAS phosphorylation is inhibited by rapamycin and impacts CPT1 expression. (A) Cytoplasmic FAS 
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 mTORC1 may control the reciprocal activity of FAS in 
different compartments. mTORC1 is activated by insulin 
and nutrients, prefers substrates like those we identifi ed in 
the dehydratase domain, and is known to suppress PPAR  
in the liver ( 22 ). FAS and mTORC1 appear to interact in 
the central nervous system where the physiological effects 
of FAS inhibition are blunted by rapamycin ( 35 ), consis-
tent with our model suggesting that mTORC1 inhibition 
would increase FAS activity. 
 Our work provides evidence that hepatic FAS is in the 
cytoplasm as well as peripherally associated with mem-
branes. These two pools are differentially regulated by nu-
trients and insulin, and they are differentially susceptible 
to phosphorylation, thus providing a conceptual frame-
work for understanding how FAS-mediated PPAR  activa-
tion is linked to the fasting state. These observations could 
have clinical implications. Selective pharmacological tar-
geting of FAS to achieve inhibition of lipid storage without 
impairing PPAR  activation could treat fatty liver and 
other disorders associated with nutrient excess.  
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